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This investigation concerns the definition and differentiation
of prostanoid receptors and the struc t u r e -activi ty
relationships of prostanoid analogues in relation to smooth
muscle responses and platelet aggregation.
In initial studies on the bullock iris sphincter preparation
it was observed that the potent prostacyclin mimetic ZK 36374
partially contracted the preparation and opposed the
contractile action of PGE2, but not that of 11,9-epoxymethano
PGH2. These effects were explained in terms of a partial
agonist action of ZK 36374 on the PGE2 receptor. By observing
this activity of ZK 36374 and the order of potency of other
PGE2 analogues on several different preparations, it was
demonstrated thatc PGE2 receptors can be divided into two
subtypes. Subtype I is associated with stimulant activity on
smooth muscle and the 16-p-chlorophenoxy-17,18,19,20-tetranor
analogue of PGE2 (ICI 80205) is a highly potent agonist;
subtype II is associated with inhibitory activity (relaxation
of cat trachea) and ICI 80205 and ZK 36374 have very low
activft y.
The bullock iris sphincter was also shown to contain a TxA2
receptor system on which the endoperoxide analogue EP 011 was
a particularly potent agonist. Two prostanoid analogues with
II
semicarbazone w-chains, EP 045 and EP 116, were shown to be
specific thromboxane receptor antagonists of high affinity.
Activities of prostanoid analogues on rat platelets were also
examined. CTA2, PTA2 and 15-oxo EP 011 gave a shape change
only, while EP 011, 11 , 9-epoxymethano PGH2 and 9,11-azo PGH2
aggregated the platelets. PGE2 potentiated the aggregatory
action but not the shape change. The properties of the
receptors in these different preparations are discussed.
On PGF2k receptor sites ICI 81008 was found to be a selective
agonist. We have also examined other compounds related to ICI
81008 which may be partial agonists, but desensitization
complicates the analysis.
PGI2 receptors mediating excitatory effects in the rabbit iris
sphincter were shown to have properties similar to those of
receptorsmediating inhibitory effects in platelets.
Finally, we have found that calcium antagonists potentiate the
contractile effect of prostanoids in the rat anococcygeus
muscle. The possible mechanisms involved have been discussed.
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Nearly fifty years ago an endogenous substance with
vasodepressor and smooth muscle stimulating activity was
first described in accessory sex glands of the ram and
seminal fluid from man independently by Goldblatt (1933) and
von Euler (1934). von Euler first referred to this new class
of pharmacological agent as prostaglandin . About 30 years
elapsed between these original observations and full
appreciation by the scientific community of the implications
for research. In the 1960's a number of 20-carbon,
unsaturated, hydroxy and keto substituted fatty acids with
prostaglandin-like activity were isolated in crystalline
form from sheep prostate glands and human seminal plasma
(Bergstrom & Sjovall, 1960; Bergstrom, Ryhage, Samuelsson &
Sjovall, 1963; Samuelsson 1963). This signalled the start of
intensive chemical effort directed towards the total
synthesis of the natural prostaglandins and related
analogues.
In the following years, two independent groups (Bergstrom,
Danielson & Samuelsson, 1964; von Dorp, Beerthuis, Nugteren
& Vonheman, 1964) demonstrated that prostaglandins are
biosynthesized from polyunsaturated fatty acid. These acid
include dihomo Y-lin°lenic acid (C20:3W6), arachidonic acids
(C20:4W6), and eicosapentaenoic acid (C20:5W3), which give
rise to the mono-, di- , or trienoic prostaglandins
respectively. Arachidonic acid, the precursor of all
di -enoic prostaglandins, is the most common fatty acid
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present in cellular phospholipids and can be obtained
directly from the diet or by desaturation and chain
elongation from dietary linoleic acid (C18:2W6). Arachidonic
acid is liberated from membrane phospholipids by the action
of phospholipases, activated by stimuli of various kinds,
mechanical, thermal, chemical, immunological and others
(Vonkeman & von Dorp, 1968; Flower & Blackwell, 1976).
Since 1973, there have been important discoveries about the
nature of the intermediates in arachidonic acid metabolism.
These substances include the prostaglandin endoperoxides
(PGG2 and PGH2) (Hamberg & Samuelsson, 1973; Willis & Kuhn,
1974; Willis, Vane, Kuhn, Scott & Petrin, 1974; Hamberg,
Svensson & Samuelsson, 1974; Hamberg, Svensson, Wakabayashi
& Samuelsson, 1974), thromboxane A2 (TxA2) (Hamberg,
Svensson & Samuelsson, 1975) and prostacyclin (PGI2)
(Moncada, Gryglewski, Bunting & Vane, 1976a; Moncada,
Gryglewski, Bunting & Vane, 1976b). Since the structural
similarity between prostaglandins and thromboxanes is
evident, and thromboxanes are derived from prostaglandins,
in this thesis the word "prostaglandin" (PG) or "prostanoid"
will be used as a general term to describe prostaglandins,
thromboxanes and the numerous metabolites and analogues
structurally related to the parent compounds.
Arachidonic acid can also be metabolized by a 5-lipoxygenase
to form a family of compounds containing a conjugated triene
structure, named leukotrienes (Murphy, Hammarstrom &
Samuelsson, 1979). Figure 1 shows the two pathways in









(11 R)-11 - hydroperoxy-5,8,12. (11 R)-11 -hydroxy-5,8,12.
14-elcoeatetreenotc acid 14-«lco*atetraenolc acid
1S-HPETE or 1S-HETE or
(15S)-15-hydroperoxy-5.8. (15S)-15-hydroxy-5,8,
























12-HPETE or 12-HETE or
(12S)-12-hydroperoxy-5.8,10, (12S)-12-hydroxy-5,8,10,







\A#y^/v' TXB, or thromboxane B,







































LTE. or leukotriene E4
h-conhch,cooh
ch,
Figure 1 Biosynthesis of prostaglandins, thromboxanes and leukotrienes
from arachidonic acid.
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LTD4 are responsible for much of the smooth muscle
stimulating activity of the slow-reacting substance (SRS-A)
liberated in anaphylaxis. The dihydroxy acid LTB4 on the
other hand has potent leucocyte-attracting properties
(Hammarstrom, 1983).
Prostanoids have two significant features: their widespread
occurrence and broad spectrum of biological activity. They
can be biosynthesized by every type of animal cell with the
exception of the red blood cell, and nearly every cell type
can respond in some way to one or more of them. The number
of reported effects of the prostaglandins and related
substances is staggering and seems to encompass most
biological functions in the body. They include effects on
all kinds of smooth muscle, on secretory functions, on
resorption of electrolytes and water, on neurotransmission,
platelet aggregability, induction of fever, chemotaxis and
other inflammatory responses, and a variety of endocrine and
metabolic effects.
Prostanoids possess such a wide range of biological
activities that it seems impossible to make useful
generalizations on their mode of action. It was proposed
that prostaglandins acted as calcium ionophores to transport
calcium directly (Gerrard, Townsend, Stoddart, Witkop &
White, 1977; Gerrard, Peterson, Townsend & White, 1976).
Ionophores are molecules with backbones of diverse
structures containing strategically placed oxygen atoms
(Pressman, 1976). The backbone can assume conformations
which focus these oxygen atoms about a ring into which an
ion of suitable size may fit. It was suggested that the
oxygens of two or possibly more prostaglandins could form a
hydrophilic cavity around a dehydrated calcium ion (Eagling,
Lovell & Pickles, 1976; Reed & Knapp, 1978). It was shown
that prostaglandins could transport calcium from a water
phase into diethyl ether at physiological pH (Gerrard,
Peterson, Townsend & White, 1976) and that a higher affinity
was shown for calcium ions in this respect than for
magnesium, potassium and sodium ions (Gerrard, White &
Peterson, 1978). On the other hand, prostaglandins may
displace calcium ions from superficial membrane-binding
sites (White, Rao & Gerrard, 1974). However, there is
considerable evidence to suggest that the versatile effects
of prostaglandins are mediated by interacting with specific
receptors. Investigations have shown that the actions of
prostaglandins on a number of isolated organs were not
modified by any of the following drugs: alpha- and
beta-adrenergic blocking agents, antihistamines,
anticholinergic drugs, serotonin antagonists, tubocurarine,
and hexamethonium; prostanoids are active at very low
concentrations; they show a high degree of chemical
specificity, i.e. small changes in chemical structure have
profound effects on potency and there are marked differences
in potency between different isomers of the same compound.
These properties suggest the existence of specific
recognition sites or receptors, Indeed, many studies have
revealed the existence of specific prostanoid-binding sites
in the membranes of a number of cell types.
The first direct evidence for a prostaglandin receptor based
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on actual competition studies between labelled and
unlabelled prostaglandins was obtained using the intact
lipocyte (Kuehl & Humes, 1972). Since then prostaglandin
binding sites have been described in a number of tissues,
e.g. corpus luteum (Powell, Hammarstrom & Samuelsson, 1973;
Rao, 1976, 1977; Lin & Rao, 1978; Mattioli, Galeati & Seren,
1983; Wright, Pang & Berman, 1980; Wright, Luborsky-Moore &
Berman, 1979), adipocytes (Kuehl & Humes, 1972; Gorman &
Miller, 1979), thyroid (Moore & Wolff, 1973), adrenal
(Dazod, Morera, Bertrand & Saez, 1974; Kapalis & Powell,
1981a, 1981b), prostate (Cavanaugh & Farmworth, 1977), ovary
(Rotondi & Knazek, 1982), oviduct (Riehl & Harper, 1981),
uterus (Johnson, Jessup & Ramwell, 1974; Kimball, Kirton,
Spilman & Wyngarden, 1975; Kimball & Wyngarden, 1975)
platelets (McDonald & Stuart, 1974; Schilliger & Prior,
1980; Shafer, Coper, O'Hara & Handin, 1979; Armstrong, Jones
& Wilson, 1983; Siegl, Smith & Silver, 1980), lymphocytes
(Melman, Weinstein, Sheaver & Bourne, 1974), thymocytes
(Schaumberg, 1973), macrophages (Opmeer, Adolfs & Bonta,
1983), blood vessels (Rucker & Schror, 1983), gut (Tepperman
& Soper, 1981a, 198lb, 1983; Miller & Magee, 1973; Kantor,
Tao & Kiefer, 1974), liver (Okamici & Terayama, 1977; Smigel
& Fleischer, 1974), brain (Comaty, Ehrenpreis & Greenberg,
1976), lung (MacDermot, Barnes, Waddell, Dollery & Blair,
1981).
However, in most cases it has yet to be established whether
these are the receptors mediating the biological actions of
prostanoids or sites related to their transport or enzymatic
inactivation, since according to the terminology by Paton
(1961) binding sites in which there is a high degree of
target specificity may be classified as receptors or
acceptors. In general a receptor is considered to be a
component of the cell which upon interaction with a specific
stimulator, generally from an external source, initiates a
series of biochemical or/and physiological events
characteristic of the cell.
Different prostanoids often produce opposite effects on the
same cell type. For instance, TxA2 activates platelets to
aggregate, while PGI2 inhibits platelet aggregation; some
types of smooth muscle are contracted by PGF2a but relaxed
by PGE2. Furthermore, different cell types respond to
different prostanoids. Tachphylaxis to one PG may leave the
response to another unchanged. Substances such as SC-19220 (P333),
7-oxa-13-prostynoic acid, or polyphlore tin phosphate block
contractions produced by some PGs but do not block the
relaxations produced by the same PGs on other smooth muscle
preparations. Some antagonists also appear to be more
effective in antagonizing responses to one PG than another
even though the actions of the PGs are the same type. From
the qualitative and quantitative differences in the
biological properties of the various natural prostaglandin
families, it is clear that several different prostaglandin
receptors must exist. In 1967, Pickles suggested that there
were more than two types of prostaglandin receptors
(Pickles, 1967). In late 1970's Jones claimed that there
were five such receptors (PGD, PGE, PGF, PGI and TxA
receptors) (Horton, 1979). This idea is supported by the
work of Kennedy, Coleman, Humphrey, Levy and Lumley (1982).
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The differentiation of prostanoid receptors is of more than
academic interest, since the number of different types and
their distribution in different tissues will largely
determine the degree of selectivity obtainable with sythetic
compounds that mimic or block the effects of the natural
compounds.
Generally, the approaches used to characterize
receptor-mediated process include the following:
(1) Measuring the rank order of potency of agonists.
(2) Desensitization using high concentrations of agonists.
(3) Use of specific antagonists.
(4) Ligand binding studies.
We have used procedures (1), (2) and (3) to define and
differentiate prostanoid receptors by observing the changes
in mechanical responses in isolated smooth muscle
preparations, and shape change, aggregation and granular
secretion in platelet suspensions.
Part One
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Actions of Prostanoids on Eyes
of Bullock, Dog, Cat, Horse and Rabbit
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Interest in the actions of prostaglandins on the eye stems
from the identification of E- and F-type prostaglandins as
components of lipid extracts (irin) from sheep (Anggard &
Samuelsson, 1964), rabbit and cat (Ambache, Brummer, Rose &
Whiting, 1966) and bullock (Posner, 1970) irides. von Dorp,
Jouvenaz and Struijk (1967) also showed that pig iris could
convert all- cis-8,11,14-ei cosatr ienoic acid into
prostaglandins El and Fla.
Several workers have made pharmacological comparisons of
prostaglandins on isolated iris smooth muscle. The dog and
cat sphincter muscles are of particular interest since PGF2a
produces a contractile effect at very low concentrations and
is much more active than PGE2 and stable TxA2-like agents
such as 11 -9-epoxymethano PGH2 (van Alphen & Angel, 1975;
Coleman, Humphrey, Kennedy, Levy & Lumley, 1981). In
contrast, the bullock iris sphincter is more responsive to
PGE2 than PGF2a (Posner, 1973). We decided to characterize
further the PGE-sensitive system in the bovine iris
sphincter, with a view to comparing it with other smooth




Bullock and horse eyes were enucleated just after slaughter,
placed in ice-cold sugar-salt solution (KC1 0.35. NaCl 6.95,
CaCl2 0.24, MgS04*7H20 0.29, KH2P04 0.16. NaHC03 1.25,
dextrose 1.0, sucrose 17 and EDTA 0.01 g/1) (Crawford, van
Alphen, Cook & Lands, 1978). and used within 12 h. Two
strips of the sphincter muscle, about 10 mm long and 2.5 mm
wide, were dissected from the upper and lower margins of the
bullock iris and from the right and left margins of the
horse iris, respectively. Tension 40-60 mg was chosen for
the bullock iris sphincter and 500 mg for the horse iris
sphincter.
Dog and cat eyes were removed during pentobarbitone
anaesthesia and rabbit eyes were enucleated immediately
after they had been killed. A loop of the sphincter muscle
was dissected by a circular cut 2 mm from the pupillary
margin, and tension 40-60 mg was chosen.
All the preparations were suspended in 10 ml of the bathing
solution containing indomethacin (1 jjM), aerated with 95% 02
and 5% C02 and kept at 37°C. The effect of drugs on muscle
tens ion was measured isometrically with a Grass force
displacement transducer (FT 03C) and recorded on a Grass
Polygraph (Model 7C). Each preparation was allowed 30-60 min
to stabilize.
Prostaglandins were dissolved in 0-9% w/v NaCl solution
(saline) with addition of small amounts of sodium
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bicarbonate when necessary. PGI2 sodium salt (Schering) was
dissolved in 0.05 M Tris HC1, pH 9.0 to give a 1 mg/ml
solution. Serial dilutions of the PGI2 stock solution were




Bullock Iris Sphincter Muscle
Relative Potencies of Prostanoids
As a routine procedure the bathing fluid contained
indomethacin; this ensured a stable basal tension over a
period of at least 5 h. The preparation is sensitive to both
11-9-epoxymethano PGH2, a thromboxane analogue, and PGE2,
each producinga. dose-dependent contraction. A number of
analogues of both TxA2 and PGE2 were tested. Doses were
added cumulatively to the organ bath. Figure E.l illustrates
a typical trace of responses of the bullock iris sphincter
preparation to cumulative doses of a prostanoid. Responses
to most prostanoids reached a steady level after 3-10 min
and were sustained for at least 10 min. Following wash-out
of the organ bath, tension of the muscle gradually returned
to the resting level. The interval between two sequences was
about one hour. The response was taken as the absolute
increase in muscle tension above the resting tension. Log
concentration-response curves were plotted.
PGE2 was used as the standard agonist for PGE2 sensitive
sites and 11.9-epoxymethano PGH2 for TxA2 sensitive sites.
Preparations were reproducibly responsive to PGE2 and
11-9-epoxymethano PGH2. Threshold responses to PGE2 (tension
change of about 20 mg) were seen with concentrations of
0.2-0.4 ng/ml and 50% maximum responses (150-400 mg) with
13
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Figure E.l Bullock iris sphincter muscle: responses to
cumulative doses of 11,9-epoxymethano PGh^. The organ-bath
contained sugar-salt solution with indomethacin 10"® M.
W = Wash.
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1-6 ng/ml. Representative log concentration-response curves
are shown in Figure E.2. Log concentration-effect curves for
all the analogues listed in Table E.l were approximately
parallel to that of PGE2. Equipotent molar ratios (EPMR)
(Table E.l) were derived from the molar concentration of
PGE2 giving a response 50% of its own maximum and the molar
concentration of the test compound producing an equivalent
response.
On eight preparations the 11.9-epoxymethano analogue of PGH2
(U-46619) showed similar contractile potency to PGE2. but
its log concentration-effect curve was always slightly
steeper and its maximum response greater (5-25%). At the 50%
maximum response level for PGE2. 11.9-epoxymethano PGH2 was
1.25 (range 0.50-2.7, n=8) times less active than PGE2.
Addition of PGEl, PGE2 or 11.9-epoxymethano PGH2 to a
preparation partially contracted with carbachol resulted in
a further increase in tension: there was no evidence for a
prostaglandin-mediated relaxant effect on this preparation.
Adrenaline (200 ng/ml) completely inhibited the contractile
action of carbachol.
Partial Agonist Action of ZK 36374
ZK 36374, a compound known to have potent PGI2-Iike activity
was found to be considerably more active than PGI2. In
addition it produced a lower maximum response than either
PGE2 or 11 -9-epoxymethano PGH2 (Figure E.2a). This was
considered of interest and further experiments were
conducted to determine whether ZK 36374 was a partial
15
Table E.l Potencies of prostanoid analogues on the bullock isolated
iris sphincter preparation













































0.16 ± 0.012 (n=4)
0.44 ± 0.078 (n=9)
44 ± 12 (n=6)
135 ± 26 (n=7)
51 ± 13 (n=5)
Individual values are the result of a comparison with PGE2 on a single
preparation. With ICI 81008, the full concentration-response relation¬
ship was not established in two experiments and the corresponding
equipotent molar ratios in parentheses relate to responses at the 20%
maximum response level. PGI^ and PGI2 produced 77 t s.e. 0.39%(n=7)
and 76 ± s.e. 2.8%(n=7) of the maximum response obtained with PGE2,
respec tively.
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Concentration (ng/ml) Concentration (ng/ml)
F igure E . 2 Bullock iris sphincter muscle preparations: cumulative concentration-response relationships for (a) PGE2
(•). 16.16-dimcthyl PGE2 ( A) and ZK 36.174 (■); (b) PGE: (•). 11 .d-epoxvmethano PGH2 ( ♦ ) and PGF2.(T)
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agonist on either the PGE- or TxA-sensitive systems.
On eight preparations the maximum response to ZK 36374
ranged between 33 and 75% (mean=47%) of the maximum obtained
with PGE2. The interaction of ZK 36374 with other agonists,
PGE2, 16,16-dimethyl PGE2, 11,9-epoxymethano PGH2, PGF2a,
PGI2 and carbachol was studied. The procedure involved the
establishment of a cumulative dose-response curve to the
full agonist followed by a second cumulative curve in the
presence of a fixed concentration of ZK 36374 (0.1 or 0.3
jug/ml). Typical results are shown in Figure E.3. The
contractile action of both 11.9-epoxymethano PGH2 and
carbachol was apparently additive with that of ZK 36374.
However, ZK 36374 opposed the contractile action of PGE2,
16.16-dimethyl PGE2, PGF2a and PGI2. This activity of
ZK 36374 is consistent with a partial agonist action at the
PGE-sensitive system.
It is noteworthy that PGI2 sodium salt was dissolved in 0.05
M Tris HC1, pH 9.0. and serial dilutions were made with
saline immediately before use. At first we made a 100 pq/ml
stock solution using the Tris HC1 buffer. The interaction of
PGI2 with ZK 36374 appeared additive. Effects of the solvent
on the response to ZK 36374 were examined. It was shown that
Tris HC1 caused a concentration-dependent potentiation of
the contractile action of ZK 36374 and PGI2, when the final
concentration of Tris HC1 was higher than 0.2 jjM. Therefore,
a 1 mg/ml stock solution of PGI2 was made. The solvent
potentiation effect was attenuated and ZK 36374 opposed the
action of PGI2.
18
o.i 1 10 100 1000 0,01 o.l 1 10 100
Concentration (ng/m!) Concentration (pg/ml)
F igure E . 3 Bullock iris sphincter muscle: interaction of ZK 36374 with (a) PGE2. (b) 16.16-dimcthyI PGE2. (c)
I 1.9-epoxymethano PGH2 and (d) carbachol. In each instance a cumulative concentration-response relationship
was first established to the full agonist alone (solid symbols), followed by a cumulative relationship (open symbols) in
the presence of a fixed concentration of 0.3 Mg/ml ZK 36374 ( ■)
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Estimates of the affinity constant of ZK 36374 were made
using the log concentration-effect curves for PGE2 and
ZK 36374 obtained on the same preparation. It was assumed
that PGE2 had a high efficacy and that for submaximal
responses receptor occupancy was both small and directly
proportional to its concentration. The concentration of PGE2
which gave a response equal to the ZK 36374 maximum response
(100% occupancy by ZK 36374) was found first. The response
which corresponded to half this concentration of PGE2 was
then found and finally the concentration of ZK 36374 which
gave a response identical in size to it was read off (Figure
E-4). The reciprocal of the ZK 36374 concentration
(corresponding to 50% occupancy) was taken as the affinity
constant. From six experiments the mean affinity constant
O
_ "1
was calculated to be 1-03 ( + 0.17 s.e.mean) x 10 M .
Thromboxane-like Analogues
Several compounds with thromboxane-like activity on other
smooth muscle preparations were tested. These were
11/9-epoxymethano PGH2, EP 011, 15-oxo EP 011,
9,11-azo PGH2, 9,11-ethano PGH2, CTA2 and PTA2. Typical
concentration-response curves are shown in Figure E.5.
EP 011, 15-oxo EP 011, CTA2 and PTA2 were slow both in
on-set and off-set on the bullock iris sphincter
preparation. Table E.2 summarizes the relative potencies of
these agents on the preparation. 11,9-Epoxymethano PGH2 was
taken as the standard agonist. For a full agonist equipotent
molar ratios were determined by calculating the quotient





concentration (M ) (log scale)
Figure E. 4 Schematic diagram: calculation of the affinity constant for a
partial agonist.
y = molar concentration of the full agonist producing a response
equal to the maximum response inducible by the partial agonist
[(1) + (2)] i.e. response induced by the partial agonist when
occupying 100% of the receptors.
0.5 y = molar concentration of the full agonist producing the response
[(3) (4)] resulting from the occupation of 50% of the
receptors occupied by concentration y.
x = molar concentration of the partial agonist producing a response
equal to that induced [(5)] by 0.5 y and is thus the concentration
of the partial agonist required for occupation of 50% of the
total population of the receptors.
The affinity constant of the partial agonist will thus be given by — .
Concentration (ng/ml)
igure E.5 Bullock iris sphincter muscle log
concentration-response curves for 1 1.9-epo.\ymethano
PGH2 (♦). EP01 1 (A), and 9. 1 1-cthano PGH: (•).
Tab !<• t. 2 Kclative put.niu'ic.s <>) thromboxane ana 1 ©gues on the bullock
isolated iris sphincter preparation
Substance Equipotent molar ratio
(Standard agonist 11,9 epoxymethano PGH^ = 1
Individual value mean - s.e.
(±) ep Oil 0.010 0.013 0.020 0.033 ± 0.0074
0.020 0.030 0.044 n = 9
0.057 0.060 0.070
(±) 15 oxo ep Oil 0.027 0.030 0.039 0.034 ± 0.0032
0.040 n = 4
9,11-azo pgh2 0.39 0.62 0.96 0.74 ± 0.15
1.00 n = 4
cta2 0.50 0.54 1.28 0.77 ± 0.25 n=3
(±) 9,11 ethano pgh2 50% 66% 70% p.a. 66 ± 6%
79%




(±) ICI 79939 pgf„
2a
0.81
Individual values are the result of a comparison with 11,9-epoxy-
methano pgh2 on a single preparation. With partial agonists on
TxA2~sensitive sites, values of the relative maximum response
(11,9-epoxymethano PGH2=100%) together with the concentration of
the partial agonist required to produce a response 50% of its own
maximum are given.
giving half of its own maximum response and the molar
concentration of the test compound producing an equivalent
response- For a partial agonist the maximum response
relative to that of 11.9-epoxymethano PGH2 is given together
with the concentration which produced a response 50% of the
partial agonist maximum. EP 011 and 15-oxo EP 011 are the
most potent contractile agents. The threshold concentration
for EP 011 is about 40 pg/ml.
There is some difficulty in establishing the absolute
maximum response using a cumulative dose regime when the
on-set of an agonist is slow. We particularly wished to know
whether CTA2 is a full agonist or not, so a single high
concentration of CTA2 (1 jjg/ml) was added to the organ bath,
which showed that CTA2 reached the same maximum as
11,9-epoxymethano PGH2 did. The 9,11-ethano PGH2 analogue
and PTA2 were less active than 11,9-epoxymethano PGH2 and
gave a lower maximum response than EP 011 or
11.9-epoxymethano PGH2 maxima (see Figure E.5). They opposed
the contractile action of 11.9-epoxymethano PGH2, but their
contractile actions were additive with that of PGE2.
Effects of the Thromboxane Antagonists EP 045 and EP 116
In a series of experiments the effects of EP 045 and EP 116
on the contractile action of several of the analogues was
determined.
It was considered essential to run control tissues
simultaneously to ensure that there was little change in
agonist sensitivity with time on the bullock iris sphincter
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preparation. On control preparations three cumulative
concentration-response relationships for PGE2 or
11.9-epoxymethano PGH2 were established at approximately
hourly intervals. In the antagonist-treated preparations
EP 045 at 1.3 _pM or EP 116 at 0.034 was added 5-10 min
before the start of the second agonist sequence and further
increased to 2.6 jiM for EP 045 or 0 . 068 jjM for EP 116 5-10
min before the start of the third sequence. These
antagonists caused a pronounced parallel shift to the right
of the 11 -9-epoxymethano PGH2 log concentration-response
curve (Figure E.6). Dose-ratios are shown in Table E.3.
From the Schild equation are obtained affinity constants of
6.9 (s.e.mean + 0.9) x 106 and 7.5 ( + 0.7) x 106 M-1,
respectively for the lower and higher concentrations of
EP 045. and affinity constants of 7.60 ( + 1.05 ) x 10® and
8.05 ( + 0 .94 ) x 10® M-"*", respectively for the lower and
higher concentrations of EP 116. EP 045 or EP 116 caused
much smaller shifts of the PGE2 concentration-response
curves (see Table E.3). More determinations would be
required to determine whether this small degree of
antagonism is significant. The agonist actions of ZK 36374
and PGI2 were not blocked by EP 045, and EP 045 and EP 116
had little effect on PGF2a and ICI 79939 PGF2a.
With 16•16-dimethyl PGE2 the situation is more complex. The
log concentration-response curve for 16,16-dimethyl PGE2
over the concentration range of 0.1-20 ng/ml was parallel to
that of PGE2 (see Figure E.2). and remained constant during
the experiment. Under these circumstances EP 045 (1.3 pM)
400 -
300-
01 1 10 100 1000
Concentration (ng/ml)
igure E.6 Bullock iris sphincter muscle: log
concentration-response curves for 1 1,9-cpoxymethano
PGH2 alone (•) and in the presence of 0.5 (O) and 1.0
( A) ng/ml EP 045.
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Table E.3 Effects of EF 04b or EP 116 on contractile response to
different agonists on the bullock iris sphincter
Treat- Agonist No. Dose-ratios for agonist cumula-




+ 0.16 0.96 + 0.18
16,16-dimethyl PGE 1 .39 1.50
Control
C.
pgi2 1.00 1.10 1.56
11,9-epoxymethano PGH2 4 1.06 + 0.07 1.27
+ 0.13
pge2 3 1.16 + 0.03 1.63
+ 0.13
16,16-dimethyl PGE2 5 1.72 + 0.15 3.2
PGI 1.47
EP 045
11,9-epoxymethano PGH2 4 10.0
+ 1.20 20. 5 + 1.80





EP 116 11,9-epoxymethano PGH2 4 27.0 + 3. 50 56.0
+ 6.30
(1 )ICI 79939 PGF„
2a
2.60
With the antagonist -treated preparations the second agonist sequence was
—6 Q
established in the presence of 1.3 x 10 M EP 045 or 3.4 x 10 M EP 116
—6 _q
and the third sequence in the presence of 2.6 x 10 M EP 045 or 6.8 x 10
M EP 116.
* indicates that a dose-ratio was obtained in the presence of 1.1 x 10 ® M
EP 116.
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produced only a small shift of the 16,16-dimethyl PGE2 curve
(see Table E.3). At higher concentrations of
16,16-dimethyl PGE2 f 0 .1-2.0 pg/ml) further small
contractions could be elicited which eventually approached
the 11.9-epoxymethano PGH2 maximum (Figure E.7). However, in
this situation some tachyphylaxis to the contractile action
of 16,16-dimethyl PGE2 occurred, such that subsequent
concentration-response curves were shifted to the right,
with slight lowering of the maximum response (Figure E.7b).
This made any effect of EP 045 on the high concentration
component of 16,16-dimethyl PGE2 action difficult to
determine (Figure E.7a).
As to EP 011 and 15-oxo EP 011, when a complete cumulative
log concentration-response relationship has been obtained on
a preparation, the response returned slowly to baseline over
a period of at least 3 hours during repeated wash-out of the
organ bath. Re-testing of the standard agonist showed that
there was some loss of sensitivity. Therefore, with these
compounds, estimates of their relative contractile
activities in the presence and absence of EP 116 were made
using the log concentration-response curves for
11,9-epoxymethano PGH2 and EP 011 or 15-oxo EP 011 on two
preparations: one was treated with 11,9-epoxymethano PGH2
and then with either EP 011 or 15-oxo EP 01.1 to establish
their cumulative dose-response relationships; on the other
preparation the procedure was to set up cumulative
concentration-response relationships for both PGE2 and
11,9-epoxymethano PGH2, wash out the agonists, expose the
tissue to a fixed concentration of EP 116 for 10-20 min and
01 I 10 100 1000 01 1 10 100 1000
Concentration (ng/ml) Concentration (ng/ml)
Figure E . 7 Bullock iris sphincter muscle: (a) Preparation A—log concentration-response curve for 16.16-dimethyl
PGE2 (A) showing distinctly the two components of the curve. Preparation B—concentration-response relation¬
ships for 16,16-dimethyl PGE2 in the absence (•) and the presence (O) of EP045 (0.5pg/ml). (b) Preparation
C—control tissue on which two consecutive cumulative concentration-response relationships for 16.16-dimethyl
PGE; were established (■.□).
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then set up a further dose-response relationship for either
EP 011 or 15-oxo EP 011. 11.9-epoxymethano PGH2 was taken as
a standard agonist, dose ratios for EP 011 or 15-oxo EP 011
with and without the antagonist were worked out by the
following formula:
EC50 EP Agonist with EP 116 EC50 11,9-EM PGH2
Dose Ration X
EC50 11.9-EM PGH2 EC50 EP Agonist
Here EP Agonist indicates EP 011 or 15-oxo EP 011 and
11.9-EM PGH2 indicates 11.9-epoxymethano PGH2.
In the absence of EP 116? EP 011 and 15-oxo EP 011 were very
active and of equal potency. and both of them had a
consistent relationship with 11,9-epoxymethano PGH2 (see
Table E.2). The equipotent molar ratios between
11,9-epoxymethano PGH2 alone and the combination of EP 011
or 15-oxo EP 011 with 1.1 ^pM EP 116 varied to a large
extent. This was 1.2-15 for EP 011 and 5.4-33 for
15-oxo EP 011. Hence the calculated dose ratios of EP 011 or
15-oxo EP 011 with and without EP 116 covered a large range:
36-460 for EP 011 and 160-970 for 15-oxo EP 011. However,
concentration-response curves for EP 011 or 15-oxo EP 011 in
the presence of 1.1 piM EP 116 had a relatively consistent
relationship with that of PGE2. Using PGE2 as a standard
agonist, the dose ratios were 14, 19, 25 for
EP 011 with EP 116 present and 63, 88, 100 for 15-oxo EP 011
with EP 116 present. EP 116 at the concentration of 1.1 pM
caused little shift of the PGE2 concentration-response
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curve (see Table E.3).
Effects of ICI 79939 PGF2a, ICI 799339 PGE2 and M/B 28767
ICI 79939 PGF2af a PGF2a analogue, is very active on the
bullock iris sphincter preparation. The equipotent molar
ratio for ICI 79939 PGF2a is 0.77 (PGE2=1.0) and 0.81
(11,9-epoxymethano PGH2=1.0). EP 116 (1.1 pM) caused a small
shift to the right of the ICI 79939 PGF2a log
concentration-response curve (dose ratio=2.6). And adding
EP 045 (2.6 /iM) against the background of a contractile
response being produced with M/B 28767 brought about a
marked fall of the response. Thus the experiment for
measuring EPMR of ICI 79939 PGF2a? ICI 79939 PGE2 and
M/B 28767 were carried out in the presence of a fixed
concentration of either EP 045 or EP 116 in order to block
TxA2 activity of these compounds. Equipotent molar ratios
are shown in Table E.4. PGE2 in the presence of either
EP 045 or EP 116 was used as the standard. Log
concentration-effect curves for ICI 79939 PGF2a and
ICI 79939 PGE2 were parallel to that of PGE2 (Figure E.8)
while the log concentration-effect curve of M/B 28767 took
on a flat shape: its threshold concentration was less than 1
response'
ng/ml; its maximum^concentration was more than 1 /ig/ml and
its curve reached a higher maximum than PGE2 (Figure E.9).
Effects of Indomethacin
In the absence of indomethacin, the tone of the bullock iris
sphincter preparation remained stable for at least 1 h.
After challenge with prostanoids, in particular with PGE2
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Table I-:.4 Activities of LCI 79939 PGF2el.lCl 79939 PGEg. and M/B 28767








in the presence of EP 045
or EP 116)
(+) ICI 79939 PGF2a















.1 1 10 100 1000
Concentration ng/ml
Fig. E.8 Bullock iris sphincter muscle: Log concentration-response curve for PGE., (•).
ICI 79939 PGE (A) and ICI 79939 PGF„ (■ ) in the presence EP 045 (1 ug/mi).d do '
33
Fig. E.9 Bullock iris sphincter muscle: Log concentration-response curve for PGE2 ( * ) and
M/B 28767 ( • ) in the presence of EP 045 (1 pg/ml) and indomethacin (10 ^ M).
34
and using Krebs solution as a bath solution, the basal tone
would increase gradually. Atropine or phentolamine failed to
depress the rise in tone. Indomethacin (1 pM) lowered the
tone and this remained constant throughout the remainder of
the experiment. In order to find out whether indomethacin
affects responses to PGs? the contractions produced by some
prostanoids were measured both in the absence and presence
of indomethacin. The results are shown in Table E.5. The
first sequence was in the absence of indomethacin. Following
wash-out the tissue was exposed to a fixed concentration of
indomethacin for 20 min, then a further dose-response
relationship for agonists was established. Following the
same procedure, the third and fourth sequences were
established.
Effects of EP 045 and EP 116 on the spontaneously increased
tone were also investigated. EP 045 (1.3-5.2 pM) inhibited
the tone dose-dependently; on the other hand EP 116 2.2 pM
had little effect on the tone.
Effects of TxA2 and PGH2
Effects of synthetic PGH2 and TxA2 generated enzymatically
from synthetic PGH2 were studied using the cascade
technique. Pairs of the bullock iris sphincter preparation
arranged in series^ were challenged with TxA2 and PGH2. For
the generation of TxA2 a given amount of PGH2 in Krebs
solution was mixed with a suspension of horse platelet
microsomes (HPM)5 a rich source of the enzyme thromboxane
synthetase (Moncada, Needleman, Bunting & Vane, 1976), and
incubated for 30 s at 0°C. GC/MS analysis, using authentic
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Table E.5 Effect of indomethacin on contractile responses to different
agonists on the bullock iris sphincter preparation
c r j 4-u • Dose-ratios for cumulativeAgon,st Sequence Indomethacn
sequences (first seqUence=1.0
in the absence of indomethacin)
11,9-epoxymethano
PGH2 second 2X10"5 0.76 1.3
third 4X10"6 0.70 1.0
fourth 10"5 0.90 1.0
PGE2 second 10"^ 1.4
third 5X10-6 2.4
16,16-dimethyl




TxB2 as an external standard, showed that during the 30 s
incubation period about 60% of the PGH2 had been converted
to TxA2 (Armstrongj Jones & Wilson, 1983). The assay tissues
were treated with a mixture of blocking agents to reduce or
abolish the actions of acetylcholine, histamine,
5-hydroxytryptamine (5-HT) and catecholamines. Indomethacin
(3 jiM) was also added to prevent thromboxane and
prostaglandin production in the assay tissues themselves.
Before PGH2 and TxA2 were superfused into the cascade
system, dose-response relationships for both
11,9-epoxymethano PGH2 and PGE2 were established. Submaximum
doses of 11.9-epoxymethano PGH2 (150 ng) and PGE2 (100 ng),
superfused for 30 s (flow rate=10 ml/min), were chosen.
In order to antagonize PGE2 activity, ZK 36374, a partial
agonist on PGE2 receptor sites, was superfused continuously
at a final concentration of 250-500 ng/ml. ZK 36374 gave a
submaximum contraction and blocked the effect of PGE2 but
not 11.9-epoxymethano PGH2.
Sufficient generated TxA2 was superfused onto the
preparations to give a response which matched that produced
by the above dose of 11.9-epoxymethano PGH2.
The further identification of the generated component as
TxA2 was based on the known short half-life of TxA2 in
aqueous solution at pH 7.6 and room temperature (22°C).
Allowing the generated TxA2 to stand at room temperature for









Figure E. 10-11 Bullock iris sphincter preparations:
Effects of PGH2 and generated TxA2. The records show tension changes
in two bullock iris sphincter preparations superfused in series.
ZK 36374 (500 ng/ml) was applied to both preparations and EP 045
(1 jug/ml) to the second preparation in the cascade (lower record)
(flow rate = 10 ml/min). A given concentration of PGH2 was chosen,
and mixed with HPM to generate TxA2. Generated TxA2 and PGH2 were
left at room temperature for 45 s and 60 s, respectively, to decay.
HPM , see P 34.
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Treatment of the second tissue in the cascade with EP 045
(final concentration (2.6 jiM) inhibited responses to the
generated TxA2, PGH2 and the 11,9-epoxymethano PGH2
analogue. Typical experiments are shown in Figure E.10-11.
The generated TxA2 produced a stronger effect than the original
amount of PGH2 (see Figure E.10-11).
Dog and Cat icis Sphincksj Massls
A limited number of dog and cat iris sphincter preparations
were available for testing of the prostanoids. PGF2a was a
potent contractile agent on both preparations. Responses to
PGF2a reached a plateau after 2-10 min and then gradually
declined. ICI 81008, ICI 79939 PGF2a. ICI 79939 PGE2.
ICI 80205 and EP 011 had relatively slow on-sets of action.
PGF2a produced a 50% maximum response at concentrations of
0.3-1.5 ng/ml on the dog iris sphincter muscle and 2.9-5.3
ng/ml on the cat iris sphincter muscle. Table E.6 summarizes
the relative activities of the prostanoids tested. All the
compounds in the table showed contractile activity. There
was no evidence for a prostaglandin-induced inhibitory
effect on either of these preparations. ICI 81008 gave the
same maximum as PGF2a did both in the dog and in the cat
iris sphincter preparation^ and showed the highest activity
of all the compounds tested. ICI 79939 PGF2a was about twice
as potent as PGF2a on the dog preparation.
ZK 36374 and PGI2 were very weak contractile agents. The
actions of ZK 36374 and PGF2a were additive as shown in
39

























(120) (>100) (1200) 900 (490)
0.19 0.19 0.19 0.19 (0.1910.00,n=4)*
60 137 230
530 530 (>1000)
40 40 45 45 46 54 (45+2.1, n=6)*
81 105 122 124 144 (115+11, n=5)*





2.4 3.1 3.1 (2.9+0.22, n=3)*
(100)
Individual values are the result of a comparison with PGF2a on a single preparation.
Values in parentheses are derived from experiments in which a complete concentration-
response curve for the test compound was not established, equipotent molar ratios
relate to responses 20% of the pgf2amaximum.






0.1 1000I 10 100
Concentration (ng/ml)
igure E.12 Dog iris sphincter preparation: log
concentration-response curve for PGF2„ acting alone
( ♦ ) and the corresponding curve (O ) in the presence of
0.3 pg/ml ZK 36374 ( ■).
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Fiqure E.12.
Some PGE2 analogues were also tested. Of particular interest
is the low activity of 16,16-dimethyl PGE2 on both
preparations, and the high potency of ICI 80205 and
ICI 79939 PGE2.
On five preparations EP 045 at 500 ng/ml (1.3 ^M), on four
preparations EP 092 at 1.0 ug/ml (2.4 ^iM) , and on two
preparations EP 116 at 500 ng/ml (1-1 ,pM) produced only
small shifts of the PGF2a log concentration-response curve
(Table E.7).
11,9-epoxymethano PGH2 had weak activity. Its full
concentration-response curve was not established. EP 045 did
not block the effect of 11.9-epoxymethano PGH2 on the dog
iris sphincter preparation.
Other TxA2 Analogues
Six compounds with TxA2-like activity were tested. They were
9,11-azo PGH2, 9,11-ethano PGH2, 15-oxo EP 011. 15 k EP 130,
15 |3 EP 130 , 15-oxo EP 130 and PTA2. All the compounds
except PTA2 showed a contractile effect. The effect of
EP 116 was tested on 9,11-ethano PGH2 and 15-oxo EP 011.
EP 116 at concentration of 500 ng/ml did not block their
contractile effects. 9,11-Azo PGH2, 9,11-ethano PGH2,
15-oxo EP 011, 15-oxo EP 130, 15 K EP 130 and 15 p EP 130
were agents which displayed slow on-sets and gave a maximum
contractile response lower than that produced by PGF2a.
Their values of the relative maximum response (PGF2a=100%)
together with their EC50 values (concentrations required to
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Table E.7 Effects of EP 045 and EP 115 on contractile responses to PGF2a
and 11,9-epoxymethano PGHp on the dog iris sphincter preparation
Number Dose-ratios for agonist cumulative
Treatment Agonist of test sequences (first sequence^!.0)
Second
Control PGF2a 5 1.0 1.0 1.2 1.4 1.8 (1.3*0.15)
EP 045 PGF2a 5 1.4 1.5 1.8 1.8 2.8 (1.9±0.25)
EP 045 11,9-epoxymethano
PGH2 2 1.0 1.3
EP 116 PGF2a 2 0.86 1.6
EP 092 PGF2a 4 1.4 1.4 1.6 1.7 (1.5+0.075)
The first sequence was in the absence of TxA2 receptor antagonists. With
TxA2 receptor antagonist-treated preparations the second agonist sequence
was established in the presence of 1.3X10-6 m pp 045, 1.1.X10"6 M EP 116
or 2.4X10-6 M EP 092.
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produce a response 50% of its own maximum) are shown in
Table E.8. In terms of EC50, 15-oxo EP 011 is the most
potent among the compounds above, and PTA2 in concentrations
of up to 200 ng/ml showed no contractile activity.
15 tx EP 130 was more active than 15 |3 EP 130. 9,11-Azo PGH2
produced a much lower maximum response relative to that of
PGF2a.
Activities of those compounds against PGF2a were also
examined, by adding cumulative doses of PGF2a to the organ
bath in the presence of a fixed concentration of one of the
compounds. PTA2 at 1 jig/ml did not affect the response to
PGF2a. 9,11-Azo PGH2 and 9.11-ethano PGH2 showed additive
interactions with PGF2a. In contrast 15-oxo EP 011, 15 k EP
130, 15 p EP 130 and 15-oxo EP 130 opposed the effect of
PGF2a (Figure E.13). In most cases, PGF2a in the presence of
one of the above four compounds failed to reach the maximum
response obtained with PGF2a alone.
The responses to 15-oxo EP 011 was intensively studied since
it was the most active compound. With low concentrations of
PGF2a (<2 ng/ml) and 15-oxo EP 011 (<50 ng/ml) responses
remained stable for 10-20 min after the responses reached
their plateau. However, responses to higher concentrations
of PGF2a or 15-oxo EP 011 faded (Figure E.14). Falling rates
of responses to PGF2a and 15-oxo EP 011 are listed in Table
E.9. The fall occurred 4-6 min after the response to
15-oxo EP 011 (100 ng/ml) had peaked and 0.5-1 min after the
response to PGF2a (>5 ng/ml) reached its peak. Higher
concentrations caused a more rapid fall of the response.
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Table E.8 Activities of TxA2 analogues on isolated dog iris sphincter
preparations.
Compound
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Figure E.13 Dog iris sphincter muscle: interaction of 15-oxo EP Oil
with PGF2a- A cumulative concentration-response relationship was
first established to the PGF2« (solid circle), followed by a cumula¬
tive relationship to the PGF2a (solid square) in the presence of a






Figure E.14 Dog iris sphincter preparations:
spontaneous fading of responses to PGF2a (upper trace)
and 15-oxo EP Oil (lower trace). W = wash.
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Table E.9 Falling rates of responses to PGF2a and 15-oxo EP Oil on the
dog iris sphincter preparation.








8.1 9.0 9.0 10 11 20
The falling rate was measured by finding the point where the response
began to fall, counting the fall (mg) within a certain time and dividing
the fall by the time (min).
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Figure E.15a and 15b shows that prolonged treatment of the
preparation with PGF2a or 15-oxo EP 011 resulted in loss of
sensitivity to PGF2a. The sensitivity after treatment with
PGF2a 20 ng/ml for 20 min was restored within 2 hours, but
the recovery of sensitivity in 15-oxo EP 011-treated
preparations took a much longer time.
The interaction of 15-oxo EP 011 with carbachol was also
studied and the contractile action of carbachol was
obviously additive with that of 15-oxo EP 011.
Horse Iris Sphincter Muscle
PGF2a Analogues
PGF2a showed contractile activity on the horse iris
sphincter preparations similar to that found on the dog and
cat iris sphincter muscle. Responses to PGF2a peaked at 2-4
min and then declined slowly. The falling rate was 0.5-2.0
mg/min. and increasing the concentration of PGF2a did not
accelerate the fall of response.
PGF2a elicited a 50% maximum response at a mean bath
concentration of 7.5 + s.e.0.84 ng/ml (n=3 8). The threshold
concentration which gave tension change of about 20 mg was
0-87 + s.e.0.15 ng/ml (n=38). The relative activities of
several other prostanoid analogues are shown in Table E.10.
ICI 81008 and ICI 79939 PGF2a exhibited relatively slow
on-sets of action and peaked at 6-10 min. EP 116 (1-1 juM)














Figure E.15a Dog iris sphincter muscle: desensitization
to PGF2a- Three consecutive sequences of cumulative con¬
centration-response relationship for PGF2a were established
on a single preparation. The second (2) and third (3) sequences
were commenced 10 min and 2 h, respectively, after exposure to
20 ng/ml PGF2a for 20 min, and the first (1) was prior to the
treatment. The preparation picked up sensitivity to PGF;?Q




Figure E.15b Dog iris sphincter muscle: desensitization by
15-oxo EP Oil. Three consecutive sequences of cumulative
concentration-response relationship for PGF2a were establi¬
shed on a single preparation. The first sequence (1) was prior
to 15-oxo EP Oil treatment, and the second (2) and third (3)
commenced 1.5 and 2 h, respectively, after exposure to
15-oxo EP Oil lOOng/ml for 20 min.
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Table E.10 Activities of prostanoid analogues on the horse iris
sphincter preparation.
Compound Equipotent molar ratio










0.14 0.18 0.19 0.25





























Individual values are the result of a comparison with PGF2a or PGE2 on
a single preparation. Values in parentheses are derived from experi¬
ments in which a complete concentration-response curve for the test
compound was not established; equipotent molar ratios related to
responses 20% of the PGF2a maximum.
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dose-response curve (dose ratio=1.6). ICI 81008 was 3-5
times more potent than PGF2a. as seen in the dog and cat
iris sphincter preparations. but gave a slightly lower
maximum response than that produced by PGF2a. In contrast,
ICI 79939 PGF2a? the most active compound among the drugs
tested, produced a maximum contractile response higher than
that obtained with PGF2a (mean=139%, range 120-180%. n=4)
(Figure E.16). There was no evidence that PGF2a produced a
relaxant effect.
PGE2 and PGI2 Analogues
The preparation possessed intrinsic tone (1.0 g), which
indomethacin 1 could not completely abolish. In the
presence of indomethacin 1 pM the preparation provided a
tone equivalent to 100-500 mg.
The PGE2 and PGI2 analogues showed different properties from
PGF2a on the horse iris sphincter preparation. On 18 out of
22 preparations^ PGE2 produced a relaxant response at
concentrations of 0.5-10 ng/ml; at higher concentration of
PGE2, a reversal of the relaxant action was seen (Figure
E.17). The extent of the PGE2-induced relaxant effect was
not obviously related to the amount of intrinsic tone
present. Since PGE2 produced dual effects the equipotent
molar ratio relative to PGF2a could not be measured. From an
experiment with PGF2a and PGE2 on a single preparation which
did not markedly relax to PGE2 it was found that the
contractile activity of PGE2 was 10-20 times less than that
of PGF2a(Figure E.18a). Of interest is the activity of
16,16-dimethyl PGE2. It produced a maximum contractile
1-0 10 100 1000
Concentration (ng/ml)
Figure E.16 Horse iris muscle preparation: cumulative concen-
PGFod
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Figure E.17 Horse iris sphincter preparation: cumulative
concentration-response relationship for PGE2-
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Concentration (ng/ml)
Figure E.18a Horse iris sphincter muscle preparation:
cumulative concentration-response relationship for PGF2a
(open circle) and PGE2 (solid circle).
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response much lower than that obtained with PGF2a (range
10-30%) (Figure E.18b) and PGE2. EC50 for
16.16-dimethyl PGE2 was 4.1 ng/ml (range 2.0-7.2. n=6).
As expected, ICI 80205 was fairly active on the preparation.
Its log dose-response curve was steeper than that of PGF2a,
and its maximum response was higher than that of PGF2a.
PGEl had more potent relaxant effect than PGE2 on the horse
iris sphincter preparation (see Table E.10). For the
contractile effect PGEl was less active than PGE2. Against
the background of PGE1(2.7 ng/ml)-induced maximum
relaxation, PGE2 did not produce any further relaxation and
at concentrations higher than 10 ng/ml it elicited a
contractile effect.
Both ZK 36374 and PGI2 produced relaxant responses at
concentrations of 10-500 ng/ml and at higher concentrations
of both ZK 36374 and PGI2 showed contractile activities.
When PGE2 was added at a concentration which produced its
own maximum relaxant effect. addition of ZK 36374 caused
only a contractile effect (Figure E.19), and vice versa.
Interaction between PGE2 and PGF2a Analogues
The interactions between PGF2a and PGE2 analogues were
investigated. In the presence of a fixed concentration of
16,16-dimethyl PGE2 which produced its own maximum
contractile response, PGF2a caused further contraction, and
vice versa (Figure E.20a and 20b). PGE2 also showed additive
effects with PGF2a and ICI 81008 (Figure E.21a and 21b),
while in the presence of a fixed concentration of
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Concentration (ng/ml)
Figure E.18b Horse iris sphincter muscle preparation:
cumulative concentration-response relationships for




Figure E.19 Horse iris sphincter preparation: log concentration-
response curve for ZK 36374 acting alone (open circle) and log
concentration response curve for ZK 36374 (solid circle ) in the
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Figure E.20a Horse iris sphincter preparation: interac¬
tion of 16,16-dimethyl PGE2 with PGFga ; log concentra¬
tion-response curve for PGF2a acting alone (open circle)
and the corresponding curve (solid circle) in the pre¬


















Figure E.20b Horse iris sphincter muscle: interaction of
PGF2a with 16,16-dimethyl PGE2. Log concentration-response
curve for 16,16-dimethyl PGE2 alone (open circle) and the
corresponding curve (solid circle) in the presence of 76










Figure E.21 a Horse iris sphincter muscle: interaction of
PGF^a with PGE2; log concentration-response curve for PGF2a
acting alone (open circle) and the curve for PGE^ (solid
circle) in the presence of PGF2a 230 ng/ml. It shows the
additive interaction of PGE2 with PGF2a.
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Concentration (ng/ml)
Figure E.21b Horse iris sphincter muscle: interaction of ICI 81008
with P6E2; log concentration-response curve for PGE2 acting alone
(open circle) and the corresponding curve (solid circle) in the
presence of 220 ng/ml ICI 81008 (solid square).
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ICI 79939 PGF2a which produced a maximum response, PGE2
caused no further contraction.
Reversal of PGE2 Relaxant Effect by Other Prostanoids
As mentioned before, PGE2 possesses relaxant activity at low
concentrations on the horse iris sphincter preparation. An
initial effort was made to raise the basal tone with other
contractile agents in order to study the PGE2 relaxant
effect in detail. Interestingly, the inhibitory effect of
PGE2 was reversed with increasing concentrations of the
contractile agents. Addition of a small dose (less than 10
ng/ml) of PGE2 to the organ bath following establishment of
a maximum response to PGF2a, a 60% maximum response to
carbachol or 25 ng/ml 15-oxo EP 011 caused a dose-dependent
contraction. One of these results are shown in Figure E.22).
Adrenaline produced an inhibitory effect on this
preparation. 15-oxo EP 011 (100 ng/ml) caused a shift to the
right of the dose-response curve of adrenaline.
TxA2-mimet ics
15-0xo EP 011, 15 oc EP 130, 15 p EP 130, 9,11-azo PGH2 and
11,9-epoxymethano PGH2 were also tested on the horse iris
sphincter preparation. All of them caused contractile effect
and displayed slow on-set. Responses to 15-oxo EP 011
varied from preparation to preparation. 15-0xo EP 011 at a
fixed concentration (150 ng/ml) produced responses 13-70% of
PGF2a maximum. In 2 out of 14 preparations 15-oxo EP 011 at
150 ng/ml reached its .own maximum, which was 13 and 33% of











Figure E.22 Horse iris sphincter preparation: reversal of P6E2
relaxant effect by 15-oxo EP 011; log concentration-response curve
for PGE2 alone (open circle) and the corresponding curve for PGE£
(solid circle) in the presence of 25 ng/ml 15-oxo EP 011 (solid
square).
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gave a response less than 40% of PGF2a maximum,
15-oxo EP 011 opposed the contractile action of PGF2a
(Fiqure E.23a) while in the cases where 15-oxo EP 011 at 300
ng/ml caused a response more than 60% of PGF2a maximum the
interaction of 15-oxo EP 011 with PGF2a appeared to be
additive (Figure E.23b), but after wash-out re-establishment
of PGF2a dose-response relationship revealed that
sensitivity to PGF2a of the preparation was markedly reduced
(Figure E.24) .
15 « EP 130 was more potent than 15 ft EP 130. 15 k EP 130 at
500 ng/ml which gave responses 50-70% of PGF2a maximum and
15 (3 EP 130 at 2-5 jig/ml which gave responses 10-35% of
PGF2a maximum opposed the contractile effect of PGF2a
(Figure E.25a and 25b). There was loss of sensitivity to
PGF2a after treatment with those two compounds (Figure
E.26 ) .
11,9-Epoxymethano PGH2 and 9,11-azo PGH2 were very weak
contractile agents on the horse iris sphincter muscle
preparation (see Table E.10,P5l).
Rabbit Iris Sphincter Mustle
PGI2 was a potent contractile agent on the rabbit iris
sphincter muscle. Responsesto PGI2 reached a plateau after
2-4 min contact. The sensitivity of this preparation to
PGI2 showed considerable variation; the lower and upper
threshold concentrations which gave tension change of about
20 mg were 5 and 200 ng/ml, respectively. Individual values
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Concentration (ng/ml)
Figure E.23a Horse iris sphincter preparation: interaction of
15-oxo EP Oil with PGF^; log concentration-response curve for
PGF^a acting alone (open circle) and the corresponding curve
(solid circle) in the presence of 150 ng/ml 15-oxo EP Oil (so¬
lid square).
Concentration (ng/ml)
Figure E.23b Horse iris sphincter preparation: interaction of
15-oxo EP Oil with PGF2a. Log concentration-response curve for
PGF^ acting alone (open circle) and the corresponding curve





Figure E.24 Horse iris sphincter: desensitization by 15-oxo
EP Oil. Two cumulative concentration-response relationships for
PGF2a were established. The first sequence (1) was prior to 15-
oxo EP Oil treatment, and the second (2) was after exposure to
15-oxo EP Oil 150 ng/ml for 20 min and wash-out.
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Concentration (ng/ml)
Figure E.25a Horse iris sphincter preparation: log concentration-
response curve for PGF2a acting alone (open circle) and the
corresponding curve (solid circle) in the presence of 500 ng/ml
15a EP 130 (solid square).
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Concentration (ng/ml)
Figure E.25b Horse iris sphincter preparation: log concentration-
response curve for PGF2a acting alone (open circle) and the cor¬











Figure E.26 Horse iris sphincter preparation: desensitization
by 15a EP 130. Two sequences of cumulative concentration-
response relationship were established to PGF2a in a single
preparation. The first sequence (open circle) was set up before
15a EP 130 treatment, and the second (solid circle) was set up
after exposure to 15a EP 130 500 ng/ml for 40 min. and wash-out.
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the
of^threshold concentrationwere 5.0, 7.0, 10, 12. 13, 14, 16,
ng/ml.
16, 20, 20, 307 34. 40, 200^ EC50 values lay between 20-600ng/
ml (individual values of EC50 : 20 , 36, 45, 45, 59, 60, 7 5,
85, 120, 150, 260, 400, 410, 600). ZK 36374, a PGI2
analogue, also showed contractile activity. The equipotent
molar ratio for ZK 36374 (PGI2=1.0) was 1.1 ± s.e.0.18, n=6
(individual values of EPMR: 0.59, 0.74, 0.94. 1.1, 1.6,
1.7). High concentrations of PGI2 were found to desensitise
the preparation. However. the sensitivity to PGI2 was
restored within 30 min of wash-out. After ZK 36374
treatment, it took a much longer time for the tissue to
recover, so a cumulative concentration-response relationship
for PGI2 was always established first on each preparation.
PGE2 produced a relaxant effect on this preparation. The
basal tone of the preparation was, however, so low that the
PGE2 relaxant effect could not be easily studied. PGI2,
ZK 36374 and carbachol were therefore used to provide tone.
The EC50 for the PGE2 relaxant effect was 5-1000 ng/ml. In
the same preparation it did not make any difference tothePGE2
response whether PGI2, ZK 36374 or carbachol was used to
provide the tone, PGE2 at concentrations up to 2 ^g/ml
showed no contractile activity.
PGEl at low concentrations produced a small relaxant effect.
As concentrations of PGEl increased, a contractile effect
was seen. PGEl gave a maximum contractile response lower
than that obtained with PGI2 (Figure E.27). On six
preparations the values was 13, 30, 35, 56, 57 and 63% of





Figure E.27 Rabbit iris sphincter preparation: log concentration-
response curves for PGI2 (open circle) and PGE1 (solid circle).
effect were 50, 75, 140, 400, 500 and 1000 ng/ml.
The interaction of PGEl and PGE2 with PGI2 was also studied,
by adding cumulative doses of PGI2 to the organ bath in the
presence of a fixed concentration of PGEl or PGE2. PGEl
opposed the contractile action of PGI2. A typical result is
shown in Figure E.28. After PGEl treatment, following
wash-out, the tissue showed loss of sensitivity to PGI2. The
influence of PGE2 on PGI2 action depended on the tissue
sensitivity to PGE2. On the preparation which was sensitive
to PGE2, the effect of PGI2 was depressed in the presence of
PGE2, while on a preparation less sensitive to PGE2, PGE2
had little effect on the response to PGI2.
11,9-epoxymethano PGH2, PGD2 , PGIl and PGF2a were very weak




Figure E.28 Rabbit iris sphincter preparation: interaction
of PGE] with PG12i log concentration-response curve for PG12
acting alone (open circle) and the corresponding curve (so¬
lid circle) in the presence of 300 ng/ml PGE] (solid square)
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The possible prostaglandin receptor types together with the
direction of response found in the different iris
preparations are summarised in Table E.ll.
It is obvious from what has been said in the results section
that information obtained on tissues in which relaxant
effects are absent, is more easily analysed in terms of
receptor classification.
Do.g and £ai ills Sshinstsx Hu.s_£l.e.s
The dog and cat iris sphincters appear to be the simplest of
the systems studied. Our results suggest the presence of a
single receptor type at which PGF2a and its closely related
analogues are the most active contractile agonists^ whereas
PGE2? PGI2 and 11.9-epoxymethano PGH2 show only weak
activity. This accords with work by Kennedy, Coleman,
Humphrey, Levy & Lumley (1982). The very low activity of
16,16-dimethyl PGE2 is in complete contrast to its high
activity on the bovine iris sphincter. ZK 36374 is also a
weak contractile agent and does not oppose the action of
PGF2a. These results may indicate that a PGE-sensitive
system similar to that found in the bullock iris sphincter
is not present in the dog iris sphincter. It is possible
that the activity of PGE2 is due to its ability to interact
with the PGF2a receptor.
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Table E.ll Summarization of receptor types and the types of mechanical
responses in the iris sphincter preparations from different animals.
Iris Sphincter
Receptor Bullock Dog Cat Hofse Rabbit
pgd2
pge2 +t +f
+ + + +
PGF2a ++ ++ +t
pgi2 +(?)+ ++
TxA2 +t
+ indicates definite pharmacological evidence for existence of receptor
t or t indicates contractile or relaxant effect associated with agonist
action at receptor.
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ICI 81008 is a potent luteolytic agent (Dukes, Ressell &
Walpole, 1974), mimicking the action of PGF2a. It shows
similar activity to PGF2a on the rabbit jejunum in vitro and
the rabbit oviduct in vivo (Welburn & Jones. 1978). Its low
activity on PGE-sensitive preparations has been documented
previously guinea-pig uterus in vitro (Dukes, Russell &
Walpole, 1974) and guinea-pig ileum in vitro (Welburn &
Jones, 1978). ICI 81008 therefore seems to be a specific
full agonist on the PGF2a receptor-
ICI 79939 PGF2a is another potent PGF2a mimetic, but it
lacks selectivity. In addition to the PGF2a receptor it
activates the PGE2 receptor on the bullock iris sphincter
preparation, which we will mention later, and the TxA2
receptor on human platelets and rabbit aortic strips (Jones,
Wilson & Marr, 1979; Jones, Peesapati & Wilson, 1982).
EP 045, EP 092 and EP 116 do not block the activity of PGF2a
on the dog iris sphincter. These compounds effectively and
specifically block responses to 11,9-epoxymethano PGH2 on
preparations sensitive to TxA2. Their affinity constants are
listed in Table Table E.12. Contraction of the dog iris
sphincter induced by 11.9-epoxymethano PGH2 is not blocked
by EP 045. This suggests that the weak contractile activity
of 11 9-epoxymethano PGH2 is due to an interaction with the
PGF2a receptor site.
Two PGE2 analogues, ICI 80205 and ICI 79939 PGE2 show
surprisingly high PGF2a-like activity (see Table E.6,P39).
However, they both show considerable TxA2-like activity as
well (Jones, Peesapati & Wilson, 1982). It therefore appears
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Table E.12 Affinity constants for EP 045, EP 092 and EP 116 on several
preparations.
Tissue EP 045 EP 092
(Affinity Constants M--1-)
*Rabbit aorta 2.0x10




















11,9-Epoxymethano PGH2 was used as agonist.
Bullock iris sphincter and rat gastric fundus preparations were in
Krebs solution containing 10~® M indomethacin, and guinea-pig ileum
was in Krebs containing 10~® m indomethacin and 2xl0~® m atropine.
* denotes data from Jones, r.l..
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that the substitution of a para-halogenated phenoxy group at
the C16 position can increase agonist potency in a number of
systems, but this is accompanied by a loss of specificity.
R44
The TxA2—mimet ics listed in Table E. 8^ elicited contraction
of the dog iris preparation. These drugs can be divided into
two groups: one group with an aromatic substituent in the
u/-chain, i.e. 15-oxo EP 011, 15 « EP 130, 15 ft EP 130 and
15-oxo EP 130, oppose the effect of PGF2a, and the other
without the aromatic substituent, i.e. 9,11-ethano PGH2 and
9,11-azo PQH2, fail to affect PGF2a action. Compounds in the
first group probably act on PGF2a sites since EP 116 does
not block 15-oxo EP 011-induced contraction, 15-oxo EP 011
desensitised preparations lose sensitivity to PGF2a, and the
interaction of 15-oxo EP 011 with carbachol is additive.
Their low maximum response seems to indicate that they might
be partial agonists on PGF2a receptor sites. But
desensitization makes it difficult to be confident that this
is the case. The long-term desensitization caused by
15-oxo EP 011 is probably due to its high 1ipophilicity
which prevents it from being washed out. 15-0xo EP 011 also
has long acting effects on thromboxane-sensitive
preparations. However, this action is easier to investigate
since thromboxane-sensitive systems are in general resistant
to desensitisation.
The two compounds with natural w-chains, i.e.
9,11-ethano PGH2 and 9,11-azo PGH2, are very weak on the
PGF2a receptor sites and do not oppose the PGF2a effect. It
is assumed that maximum response induced by a partial
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agonist requires 100% occupancy of the receptor. However,
if both 9,11-ethano PGH2 and 9,11-azo PGH2 have low
affinity, their binding to the PGF2a receptor may be
precarious and readily be displaced by PGF2a which merges
firmly with the receptor. Or an alternative explanation
could be that partial agonists with low affinity might not
occupy all the receptors for maximum response, so that there
were spare receptors for a full agonist to act on. To oppose
PGF2a action much higher concentration will be required.
Their contractile effect in this preparation is not due to
activation of TxA2 receptors, since EP 116 did not block the
contraction. And it is unlikely for them to produce
contraction by non-specific activities, for example,
ionophore-like activity, as their EC 50 values are
around 100 ng/ml, A PGF2a receptor antagonist will be needed
before further conclusions can be drawn.
One thing worth mentioning is the suggestion by Crawford,
van Alphen, Cook and Lands (1978) that there is a
TxA2-sensitive system in the cat iris sphincter. They found
that PGH2 was as potent as PGF2a, whereas the epoxymethano
analogues, 11,9-epoxymethano PGH2 and 9,11-epoxymethano PGH2
were very weak. The epoxymethano analogues did, however,
inhibit the PGH2-induced contractions. They argue that since
the formation of PGF2a from PGH2 is a non-enzymic process
(Chan, Nagasawa, Takeguchi & Sih, 1975) and the epoxymethano
analogues are known to be effective inhibitors of the
conversion of PGH2 to TxA2 in platelet microsomes (Sun,
1977), then TxA2 synthetase action must mediate the
contraction following PGH2 addition.
82
However, it has been shown that 11,9-epoxymethano PGH2 has
the same profile of activity as TxA2 on a number of smooth
muscle preparations (Coleman, Humphrey, Kennedy, Levy &
Lumley, 1981), The low activity of 11,9-epoxymethano PGH2 on
the dog and cat iris sphincter muscle and the inability of
EP 045 to block the weak activity of 11.9-epoxymethano PGH2
on the PGF2a-sensitive preparation indicate that the TxA2
receptor site does not exist on these two preparations. This
is supported by work from Coleman, Humphrey et al. (1981).
They have demonstrated that PGH2 is also active in the dog
iris sphincter, that imidazole, a TxA2 synthetase inhibitor,
does not affect the PGH2 action and that generated TxA2 is a
very weak agonist. Since we have shown that the dog and cat
iris sphincter muscles have similar properties in terms of
prostaglandin receptors, the results from the two
preparations may be comparable. Further studies on the
metabolism of PGH2 in these iris preparations may be useful.
The 9,11-peroxy link in PGH2 is extremely easy to reduce
(Stannous Chloride in ethanol/water, room temperature, 5
min), and it is possible that a rapid enzymic or non-enzymic
reduction to PGF2a occurs in the tissue.
Bullock Iris Sphincter Muscle
Our results suggest that the bullock iris sphincter muscle
is more complicated: it contains two different types of
prostanoid receptor. One is more sensitive to PGE analogues
and the other to thromboxane analogues. However, it is
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amenable to analysis since we have specific TxA2 receptor
antagonists available.
The PGE-sensitive system responds to PGE2 and its
16,16-dimethyl and 17,18,19,20-tetranor-16-p-chlorophenoxy
analogues. The order of agonist potency on the
PGE2-sensi tive system is ICI 8(5 20 5> 16 , 16-dimethyl PGE2>PGE2>
PGEl> 11-deoxy PGE1> PGF2a> PGI1> PGI2> PGD2. ICI 80205 and
16,16-dimethyl PGE2 are highly active, about 5 times and 2
times more active than PGE2, respectivelyj PGEl and PGF2a
are less active (Table E.l, P15).
The system is further characterized by the unique action of
ZK 36374. This stable analogue is structurally very close to
PGI2 and shows properties similar to PGI2 on bovine coronary
artery, human platelets (Schror, Darius, Matzky & Ohlendorf,
1981) and rabbit iris sphincter (see results from rabbit
iris sphincter muscle in this section). Its potency is
equivalent to PGI2 on the human platelets (inhibition of
aggregation) and on the rabbit iris sphincter (contractile
effect). On the bovine iris sphincter preparation, ZK 36374
elicits threshold contractile effects at concentrations of
1-2 ng/ml whereas PGI2 concentrations for similar responses
are 10-30 times higher. Moreover, ZK 36374 seems to act as a
partial agonist, giving a lower maximum than PGE2 and
opposing the actions of PGE2. 16,16-dimethyl PGE2, PGF2a and
PGI2, but not those of 11.9-epoxymethano PGH2 and carbachol.
EP 045, a TxA2 receptor antagonist, does not block the
effect of ZK 36374. Thus, ZK 36374 appears to be a partial
agonist on PGE2-sensitive sites.
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PGI2 and PGIl also showed maxima lower than PGE2. That is
76% for PGI2 and 77% for PGIl. PGIl was about twice as
potent as PGI2: this is in contrast to the much greater
potency of PGI2 on the rabbit iris sphincter preparation.
The interaction of PGI2 or PGIl with PGE2 has not been
studied, but it may be proposed that PGI2 and PGIl are
partial agonists on PGE2-sensitive sites because of the
structural similarities between PGIl, PGI2 and ZK36374, and
the inability of EP 045 to block PGI2 action. However^ it is
possible that instability of PGI2 in aqueous solution
favours the attainment of a lower maximum response.
The other prostanoid-sensitive contractile system shows
properties similar to those found for the rabbit aorta and
the dog saphenous vein (Jones. Wilson & Marr, 1979; Jones &
Wilson, 1980; Jones. Peesapati & Wilson, 1982) (Table E.13).
Thus the 11.9-epoxymethano PGH2 analogue is a potent full
agonist. The results in this study have indicated that the
system on which 11.9-epoxymethano PGH2 acts is a
TxA2-sensitive system because the actions of both
generated TxA2 and 11,9-epoxymethano PGH2 can be blocked by
EP 045, and not by ZK 36374, and TxA2 is more potent than
PGH2 in the presence of indomethacin. This is consistent
with recent studies which have shown that
11j9-epoxymethano PGH2 has the same profile of activity as
TxA2 on smooth muscle and can be considered as a selective
TxA2 mimetic despite being chemically an analogue of PGH2
(Coleman^ Humphrey? Kennedy? Levy & Lumley, 1981). The use
receptor
of the stable thromboxane^agonist5 11,9-epoxymethano PGH2,
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Table E.13 Activities of TXA2 agonists on bullock iris sphincter,





pgh2 1.0 1.0 1.0
9,11-azo pgh2 0.74 1.4 1.2







BIS, RA and DSV indicate bullock iris sphincter, rabbit aorta and dog
saphenous vein, respectively.
PTA2 is a partial agonist in all the preparations. Lower and upper
values of the relative maximum response (11,9-epoxymethano PGH2=100%)
together with the concentration of the partial agonist required to
produce a response 50% of its own maximum are given.
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considerably simplifies the investigation of compounds with
thromboxane blocking activity. The action of the
11j9-epoxymethano PGH2 analogue is blocked by the
semicarbazone analogues, EP 045 and EP 116. The affinity
constant for EP 045 on the bovine iris sphincter (7.2x10
M~*) is less than those found previously for the
11.9-epoxymethano PGH2 analogue/EP 045 combination on the
dog saphenous vein (2.2x10^ M~^) and guinea-pig trachea
7 — 1
(3.3x10' M x). However. recently Jones (Personal
Communication) has found that the affinity constant for a
new batch of EP 045 on the bovine iris sphincter is 4.6x10^
M-^. EP 116 is about 100 times more potent than EP 045 in
blocking the action of the 11.9-epoxymethano PGH2 analogue
on the bovine iris sphincter preparation.
6
The rank order of potency for the TxA2 mimetics is EP 011 >
15-oxo EP 011> 9,11-azo PGH2 >, CTA2> 11,9-epoxymethano PGH2.
The two 16-p-fluorophenoxy compounds are considerably more
powerful agonists than 11.9-epoxymethano PGH2 (factor of
about 30), and their threshold concentration is about 0.1
nM. 9,11-Azo PGH2 and CTA2 have activities similar to
11.9-epoxymethano PGH2. EP 011, 15-oxo EP 011 and CTA2
exhibit a slow on-set and prolonged duration of action: this
profile of action has been observed on all
thromboxane-sensitive smooth muscle preparations examined to
date. The 9,11-ethano PGH2 and the pinane TxA2 analogue are
partial agonists.
Weak thromboxane-like activity on smooth muscle has been




Wilson, 1980). On the rabbit aorta and dog saphenous vein,
16,16-dimethyl PGE2 is 33 and 55 times respectively less
active than 11,9-epoxymethano PGH2 in terms of contractile
action. The additional contractions seen with high
concentration of the 16,16-dimethyl analogue on the bovine
iris sphincter could be due to this type of thromboxane
activity.
The large variation in the dose-ratio measurements for
EP 011 with and without EP 116 and the relatively constant
relationship between the PGE2 and the EP 011 dose-response
curves in the presence of a high concentration of EP 116
indicate that EP 011 may possess significant PGE2-like
activity. A similar argument may be applied to 15-oxo EP 011
but this compound is about 4 times less active than EP 011
in terms of the PGE2-like contractile activity. Recently,
Jones (unpublished data) has shown that when
11,9-epoxymethano PGH2 is used as an agonist on the bullock
iris sphincter, dose-ratios greater than 100 can only be
obtained with high concentrations of EP 092 on those
preparations which are relatively insensitive to PGE2. This
indicates that high concentrations of 11,9-epoxymethano PGH2
can act on PGE2 receptor sites, too.
It has been shown that ICI 79939 PGF2a and ICI 79939 PGE2
have TxA2-like activity (Jones, Peesapati & Wilson, 1982).
On the rabbit aorta equipotent molar ratios are 3.1 for
ICI 79939 PGF2a and 4.3 for ICI 79939 PGE2
(11,9-epoxymethano PGH2=1.0). Moreover, on the guinea-pig
ileum where PGE2 is the most active substance,
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ICI 79939 PGF2a was fairly active (Welburn & Jones, 1978).
It is unlikely in the latter study that ICI 79939 PGF2a
exerts its contractile action by binding to PGF2a or TxA2
receptors since ICI 81008, a selective PGF2a analogue,. and
11,9-epoxymethano PQH2 were very weak on the guinea-pig
ileum preparation (Welburn & Jones, 1978; Kennedy, Coleman,
Humphey, Levy & Lumley, 1982). In order to study the
PGE2-like activity of ICI 79939 compounds on the bullock
iris sphincter preparation TxA2 receptor antagonists were
used to block the TxA2-sensitive system. In the presence of
EP 045 ICI 79939 PGE2 is 6 times more active than PGE2, and
in the presence of EP 045 or EP 116 ICI 79939 PGF2a is about
half as active as PGE2. PGD2, PGI2 and ICI 81008 are very
weak agents on this preparation. These findings indicate
that ICI 79939 PGF2a may have potent agonist actions on
PGE2-sensitive sites. This idea is supported by Jones's
recent work (unpublished data), which shows that EP 092 at a
concentration as high as 1.0 jjM, produces no or very weak
blocking effect on the response to ICI 79939 PGF2a on the
bullock iris sphincter.
The low threshold concentration and higher maximum of
M/B 28767 imply that M/B 28767 may interact with both
PGE2- and TxA2-sensitive sites, even in the presence of a
TxA2 receptor blocker. And M/B 28767 may have marked
TxA2-like action since its concentration-response curve
shifts further to the right as an increasing concentration
of EP 045 was added.
Indomethacin producesaninhibitory effect on smooth muscle
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contraction induced by varied stimulants (Northover? 1977).
It has been reported that contractile responses of smooth
muscle to prostaglandins were inhibited more completely by
indomethacin than responses to other spasmogens (Sorrentino,
Capasso & Dirosa, 1972). The concentrations of indomethacin
used by these investigators were in excess of 10 ^uM. In this
study we have shown that indomethacin at 1.0 pM has no or
little effect on responses to prostaglandins. At higher
concentrations indomethacin inhibited PGE2 action, but did
not affect response to 11,9-epoxymethano PGH2.
EP 116 is• about 100 times more potent than EP 045 in terms
of blocking the response to 11.9-epoxymethano PGH2. The
inability of EP 116 to inhibit the spontaneous rise in
tension probably indicates that the increase in tension is
not due to endogenous synthesis of TxA2 in the bullock iris
sphincter. In addition, the tension could not be depressed
by atropine or phentolamine. We assume that in addition to
TxA2 receptor blocking activity EP 045 may perhaps possess
another activity inhibiting endogenous synthesis of
PGE2. It is unlikely that EP 045 produced the inhibition in
tone by affecting leukotriene synthesis since indomethacin,
which has no effect on leukotriene synthesis, suppressed the
increased tone.
The slow on-set for certain lipophilic PG analogues at low
concentrations may indicate that PG receptors are situated
adjacent to a lipophilic minimilieu. The lipophilic agonists
will concentrate themselves in this area, then bind to their
receptors. The time course of equilibrium between
receptor-bound and free agonists will depend on the
concentrating speed of the agonist. Therefore^ equilibrium
in the minimilieu will be established slowly and this will
be reflected in a slow on-set of the contractile effect. It
is apparent according to this hypothesis that it is
difficult to estimate the true potencies of these lipophilic
PG analogues. The potency of the lipophilic agonists may be
enhanced due to accumulation of the compounds in the
minimilieu.
Hqcss Icis Sphincter Musqle
The horse iris sphincter muscle possesses at least three PG
receptor systems: one is PGF2a-sensitive system mediating
contraction only and the other two are PGE2-sensitive
systems mediating both contractile and relaxant actions.
The PGF2a receptor site resembles that in the dog and cat
iris sphincter. It is characterized by the high agonist
activity of ICI 81008, a specific PGF2a mimetic, and the
inability of the thromboxane receptor antagonist EP 116 to
block the contractile effect.
Evidence for the presence of a PGE2 receptor mediating
contraction mainly comes from a study of the activity of
16,16-dimethyl PGE2. This compound is a potent agonist but
elicits a maximum response much lower than that obtained
with PGF2a. The existence of the PGE2 receptor is further
substantiated by the high activity and high maximum of
ICI 79939 PGF2a, reflecting the fact that ICI 79939 PGF2a
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has both PGF2a and PGE2 activities, as proved in the dog and
bullock iris sphincter. Furthermore, ICI 80205, which also
has high activity on both PGE2 and PGF2a receptor sites (see
bullock, dog and cat iris sphincter) shows the same
properties as ICI 79939 PGF2a. Additional support comes from
the additive interactions of 16,16-dimethyl PGE2 with PGF2a
and of ICI 81008 or PGF2a with PGE2. One can predict that
with higher concentrations PGF 2a will produce further
contractions by activating PGE2 receptors. The observation
that ICI 79939 PGF2a has higher activity than ICI 81008 on
this preparation is probably due to a summation of the
activities of ICI 79939 PGF2a on both PGF2a and PGE2
receptor sites.
It is difficult to study the inhibitory PGE2 system, since a
limited relaxant response could be elicited. This PGE2
system appears somewhat different from that in the cat
trachea (see cat trachea). In the cat trachea the order of
potency for inhibitory activity is PGE2> PGE1>> ZK 36374 >y
PGI2, PGE2 is about 1000 times more potent than ZK 36374 and
PGI2. PGEl is about half as potent as PGE2. On the horse
iris sphincter, PGEl is more potent than PGE2, and PGI2 and
ZK 36374 show relatively high activity. The ostensive
relaxant effect produced by low concentrations of PGE2 may
however be the algebraic summation of a relaxant and a
contractile effect. It is always tempting to think that the
"dominated effect" must be small in magnitude. However, it
is possible that both contractile and relaxant effects are
intense and that the relaxant effect is just powerful enough
to give a relaxation. If this is so then the measured
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agonist potencies for the relaxant effect may bear little
relationship to their true magnitude. Thus, the high
activity of PGEl can be explained by a lower activity of
PGEl on the contractile PGE2 receptor sites than on the
inhibitory PGE2 receptor sites in relation to PGE2. The
relatively high potency of PGI2 and ZK 36374 may indicate
the existence of a PGl2-sensitive system.
The reversal of PGE2 relaxant effect by PGs and carbachol
seems to be neither an event which occurs at the receptor
level nor due to potentiation by PGE2 of the contractile
actions due to other stimulants, because adrenaline-induced
inhibitory effect was also opposed by a PG analogue.
Contractile agents were used in the cat trachea and
guinea-pig trachea to study PGE2 relaxant action. On the
guinea-pig trachea, PGE2 action was not opposed by
stimulants (Jones, R.L., Personal Communication), while on
the cat trachea high concentration of carbachol opposed the
PGE2 relaxant action (Jones, 1970), a case similar to the
horse iris sphincter.
It is generally believed that relaxation of smooth muscle
and inhibition of platelet aggregation are produced by an
increase of cyclic AMP level via activation of plasma
membrane receptors. In platelets, agents such as ADP or
adrenaline lower the increased cyclic AMP concentration
caused by PGEl (Robison, Arnold & Hartmann, 1969; Ball,
Brereton, Fulwood, Ireland & Yates, 1970; Moskowitz,
Harwood, Reid & Krishna, 1971; McDonald & Stuart, 1973). One
can assume that in the horse iris sphincter carbachol and
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other PGs may lower the increase in cyclic AMP concentration
induced by PGE2.
The high sensitivity of the preparations to PGF2a tempted us
to try 15-oxo EP 011 and the like again. Fortunately,
tachyphylaxis to the natural agonist PGF2a was not
encountered. However, we encountered an additional problem
the existence of a PGE2 receptor. As demonstrated
before, 15-oxo EP 011 at high concentrations activates PGE2
receptors. The contraction elicited by 15-oxo EP 011 could
be due to activation of both PGF2a and PGE2 receptors.
Depending on the sensitivity of the preparation to PGE2,
15-oxo EP 011 either shows an "additive" interaction with
PGF2a or opposes the action of PGF2a. The desensitization to
PGF2a after treatment with 15-oxo EP 011 confirms the notion
that 15-oxo EP 011 acts on the PGF2a receptor sites.
Rabbit Iris Sphincter Muscle
There are two types of PG receptors in the rabbit iris
sphincter muscle: PGI2 and PGE2 receptor sites.
In contrast to its inhibitory effect on platelets and many
vascular preparations, PGI2 elicits a contractile response
on the rabbit iris sphincter. ZK 36374, a stable analogue of
PGI2, also produces contraction, and is equipotent with
PGI2, which is in agreement with the investigations on
bovine coronary artery and human platelets (Schror, Darius,
Matzky & Ohlendorf, 1981).
PGE1 probably acts as a partial agonist on PGI2 receptor
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sites in eliciting the production of cyclic AMP by human
platelets (Tateson, Moncada & Vane, 1977). An attempt was
made to study whether PGEl shows partial agonist activity on
this preparation. However, the presence of an inhibitory
PGE2-sensitive system makes it difficult to analyse the
results, since PGEl is always a potent agonist on PGE2
receptor sites. The low maximum response of PGEl relative to
PGI2 might be due to an inhibitory effect related to an
agonist action of PGEl on PGE2 receptor sites. Nevertheless,
that the preparation loses its sensitivity to PGI2 after
treatment with PGEl, and PGEl opposes PGI2 action implies
that PGEl may be a partial agonist on the PGI2 receptor
sites mediating contraction, as on the PGI2 receptor sites
mediating cyclic AMP production. Obviously, a definitive
explanation must await the discovery of specific PGE2
receptor antagonists.
PGE2 receptor sites in this preparation mediate relaxation,
as we have mentioned above. That it reduces the tone
elicited by both PGI2 and carbachol indicates that its
inhibitory effect is not due to acting on PGI2 receptor
sites. This is verified by the fact that PGE2-induced
inhibitory effect on PGI2 varies with the sensitivity of the
preparation to PGE2.
It has been found that PGE2 is about 1000-10000 times less
active than PGI2 in inhibiting platelet aggregation induced
by collagen or ADP (Andersen, Eggerman, Harker, Wilson & De,
1980). However, PGE2 decreases the effectiveness of PGI2,
PGEl and PGD2 to inhibit platelet aggregation and to
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increase cyclic AMP concentration (Andersen et al., 1980;
Bonne, Martin, Watada & Regnault, 1981) . The latter group
also found that PGE2 by itself inhibited platelet
aggregation and increased the production of cyclic AMP, and
depressed the rise in cyclic AMP induced by adenosine and
sodium fluoride. These findings suggest that PGE2
counteracts the antiaggregating action of PGI2 and PGEl by
inhibiting the adenylate cyclase system. However, PGE2 was
as potent as PGEl to displace (3H)-PGEl from its high
affinity specific binding sites in platelet suspension, but
did not displace PGD2 from its own receptor (Bonne et al.,
1981). It has been suggested that PGEl and PGI2 share a
receptor distinct from that acted on by PGD2 (Whittle,
Moncada & Vane, 1978; Miller & Gorman. 1979), and PGI2 is
the natural or endogenous ligand for the PGEl receptor. And
it has been shown that a type of PGE2 receptor exists in
platelets which potentiates platelet aggregation induced by
TxA2 (Weiss, Willis, Kuhn & Brand, 1976). Since PGEl is more
active on PGE2 receptors than on PGI2 receptors and the
concentration of (3H)-PGEl used was 5 nM in the study of
Bonne and his colleagues (1981), the labelled ligand
probably bound mainly to PGE2 receptors. However, the
possibility cannot be entirely precluded that PGE2 is an
antagonist or a partial agonist on PGI2 receptor sites. To
either which
prove that one need^a preparation^contains PGI2 receptors
only or PGE2 antagonists.
It has been shown that the rabbit iris converts
1-[14C]-arachidonic acid into 6-keto-PGFla, a PGI2
metabolite, and PGE2 (van Alphen, Dutilh & de Deckere, 1978;
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Bhattacherjee, Kulkarni & Eakins, 1979). Since PGs can not
be stored, but are synthesized and released when required in
response to stimuli, it is reasonable to assume that they
should have biological targets in or near the tissue where
they are synthesized. The conversion of arachidonic acid
into 6-keto PGFla and PGE2 may support our conclusion that
there are PGI2 and PGE2 receptors in the rabbit iris
sphincter, unless, of course, these PGs are produced by the
iris dilator muscle. Intriguingly, the same investigators
have also found that the cat iris is capable of transforming
arachidonic acid into 6-keto PGFla and PGE2 in high
proportion. However, PGE2 and PGI2 are very weak agonists on
the cat iris sphincter and dilator muscle (see our results;
van Alphen & Angel, 1975). According to our hypothesis, PGI2
and PGE2 must have targets in or near those muscles,
mediating biochemical or physiological events rather than
the mechanical responses, possibly changing membrane
permeability to ions or activity of an enzyme, eliciting
blood vessel response in a tissue, or modifying
neurotransmitter release. Therefore, we have to point out
that in this study we define and differentiate PG receptors
only in terms of mechanical responses or platelet
aggregation.
Section Two
Actions of Prostanoids on the Cat Trachea
ReJe.-r&ncji ; pP3J\f"-3 7°
97
JtfXBDDU£TI£U
The pharmacological effects of prostaglandins on the
respiratory tract were first described by Main (1964) and
Horton and Main (1965) in several mammalian species.
Tracheal or bronchial smooth muscle of several species
including man is relaxed in vitro by both PGEl and PGE2
(Main, 1964; Horton & Main, 1965; Sheard, 1968; Sweatman &
Collier, 1968; Mathe, Strandberg & Astrom, 1971).
PGF2a was discovered first in extracts of the lung
(Bergstrom, Dressier, Krabigh, Ryhage & Sjovall^ 1963).
PGF2a contracts tracheal and bronchial smooth muscle
including human tissue both in vitro and in vivo (Anggard &
Bergstrom, 1963; Sweatman & Collier, 1968; Mathe, Strandberg
& Astrom, 1971). Polyphloretin phosphate blocks the
bronchoconstrictor action of PGF2a but not the
bronchodilator action of PGE2.
TxA2 is the most powerful bronchoconstrictor in the
guinea-pig (Svensson, Strandberg, Tuvemo & Hamberg, 1977).
PGI2, which can be formed in lung tissue (Gryglewski, Korbut
& Ocetkiewicz, 1978; Omini, Brunelli, Folco, Marini,
Pasargiklian & Berti, 1981) shows bronchodilator effects in
vivo in dogs and guinea-pigs (Wasserman, Ducharme, Wendling,
Griffin & Degraaf, 1980) and is more potent than PGEl in
relaxing human respiratory tract smooth muscle in vitro
(Karim, Adaikan & Kottegoda, 1980).
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It is of interest that the cat trachea is not contracted by
either PGF2a or TxA2. Contractions of the smooth muscle
produced by other stimulants are however inhibited by PGs,
of which prostaglandins of the E series are the most potent.
A review of the literature indicates that two subtypes of
PGE receptor may exist. For example, on the guinea-pig ileum
the contractile action of PGE2 on the longitudinal muscle is
blocked by both the benzoxazepine SC-19220 and polyphloretin
phosphate (PPP) whereas its relaxant action on the circular
muscle is unaffected by those two agents (Bennett & Posner,
1971). In addition, the contractile action of PGE2 on the
rat stomach fundus is blocked by SC-19220 but contraction of
the chick ileum is not (Coleman, Kennedy, Levy & Penning,
1980).
We have found that 16,16-dimethy1 PGE2 and ICI 80205 are
potent agonists, and ZK 36374 is a partial agonist on PGE2
receptor sites mediating an excitatory response in the
bullock iris sphincter. Attracted by the unique properties of
an
cat trachea, i.e. PGs cause^inhibitory response only, we
have examined the PGE2 analogues and ZK 36374 on this
preparation and attempted to provide further evidence for
the existence of receptor subtypes for PGE2.
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The cat trachea was dissected out under pentobarbitone
anaesthesia, and cut transversely between the segments of
cartilage. Two of these rings were tied together to form a
chain and then the cartilage side was cut off. The
preparations were suspended in 10 ml organ baths containing
Krebs solution (NaCl 6.9, KC1 0.35, MgSO^H^ 0.29, KH2P04
0.16. glucose 2.0, NaHC02 2.1, CaCl2 0.28 g/1), gassed with
95% 02 and 5% C02 » and kept at 37°C.
Tension changes were measured isometrically with a Grass
force displacement transducer (FT 03C) and recorded on a




The cat tracheal muscle contracts to carbachol, ( an
acetylcholine analogue) and 5-hydroxytryptamine(5-HT). The
concentrations which produced a response 50% of their own
maximum were in a range of 0.1-0.7 pM, mean=0.32 ± s.e.0.042
(n=21) , for carbachol and 2.0-5.0 juM for 5-HT. PGE2,
PGF2a, PGD2, 11.9-epoxymethano PGH2, PGI2 and ZK 36374
produced neither contractile nor relaxant effects on this
preparation when it was in the resting state. As the cat
trachea preparation possesses negligible tone in vitro; it
was contracted with carbachol at concentrations between 0.05
and 0.2 jjM to give a response about 60% of its own maximum
so that the inhibitory effect of a prostanoid could be
investigated. In a few preparations 5-HT (2.0 jjM) was used
for this purpose. Prostanoids were added to the organ bath
after the dose of carbachol or 5-HT had produced a sustained
contraction. The response to the fixed concentration of
carbachol was highly reproducible. Doses of prostanoids were
added cumulatively. Figure T.l illustrates a typical trace
of responses of the cat tracheal muscle preparation to
cumulative doses of PGE2. Responses to PGE2 reached their
nadir in 2-4 min. In most cases responses to PGE2 were
sustained for at least 2 min or more, but in a few cases
responses showed a tendency to return to the tone level
provided by carbachol. After wash-out of the organ bath; the
tension of the muscle returned to the resting level. The





Figure T.l Cat tracheal preparation: responses to cumulative dose of PGE




response was taken as the reduction in the
carbachol-produced tension. Log concentration-response curves
were then plotted.
PGE2 Analogues
PGE2 is a potent relaxant agent and was used as the standard
agonist. In most cases. 15 out of 19, threshold responses
(tension change of about 100mg) were seen with
concentrations of 3-10 ng/ml and 50% maximum responses with
18-60 ng/ml. In one preparation which was very sensitive to
PGE2 the EC50 was 0.28 ng/ml and in three preparation EC50
values were 115,130 and 170 ng/ml. Representative log
concentration-effect curves for PGE2, PGEl, 16,16-dimethyl
PGE2 and ICI 80205 are shown in Figure T.2a and T.2b. Log
concentration-effect curves for these compounds were
parallel to that of PGE2. Equipotent molar ratios were
obtained from the molar concentration of PGE2 giving a
response 50% of its own maximum and the molar concentration
of the test compound producing a commensurate response
(Table T.l). On ordinary preparations PGI2 and ZK 36374 at
1 pg/ml produced no effect and ZK 36374 did not oppose the
inhibitory effect of PGE2 (Figure T.3). On the one highly
PGE2-sensitive preparation (the threshold concentration was
0.2 ng/ml) ZK 36374 and PGI2 showed relaxant effects (Figure
T.4). PGE2 was about a thousand times more active than ZK
36374 and PGI2.
PGF2a Analogues














Figure T.2a Cat tracheal preparation: log concentration-response curves

















Figure T.2b Cat tracheal preparation: log concentration-response curves
for PGE2> 16,16-diniethy 1 PGE2 and ICI 80205. Tone was provided with
0.3 carbachol.
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Table T.l Potencies of prostanoids on the cat tracheal muscle
preparation
Compound Equipotent molar ratio (PGE2=1.0)
Individual value mean s.e. n
PGE l 1.3 2.3 2.6 3.0 2.3±0.36 4
16,16-dimethyl PGE2 7.4 8.3 9.3 14 9.8±0.73 4
ICI 80205 69 75 90 78±6.2 3
Individual values are the result of a comparison with PGE2 on a single
preparation. With ICI 80205 the full concentration-response relationship
was not established, and the corresponding equipotent molar ratios









PGE2 ^ PGE2 in the presence
\ Of 1.1 wg/inl
ZK 36374
1 1 1
l.o 10 100 1000
(concentration ng/ml)
Figure T.3 Cat tracheal preparation: log concentration-response curves
for PGE2 alone and PGE2 in the presence of 1.1 ug/ml ZK 36374. Tone was
provided with 1 t,M carbachol.
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o.l 1.0 10 100 1000
Concentration (ng/ml)
Figure T.4 The highly PGE2~sensitive cat tracheal preparation: log concentration-
response curves for PGE2, ZK 36374 and PG12- Tone was provided with 0.1 vM carbachol.
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preparation, but the response faded rapidly. Subsequent
addition of PGF2a failed to produce a relaxation (Figure
T.5). Propranolol at 1 pM did not oppose the relaxant effect
of PGF2a, but antagonized the action of adrenaline which
showed relaxant activity on the cat tracheal muscle
preparation. PGF2a also caused relaxation when the
preparation was contracted with 5-HT and again tachyphylaxis
followed the relaxation. The sensitivity of the preparation
to PGE2 was not altered by the desensitization to PGF2a (see
Table T.2).
Some other PGF2a analogues were also studied. It was found
PGF20L
that ICI 81008, ICI 79939Aand 13,14-didehydro PGF2a (at 100
ng/ml) behaved in the same way as PGF2a, producing a
relaxant effect followed by tachyphylaxis. There was
cross-desensitization between ICI 81008 and PGF2a (Figure
T. 6) .
Effect of Other Drugs
PGD2, 11.9-epoxymethano PGH2, EP 011 and 15-oxo EP 011 at 100
ng/ml showed no relaxant effect on most of the cat tracheal
muscle preparations. On one preparation 15-oxo EP 011 at 500
ng/ml gave a small relaxant effect. Although tachyphylaxis
to 15-oxo EP 011 occurred, it seemed not to affect the
response to PGF2a and PGE2.
The effects of drugs on the relaxant response to PGE2 are
summarized in Table T.2. EP 045, 15-oxo FP 011 and ZK 36374
did not show either contractile or relaxant activities on
the preparations where they were tested. Verapamil depressed
Cnr7aCM°'PGEzCarbacholPGF?aF,̂2 0.2uM100ng/ml'"' ng/ml FigureT.5Cattrachealpreparation:desensitiz tionoPGF2^*wconsecutivesequ ncesar iedi inglpreparation. Theintervalwasaboutnhour.Intfirstsequ nce,PGE2loneest d;cGF2a100g/mlddt theorgan-bath.Afterac yphyl xisccur ed,se ondd sefPGF2a(100n /ml)wasaddintorg .Ipro ceeff . Thenarep atedconcentration-responser la io hipfPGE2ws tuit prese cf200g/mlGF2a-p para iohow nochangeit esensitivityoPGE2-Towaspr videdith0.2uMcarb c ol.W= .
11 0
Carbachol ICI 81008 PGF2a PGE2 PGE2
0.2 yM 100 ng/ml 200 ng/ml 20 ng/ml 100 ng/ml T
10 min
I 1 0.8 g
Carbachol PGF2q 1C1 81008 PGE? PGE? PGE2
0.2 uM 100 ng/ml 100 ng/ml 10 ng/ml 20 ng/ml 100 ng/ml
Figure T.6 Cat tracheal preparation: cross-desensitization to PGF2ri and ICI 81008.
The experiments were conducted on two separate preparations. Having been challenged
with PGF2q and ICI 81008, the preparations were still sensitive to PGE?. The
organ-bath contained Krebs solution. Tone was provided with carbachol 0.2 uM.
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Table T.2 Effects of other drugs on relaxant responses to PGE2 or PGE^
on the cat tracheal muscle preparations.
Treatment Dose-ratios for PGE2 or PGE-j




(second sequence) 0.71 1.0
E.P 045 1 0.68 0.75 0.86 0.89 (0.80±0.049, n=4)
verapamil 10 nM 1.1 2.1 3.7
PGF2a 0.2 1.0 2.4
1.1 1.4
15-oxo EP Oil 0.5 0.67
EP Oil 1.2 1.1








ICI 81008 0.1 0.67
PGE1 as agonist
PGF2a 0.5 0.80
Values in the parenthesis indicate mean+s.e.
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the contractile response to carbachol. its pA2 value was
about 6.0. In order to study the relaxant effect of PGE2 in
the presence of verapamil, the concentration of carbachol
was increased to give a similar tone level to that produced
by carbachol alone. Verapamil slightly shifted the PGE2
dose-response curve to the right. EP 045 neither blocked the
relaxant effect of PGE2 nor the contractile effect of
carbachol, it raised slightly the tone produced by
carbachol.
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The results suggest that the cat tracheal muscle has two
types of prostanoid receptorswhich mediate relaxation. One
is sensitive to PGE2 analogues and is not readily
desensitized. The other type responds to PGF2a analogues and
is readily desensitized.
On the PGE2 receptor site, PGE2 is the most potent agonist
among the naturally-occurring prostanoids as shown by Horton
and Main (1965) and Apperley. Coleman. Kennedy & Levy
(1979). The order of potency for PGE2 and PGI2 analogues is
PGE2> PGEl> 16.16-dimethyl PGE2> ICI 80 205>> ZK 36374^, PGI2.
and ZK 36374 does not oppose the relaxant effect of PGE2. In
contrast, ICI 80205 and 16,16-dimethyl PGE2 are more potent
than PGE2 on the bullock iris sphincter, rat stomach fundus
and rat anococcygeus muscle, and ZK 36374 is a partial
agonist on these preparations (see bullock iris sphincter,
rat stomach fundus and rat anococccygeus muscle). These
results indicate that the PGE2 receptor mediating the
relaxant effect on the cat tracheal muscle is different from
the
that mediating^contractile effect on the other preparations
mentioned above. This is substantiated by the finding that
SC-19220 caused concentration-related parallel shifts to the
right of dose-response curves for PGE2 on PGE-sensitive
preparations such as the guinea-pig ileum and guinea-pig and
dog fundus, but had no effect on PGE2-induced relaxation of
cat trachea (Kennedy, Coleman, Humphrey, Levy & Lumley,
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1982).
We have found (data not shown) a similar PGE2 receptor
system in the dog hind limb where PGE2 is the most potent
prostanoid, PGEl, 16.16-dimethyl PGE2 and ICI 80205 are
weaker than PGE2. However, PGI2 and ZK 36374 show higher
activity in the dog hind limb than in cat trachea
preparation relative to PGE2. This awaits more work to
exclude a PGI2 receptor site in the dog hind limb.
The other type of prostanoid receptor shows a distinctive
property tachyphylaxis to PGF2a analogues. It seems not
to be due to inactivation of PGF2a on the PGF2a-desensitized
preparation since successive addition of PGF2a produced no
effect and ICI 81008 and ICI 79939, Stable PGF2a analogues
induced tachyphylaxis, too. It is unlikely that PGF2a
analogues act on PGE2 receptor sites to produce such an
effect since the PGF2a analogue—desensitized preparations
maintained the same sensitivity to PGE2 as before they were
treated with PGF2a analogues.
Tachyphylaxis to prostanoids has been observed previously
both in vitro and in vivo. Marked tachyphylaxis on the rat
uterus preparation was demonstrated with several
prostaglandins (Adamson, Eliasson & Wiklund. 1967; Eliasson,
Brzdekiewicz & Wiklund, 1969). In experiments on
anaesthetised chicks PGF2a injected intravenously increases
gastrocnemius muscle tension due to an action of PGF2a on
neurones within the chick spinal cord (Horton & Main, 1967)
and tachyphylaxis to successive doses of PGF2a often
develops if the interval between doses is short.
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Tachyphylaxis to the action of PGF2a has also been observed
on application to single neurones in the brain stem
(Avanzino, Bradley & Wolstencroft, 1966). In dogs exhibiting
marked sinus arrhythmia injection of PGE2 through a common
carotid artery abolishes or markedly reduces the arrhythmia
and tachyphylaxis occurred after 2 or 3 injections repeated
at 20 min intervals (McQueen & Ungar, 1969). In human
isolated bronchial smooth muscle tachyphylaxis to SRS-A and
PGF2a could be produced and there was no cross tachyphylaxis
between these substances (Sweatman & Collier, 1968).
Although the significance of tachyphylaxis to prostaglandins
is not clear, the effect can be a useful tool for defining
and differentiating receptors. Agonist-specific
desensitisation of receptor-adenylate cyclase systems has
been used to probe prostanoid receptors in several tissues
(Remold-0 Donnelly 1974; Newcombe, Ciosek, Ishikawa & Fahey,
1975; Su, Cubeddu & Perkins, 1976; Lefkowitz, Millikin,
Wood, Gore & Mukherjee, 1977). Cooper and Schafer, Puchalsky
and Handin (1979) reported that pre-incubation of human
platelets with PGD2 (10 pM) for 2 h followed by washing
desensitized platelet adenylate cyclase to PGD2 more than to
PGE1. In addition, Miller and Gorman (1979) showed that
prior exposure of human platelets to PGEl (0.28 pM) , PGE2
(2.8 pM) or PGI2 (0.28 pM) for 5 min rendered platelets
desensitised to a subsequent challenge by these
prostaglandins but not to PGD2. The corollary was also true:
preincubation with PGD2 (0.28 pM) desensitised platelets to
a subsequent challenge with PGD2, but responses to PGEl,PGE2
or PGI2 were unaltered.
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PGF2a does not exert its inhibitory effect by releasing
neurotransmitters from the adrenergic nerve endings as
propranolol failed to antagonize PGF2a action. And in view
of the weak activities of PGD2, PGI2 and 11,9-epoxymethano
PGH2 it is reasonable to assume the there is a PGF2a type of
receptor mediating relaxation in the cat tracheal muscle.
Ligand binding measurements would be required to make
further differentiation between PGE2 and PGF2a receptors in
this preparation.
The relaxation and tachyphylaxis produced by PGF2a analogues
were not specific for carbachol-contracted preparations;
similar activity was seen on 5-HT-contracted preparations.
Thus, the inhibitory effect of PGF2a is probably not
specifically associated with either acetylcholine or 5-HT
receptors.
In this study a contractile agent concentration which
produced a response about 60% of its own maximum was chosen.
Increasing the contractile agent concentration results in
reduced relaxant responses to prostanoids, as demonstrated
by Jones (1970) (Figure T.7). This was further proved by two
separate groups of experiments. In one group of experiments
where low concentrations of acetylcholine (about 0.1 ^uM) were
used, PGEl showed high activity (threshold
concentration <2 ng/ml) (Horton & Main. 1965); in the other
group of experiments where a high concentration of
acetylcholine (about 55 ^pM) was used, the EC50 value for
PGE2 was about 350 ng/ml (Kennedy, Coleman, Humphrey, Levy &




Figure T.7 Cumulative dose response curves to acetylcholine
chloride on the cat tracheal chain preparation in the presence
of PGEi and PGA]. Figures adjacent to the curves refer to
PG concentrations in yg/ml. Ordinate: tension in g. Abscissa:
acetylcholine concentration in ug/ml (logarithmic scale).
(Data from Jones R.L., 1970, Ph.D. Thesis).
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responses to PGF2a as well. In the former group, the activity
of PGF2a was about one-thirtieth of the PGEs and response to
PGF2a took a "hook" shape: a rise in tone followed a
relaxant response (Figure T.8), but in the latter group
PGF2a was about 100 times less active than PGE2. The use of
an appropriate concentration of the contractile agents,
enabled us to show in this study the high activity of PGE2
and the tachyphylaxis to PGF2a.
In anesthetized, vagotomized and mechanically ventilated
cats bronchoconstricted by 5-HT, PGE2 produced a greater
reduction in central airway constriction than PGI2, and
6-keto PGElj a PGI2 metabolite, was also more potent than
PGI2 (Spannhake, Levin, Hyman & Kadowitz, 1981). According
to the results from this study it is possible that 6-keto
PGEl acts on PGE2 receptor site to produce the
bronchodilator effect.
That verapamil^ a calcium channel blocker^ failed to affect
relaxant responses to PGE2 probably indicates that this
inhibitory effect of PGE2 does not rely on extracellular
calcium.
EP 045 does not influence the responses to PGE2 and
carbachol. This further shows the selectivity of EP 045. The
rise in tone caused by EP 045 may be due to its inhibition
of the biosynthesis of endogenous PGE2 in the trachea.
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I min
Figure T.8 Isometric responses of cat isolated trachea, suspended
in 4 ml organ-bath containing Krebs-Henseleit solution. At the dots
acetylcholine 12.5 ng/ml was added. F2 = PGF2a, 0.75 pg/ml;
= PGE], 1.9 ng/ml; W = wash. The "hook" shape can be seen
in the response to PGF2«. (Data from Horton E.W. & Main I.H.M.,
1965, Br.J.Pharmac. 24, 470-476)
Section Three
Actions of Prostanoids on the Rat Gastric Fundus and Colon,
and Guinea-Pig Ileum and Colon
■e^rbnC i "t <Cti <m s : pP 3 - Si O
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PGs occur in a wide variety of gastrointestinal tissues.
Many studies on gastrointestinal motility have dealt mainly
with prostaglandins of the E and F series which until
recently were thought to be the major PGs formed by many
tissues. In general, PGE2 relaxes circular but contracts
longitudinal smooth muscle whereas PGF2a contracts both
types. PGD2 produces contractile effect on the longitudinal
muscle of rat and human stomach, rabbit jejunum and
guinea-pig intestine (Horton & Jones, 1974; Hamberg,
Hedqvist, Strandberg, Svensson & Samuelsson, 1975; Bennett,
Hensby, Sanger & Stanford, 1981; Bennett & Sanger, 1980),
and on the circular muscle of guinea-pig colon (Bennett,
Pratt & Sanger, 1980). On both longitudinal and circular
muscle preparations from human stomach
11 - 9-epoxymethano PGH2 is the most potent excitatory
prostanoid. This contrasts with gastro-intestinal
preparations from laboratory animals where PGE2 is thought to
be the most potent prostanoid, although PGF2a or TxA2 may
have considerable potency in some tissues. For instance,
TxA2 contracts the rat gastric fundus, and is about 10 times
less potent than PGE2 (Bunting, Moncada & Vane, 1976). In
guinea-pig ileum, 11,9-epoxymethano PGH2 is about 100 times
less active than PGE2 (Chijimats et al-, 1977; Bennett et
al., 1978). PGI2 seems less potent than other prostanoids in
most of these preparations.
Recently, several drugs have been examined as antagonists of
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various prostanoids in the gut, partly to characterise the
types of prostanoid receptors present ( Bennett, Jarosik,
Sanger & Wilson, 1980; Bennett, Pratt & Sanger, 1980; Sanger
& Bennett, 1980; Sanger & Bennett, 1980a). The antagonists
are the benzoxazepine derivative SC-19220, the
beta-adrenoceptor stimulant trimethoquinol and the PG
synthesis inhibitors sodium meclofenamate and indomethacin.
On the longitudinal muscle of rat gastric fundus SC-19220,
trimethoquinol and sodium meclofenamate show differing
blocking activity and this may indicate the presence of
different types of prostanoid receptor. PGE2 probably acts
on receptors different from those activated by
11,9-epoxymethano PGH2, since SC-19220, meclofenamate or
trimethoquinol antagonized these compounds to different
extents, and in particular, none of the drugs antagonised
contractions to both PGE2 and 11,9-epoxymethano PGH2. In
addition trimethoquinol reduced contractions to PGEl but not
to PGE2; thus the authors suggested that there are separate
receptors for PGEl and PGE2 (Bennett, Jarosik, Sanger &
Wilson, 1980).
It has been proposed that in the longitudinal muscle of
guinea-pig ileum, PGEl, PGE2 and PGF2a may activate similar
receptors (Bennett & Posner. 1971; Illes & Knoll, 1975).
Contractions to PGD2, PGE2 or PGF2a were antagonised with
low concentrations of meclofenamate which had little effect
on contractions to acetylcholine on this preparation
(Bennett, Pratt & Sanger, 1980). Recently. prostanoid
receptors in the longitudinal muscle of guinea-pig ileum
have been characterised by determining the order of agonist
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potency and their sensitivity to antagonism by SC-19220. The
order of potency for prostanoid-induced contraction is PGE2>
PGE1> PGF2a> 11,9-epoxymethano PGH2> ICI 81008 (Coleman,
Humphrey, Kennedy, Levy & Lumley, 1980). SC-19220
antagonised contraction of guinea-pig ileum to PGE2 or PGF2a
without greatly affecting that to acetylcholine or
histamine; the pA2 values for PGE2 or PGF2a antagonism were
similar (5.4 for PGE2 and 5-3 for PGF2a) (Coleman, Kennedy
& Levy, 1980), supporting the results of Bennett and Posner
(1971) and suggesting PGE2 and PGF2a share the same
receptor. Since in the longitudinal muscle of guinea-pig
ileum receptors for PGEl and PGE2 seem similar (Illes &
Knoll, 1975), it is probable that PGEl, PGE2 and PGF2a
activate the same receptor.
Since we had available several TxA2 receptor antagonists, a
specific PGF2a agonist (ICI 81008) and a possible partial
agonist on the PGE2 receptor (ZK 36374), we chose the rat
gastric fundus and guinea-pig ileum, which are most
sensitive to PGE2 analogues, in order to differentiate
further the PG receptors on these preparations and to test
whether ZK 36374 is a partial agonist on other PGE-sensitive
systems. At the same time certain other preparations from
these two species were also studied.
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METHODS
Gastric fundi and colons were removed from male Wistar rats,
and ilea and colons from male guinea-pigs immediately after
they had been stunned and bled.
Two strips of gastric fundus, about 1.5 cm long and 2 mm
wide, were cleaved parallel to the longitudinal muscle
fibres, one from each side of the greater curvature. Each
preparation was mounted under 1.0 g tension in a 10 ml organ
bath containing Krebs solution (NaCl 6.9, KC1 0.35,
MgS04-7H20 0.29, KH2P04 0.16, glucose 2.0, NaHCC^ 2.1, CaCl2
0.28 g/1). gassed with 95% 02 and 5% C02. and kept at 37°C.
The bathing solution for the rat gastric fundus contained
indomethacin 1.0 pM. Responses were measured
isotonically with a Washington isotonic lever transducer
(Type T.II), and recorded on a Grass Polygraph (Model 7C).
The guinea-pig ileum and colon and the rat colon, each about
2 cm long, were mounted under 0-5 g tension in Tyrode's
solution (NaCl 8.0, KC1 0.2, MgS04'7H20 0 . 26, NaH2P04-2H20
0.07- glucose 1-0, NaHCC>3 1.0, CaCl2 0.2 g/1), aerated with ,
air, and kept at 37°C. The bathing solution for the
guinea-pig ileum contained atropine sulphate (0.02 jiM) . The




All the prostanoids tested produced concentration-dependent
contraction of the longitudinal smooth muscle of rat gastric
fundus. PGE2 is the most potent prostanoid. A typical trace
of responses of the rat gastric fundus preparation to
cumulative doses of PGE2 is shown in Figure G.l. Responses
to naturally-occurring prostanoids peaked at 2-4 min and
remained steady for at least 20 min. A full dose-response
relationship was established in 30-40 min; following
wash-out, the response returned to the resting level in
about half an hour. The interval between two sequences was
about 1 hour. ICI 81008, ICI 79939 PGF2a^ 15-oxo EP 011 and
EP 011 each displayed a relatively slow on-set of action,
the contraction reaching a stable level in 5-10 min. ICI
80205 and 16,16-dimethyl PGE2 were the slowest in on-set. It
took 20-30 min for these compounds to produce a stable
submaximal response. Therefore, the naturally-occurring
prostanoids were always tested first and each comparison of
potency was made on a single preparation.
PGE2 Analogues
For the standard agonist PGE2. a mean threshold
concentration (tension change of about 5% maximum response)
of 0.16 ng/ml (range 0-02-0.25 ng/ml. n=49) was calculated.
A 50% maximum response was shown with a mean concentration
4'
W
PGE2 0.2 0.3 0.5 1.0 3.0 5.0 10 30 50
(ng/ml)
Figure G.l Rat gastric fundus preparation: responses to
cumulative doses of PGE2. The bathing solution contained
indomethacin 10 M. Changes in response were recorded
isotonicallv. W = wash.
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of 1.7 ng/ml (range 0-3-8.8, n=49). The PGE2 analogues
examined were PGE2. 16,16-dimethyl PGE2 and ICI 80205. The
relative potenciesof these compounds are shown in Table G.l.
Equipotent molar ratios were measured using the EC50 value
of PGE2 and the molar concentration of the tested compound
giving an equivalent response. ICI 80205 is the most potent
contractile agent tested on the rat gastric fundus
preparation.
In view of the fact that ICI 80205 and 16/16-dimethyl PGE2
have TxA2-like activity and EP 045, a TxA2 receptor
antagonist, blocks the action of 11,9-epoxymethano PGH2 on
this preparation, a group of experiments were designed to
measure the potency of the PGE2 analogues both in the
presence and absence of EP 045. The results are summarized
in Table G.2. In control experiments (without EP 045) the
usual procedure was carried out, but in EP 045-treated
preparations 1 /ig/ml EP 045 was added 10 min before the
start of first agonist sequence (PGE2) and the same dose of
EP 045 was added again 10 min before the start of the
second agonist sequence (ICI 80205 or 16,16-dimethyl PGE2).
Since ICI 80205 and 16,16-dimethyl PGE2 were slow in on-set
and off-set, only two concentration-response relationships
were established on one single preparation. In both control
and EP 045 treated preparation PGE2 was taken as a standard.
Considering the possibility that the sensitivity of the
preparation to PGE2 might be changed with time, a second
sequence of PGE2 was run in both control (without EP 045)
and EP 045-treated preparations. Table Q.2 shows that there
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Table G.l Activities of PGE2 analogues on the isolated rat gastric
fundus
r , Equipotent molar ratioCompound (PGEr1.0)
individual value meants.e. n
ICI 80205 0.015 0.042 0.047 0.059 0.041*0.0093 4
16,16-dimethyl PGE2 0.14 0.17 0.35 0.36 0.42 0.29±0.056 5
PGEi 3.0 4.3 5.0 6.5 4.7+0.073 4
Individual values are the result of a comparison with PGE2 on a single
preparation.
Table G.2 Potencies of PGE2 analogues on the isolated rat gastric






















For legend see text.
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was little change in sensitivity to PGE2 in both cases, and
that EP 045 at 1 jjg/ml had little effect on responses to ICI
80205 and 16,16-dimethyl PGE2.
Figure G.2a and 2b show representative log
concentration-response curves of PGE2 analogues.
16;16-dimethyl PGE2 reached the maximum similar to that of
PGE2 both in the presence and absence of EP 045. The log
concentration-response curve for ICI 80205 over the
concentration range of 0.02-0.5 ng/ml was approximately
parallel to that of PGE2. At higher concentrations of ICI
80205 further contractions could be elicited which reached a
higher maximum (11 + s.e.2.5% n=4 for control preparations
and 11 + s.e.2.3% n=4 for EP 045-treated preparations) than
that produced by PGE2.
PGI2 Analogues
PGI2 and ZK 36374 was also tested in the rat gastric fundus
preparation. PGE2 was used as the reference compound. The
sequence was to establish PGE2 concentration-response
relationship first, then those of PGI2 and ZK 36374.
Representative concentration-response curves are shown in
Figure G.3.
The concentration-response curve of PGI2 was not parallel to
that of PGE2, being flatter and covering a larger
concentration range. PGI2 gave a range of 83-107% of the
relative maximum response (PGE2=100%) with a mean value of
99 + s.e.2.4 (n=10). PGI2 elicited threshold response
(tension change of about 5% maximum response) at a mean
1
1.0 10
Concentration (ng/ml) (log scale)
Figure G.2a Rat gastric fundus preparation: cumulative
concentration-response relationships for PGE2 (solid circle)







0.1 1.0 10 100
Concentration (ng/ml)
1igure G.2b Rat gastric fundus preparation: cumulative
concentration-response relationships for PGE2 (open circle) and






1.0 10 100 1000
Concentration (ng/ml)
Figure G.3 Rat gastric fundus preparation: log concentration-response
curves for PGE2 (solid circle), ZK 36374 (open circle) and PGI2 (solid
square ).
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concentration of 7.6 + s.d.5.1 ng/ml (n=10. range 2.0-20
ng/ml) and 50% maximum response at a mean concentration of
79 + s.d.55 ng/ml (n=10, range 38-210 ng/ml). PGI2 was about
65 times less active than PGE2. On the other hand ZK 36374
was more active than PGI2 in the preparation: threshold
responses were seen with a mean concentration of 0.93 +
s.d.0.32 (n=13. range 2.7-13 ng/ml) (see Table G.3).
On most preparations. 13 out of 15. ZK 36374 produced less
than 80% of the relative maximum response (PGE2=100%, mean +
s.e.=69 + 2.7%, n=13, range 53-80%). On the two other
preparations both PGE2 and PGI2 showed high activity: EC50
values for PGE2 were 0.5 ng/ml and for PGI2 were 38 and 44
ng/ml. On these preparations ZK 36374 produced a maximum
responses which were 100% and 93% of the PGE2 maximum and
was 11 and 12 times less potent than PGE2.
The interaction of ZK 36374 with PGE2, PGF2a,
11,9-epoxymethano PGH2 and carbachol was also studied on
some of the 13 preparations. In the presence of a fixed
concentration of ZK 36374 (200 or 300 ng/ml) cumulative
doses of one of the full agonists were added to the organ
bath. As shown in Figure G.4^ ZK 36374 opposed the
contractile action of PGE2. The contractile action of
PGF2a, 11.9-epoxymethano PGH2 and carbachol was additive
with that of ZK 36374. This further confirmed that ZK 36374
is a partial agonist at the PGE2 receptor site mediating
contraction.
Estimates of the affinity constant of ZK 36374 were made





Figure G.4 Rat gastric fundus preparation: interaction of ZK 36374
with PGE^- A cumulative concentration-response relationship was
first established to PGE2 (open circle) alone, followed by a
cumulative relationship to PGE^ (solid circle) in the presence of a
fixed concentration of 200 ng/ml ZK 36374 (solid square).
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preparation. From 9 preparations the mean affinity constant
7 — 1
was estimated to be 8.3 ( + s.e.l.5)xl0' M .
PGI2 analogues were tested in the presence and absence of
TxA2 receptor antagonists to see if any TxA2-like activity
could be detected. The procedure was to add a TxA2 receptor
a
antagonist ascertain concentration into the organ bath 10
min before the start of first agonist sequence (PGE2) and to
add the same dose of the antagonist 10 min before the start
of the second agonist sequence (PGI2 or ZK 36374). The
results are shown in Table G.3. EP 116 at 500 ng/ml had
little effect on the PGI2 maximum response. On two
preparations ZK 36374 produced low maximum responses/ 32%
and 49% relative to PGE2 and opposed the response to PGE2.
The affinity constants are 2.3x10^ M-^" and 8.3x10^ M--*",
respectively. On two other preparations ZK 36374 produced a
high maximum (91% and 95% relative to PGE2) and was 6 and 8
times less active than PGE2. More experiments would be
g
required to determine whether EP 045 produces^ significant
effect on responses to ZK 36374, since the maximum response
to ZK 36374 varied a lot with preparations.
PGF2a Analogues
PGF2a is about 7 times less active than PGE2 on the rat
gastric fundus. Its mean threshold concentration is 1.2
ng/ml ( + s.d.0.44, n=17. range 0-6-2.0) and EC50 mean value
is 11 ng/ml ( + s.d.4.7, n=17, range 5.0-22). The maximum
response of PGF2a relative to that of PGE2 was variable- On
5 out of 10 preparations, PGF2a produced slightly higher
maximum and a steeper response than PGE2 (Figure
135
Table G.3 Activities of PGI2 analogues on the rat gastric fundus in the presence
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Figure G.5 Rat gastric fundus preparation: cumulative concentration-
response relationships for PGE^ (open circle) and PGF2a (solid circle).
\
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G.5) and on the other 5 preparation PGF2a showed the same
maximum as PGE2.
ICI 81008 was more potent than PGF2a and produced a maximum
response lower than that obtained with PGF2a (mean + s.e.=71
+ 8.1%, range 48-85%, n=4) (Figure G.6). Its EC50 values
were 0.35, 0.65, 0.85 and 1.0 ng/ml (mean=0.71 + s.e.0.14
ng/ml, n=4). The interaction of ICI 81008 with PGE2 and
PGF2a was studied.
Figure G.7a and 7b show that the action of both PGE2 and
PGF2a is additive with that of ICI 81008. In order to
exclude the possibility that ICI 81008 may be a partial
agonist on the PGF2a receptor site, experiments were done in
which ICI 81008 was added into the organ bath when the
preparation was contracted by PGF2a at a concentration
producing a response near maximum. A typical result is
illustrated in Figure G-8. Apparently, ICI 81008 did not
oppose the contraction produced by PGF2a. When preparations
were contracted with a concentration of ICI 81008 producing
its own maximum response^ adding PGE2 and PGF2a gave a
further contraction, and PGF2a was 50 times less active than
PGE2.
ICI 79939 PGF2a was very active on the preparation, being
about 25 times more potent than PGF2a and its
concentration-response curve was approximately parallel to
that of PGF2a (Figure G-9). The activity of ICI 79939 PGF2a
was also studied in the presence of the TxA2 receptor
antagonists, EP 116 or EP 045. The results show that EP 045








Figure G.6 Rat gastric fundus preparation: cumulative concentration-
response relationships for PGF2a (solid circle) and ICI 81008 (open
circle).
% Maximum response




Figure G.7a Rat gastric fundus preparation: interaction of ICI 81008
with PGE2; log concentration-response curve for PGE2 acting alone
(open circle) and the corresponding curve (solid circle) in the




Concentration (ng/ml) (log scale)
Figure G.7b Rat gastric fundus preparation: interaction of ICI 81008
with PGF2q; log concentration-response curve for PGF2q acting alone
(open circle) and the corresponding curve (solid circle) in the
presence of 70 ng/ml ICI 81008 (solid square).
141
Figure G.8 Rat gastric fundus preparation: interaction of
ICI 81008 with PGF„ . Adding ICI 81008 does not opposes the
response to PGF2Q- The bathing solution contains indomethacin











Figure G.9 Rat gastric fundus preparation: log concentration-response curve
for PGF (open circle) and ICI 79939 PGF„ (solid circle)2a
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79939 PGF2a (Table G.4). PGD2 was tested on two preparations
which had been previously treated with high concentrations
of both PGF2a (150 ng/ml) and ICI 81008 (200 ng/ml). PGD2 at
concentrations 100-1000 times those of PGF2a used initially
gave small contractile effects, and PGD2 was about 100 and
240 times less active than PGF2a.
Effects of TxA2 Antagonists
The activity of 11.9-epoxymethano PGH2 is lower than PGE2,
but similar to PGF2a. The concentration-response curve of
11.9-epoxymethano PGH2 was steeper and its maximum response
greater than that of PGE2 (Figure G.10) on the rat gastric
fundus. On 14 preparations threshold concentrations were
calculated to be 1.1 + s.d.0.66 and EC50 values 9.8 +
s.d.6.8 ng/ml. EP 045 and EP 116 caused a pronounced shift
to the right of the 1179-epoxymethano PGH2 log
concentration-response curve (Table G.5). From the
Gaddum-Schild equation were obtained affinity constants of
8.22 + s.e. 0.91x10® M--'- for EP 04 5 at 1.31 pM, 1.5 +
s.e.0.30x10® and 2.1 + s.e.0.51x10® M-"'" for EP116 at 45
nM and 90 nM respectively-
Effects of TxA2 antagonists on the responses to PGE2 and
PGF2a were studied in two ways: one was to set up a
concentration-response relationship of an agonist, add a
TxA2 antagonist at a fixed concentration into the organ
bath, and 10 min later set up the second
concentration-response relationship in the same preparation.
After plotting the log concentration-response curves, dose
ratios were calculated (see Table G.5). The other way was to
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in the presence of
EP 045 lpg/ml
ICI 79939 PGF2a
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EP 116 500 ng/ml












Individual values are the result of a comparison with PGF2a on a single preparation.
For measuring the potency of ICI 79939 PGF2a in the presence of a TxA2 antagonist
experiments were done by adding one of the TxA2 antagonists into the organ bath
10 min before the start of the first cumulative concentration-response relationship
(PGF2a) and 10 min before the start of the second cumulative concentration-response
relationship (ICI 79939 PGF2q)- In these cases PGF2a in the presence of a TxA2






Figure G.10 Rat gastric fundus preparation: log concentration
response curves for PGEp (open circle) and 11,9-epoxymethano
PGHp (solid circle).
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Table G.5 Effects of EP 045 and EP 116 on contractile response to different
agonists on the rat gastric fundus preparation
Treatment Agonist Number of
Dose-ratios for the second agonis
test . . .




5 0.74 1.1 1.1 1.1 1.6
(1.1+0.14)
thano PGH2 2 1.1 1.3




thano PGH„ 5 7.7 10 11 12 14
(11+1.0)
EP 116 pge2 4 0.9 1.4 1.6 1.6
(1.4±0.17)
1.1 p m




thano PGH0 3 5.0 8.5 9.6
0.045 m M (7.7+1.4)
ep 116 11,9-epoxvme-
0.090 pM
thano PGH2 3 11 22 26
(2014.5)
* Values obtained during a third agonist cumulative sequence.
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establish the concentration-response relationship of an
agonist in the absence of a TxA2 antagonist on one tissue
and the concentration-response relationship in the presence
of a TxA2 antagonist on another tissue. After plotting the
log concentration-response curves, EC50 values were
estimated (Table G.6). The two groups of results were
consistant with each other. They revealed that EP 045 and EP
116 had little effect on responses to PGE2, but caused a
small shift to the right of the PGF2a concentration-response
curve.
Other TxA2 Analogues
EP 011? 15-oxo EP 011 and PTA2 were tested. The log
concentration-response curve for EP 011 at the concentration
less than 10 ng/ml was approximately parallel to that of
11 -9-epoxymethano PGH2, while at higher concentration of EP
011 further small contractions could be elicited (Figure
G.ll). EP 011 was about 20 times more potent than
11 -9-epoxymethano PGH2. 15-0xo EP 011 showed similar potency
to that of EP 011. EP 045 at 0.5 jjg/ml or EP 116 at 0.5
^ig/ml blocked the effects of EP 011 or 15-oxo EP 011.
PTA2 was very weak on this preparation. EP 116 at 0.5 jjg/ml
and EP 045 at 1.0 ^g/ml had a weak effect on the response to
PTA2. In the presence of TxA2 antagonists treatment of
preparations with PTA2 0.5-1.0 jag/ml for 10-40 min did not
oppose the contractile actions of PGE2 and PGI2.
Effect of Verapamil
Verapamil at 5.0 pM shifted the concentration-response
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Control 1.7+0.27 (n=49) 11+1.1 (n=17)
EP 045(1.3 uM) 1.4+0.21 (n=15) 25±9.8 (n=3)
EP 116(1.1 uM) 1.1+0.22 (n=7) 27+4.5 (n=5)




I-igure G.ll Rat gastric fundus preparation: log concentration-
response curves for 11,9-epoxvmethano PGH2 (open circle) and
EP Oil (solid circle).
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curves of both 11,9-epoxymethano PGH2 and PGE2 to the right
and lowered the maximum response (Figure G.12a and 12b).
Guinea-Piq Ileum Longitudinal Muscle
The guinea-pig ileum longitudinal muscle preparation was
suspended in Tyrode's solution containing atropine 0-02 jiM
since it has been found that prostaglandins can produce
contraction partly by stimulating intrinsic cholinergic
nerves (Bennett, Eley & Scholes, 1968).
The preparation contracted to PGE2, PGI2, PGF2a and
11,9-epoxymethano PGH2 (PGD2 was not tested). Responses to a
fixed concentration of a prostanoid showed considerable
variation on the same preparation, when the interval between
two single doses was less than 2 min. The interval between
two single doses was therefore increased from 2 min to 3-5
min in order to obtain^reproducible response. PGE2 is the
most potent of the agonists tested: threshold responses were
seen with concentrations of 1.4 + 0.60 ng/ml (mean + s.d.,
n=12) and the EC50 was 20 + 11 ng/ml (mean + s.d., n=12) .
The effects of PGE2 were not influenced by indomethacin (1.0
pM) .
PGI2 and ZK 36374 were fairly active but showed irregularly
shaped log concentration-response curves. It was therefore
difficult to measure their potency relative to PGE2. Figure
G.13 shows typical concentration-response curves for PGE2,
PG12 and ZK 36374 .
PGF2a and 11,9-epoxymethano PGH2 were weak contractile
% Maximum
response to PGE2 alone
Concentration (ng/ml)
Figure G.12a Rat gastric fundus preparation: inhibitory effects
of verapamil on the contractile response to PC.E?. A cumulative
concentration-response relationship was first established to PGE
(open circle), followed by a cumulative relationship (solid circ
in the presence of a fixed concentration of 5 x 10~® M verapamil
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l.o 10 100 1000
Concentration (ng/rnl )
% Maximum response
to 11,9-epoxymethano PGH2 alone
Figure G.12b Rat gastric fundus preparation: inhibitory effects of
verapamil on the contractile response to 11,9-epoxymethano PGH^. A
cumulative concentration-response relationship was first established
to 11,9-epoxvmethano PGfIn (open circle), followed by a cumulative
relationship (solid circle) in the presence of a fixed concentration




Figure G.13 Guinea-pig ileum preparation: concentration-
response relationships for PGE.5 (open circle), PGI^ (solid
circle) and ZK 36374 (solid square).
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agents. At 100 ng/ml they produced small contractile
effects.
Effects of Cyproheptadine, Methysergide, Dibenamine and
Mepyramine
Cyproheptadine (a 5-HT and histamine antagonist),
methysergide (a 5-HT antagonist), dibenamine (an
alpha-adrenergic blocker), and mepyramine (a histamine
antagonist) at 1 pM for each compound, were studied in order
to see whether they have any effects on responses to
prostaglandins. Fixed submaximum concentrations of PGE2 (10
ng/ml) and PGI2 (50 or 100 ng/ml) were chosen. The
experiments in the absence and presence of one of these
antagonists were conducted on a single preparation in the
following way: a fixed concentration of PGE2 or PGI2 was
added into the organ bath, and left until the response
reached its plateau. Following 2 or 3 wash-outs, a fixed
concentration of one of the antagonists was added and
allowed 3 to 5 min contact with the preparation, then the
same amount of PGE2 or PGI2 was added. Responses were
counted as the height (mm) of clear rise above the basic
tone level. The results are shown in Table G.7.
Cyproheptadine significantly reduced the contractile effects
of both PGE2 and PGI2. Methysergide inhibited responses to
PGI2, but had no effect on responses to PGE2. In certain
cases methysergide caused a contraction. This may be due to
its partial agonist activity on 5-HT receptor sites
(Apperley, Feniuk, Humphrey & Levy, 1980). Mepyramine seemed
to enhance the action of PGE2.
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Table G.7 Effects of some neurotransmitter receptor antagonists on the
response to PGE2 and PGI2 on the guinea-pig ileum preparation.




























All the naturally-occurring prostanoids and also
llj9-epoxymethano PGH2 contracted both guinea-pig colon
longitudinal muscle and circular muscle preparations.
Responses to the prostanoids were elicited rapidly, reaching
a maximum in 2-3 s, then fading. 11,9-Epoxymethano PGH2 was
very potent on the circular muscle. PGF2a and PGD2 had
similar activities on both the longitudinal and circular
muscle preparation.
Rat Colon Longitudinal Muscle
These experiments was carried out to compare the activity of
PGF2a with that of 15 cx EP 130, since it is known that the
preparation is very sensitive to PGF2a rather than other
prostanoids.
The preparation has spontaneous phasic activity and
responded quickly to PGF2a. The contractile response started
2-3 s, reached a maximum in 10-20 s, and relaxed
spontaneously. The contractile action of 15 cx EP 130 was
slow in on-set and off-set. Responses to 15 tx EP 130 peaked
after 2-4 min and were sustained. The response was
accompanied by a rise in phasic activity, which could be
inhibited by atropine (2 pM) . Following wash-out the
response returned to the basic tone level gradually.
Concentration-response curves for PGF2a and 15 cx EP 130 are





Figure G.14 Rat colon preparation: concentration-
response curve for PGF„ (open circle) and 15 a EP 130
(sol id circ1e ).
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Threshold concentrations for PGF2a ranged from 0-5 to 3.0
ng/ml and EC50 values were 7.5-20 ng/ml. On the other hand,
15 (x EP 130 produced only 27-40% of the maximum response
obtainable with PGF2a. Its threshold concentration was less
than 100 ng/ml, and its EC50 values had a range of 100-300
ng/ml. The interaction of 15 (X EP 130 with PGF2a was also
studied. A fixed concentration (lpg/ml) of 15 <x EP 130 was
added into the organ bath first. Between 2-6 min later when
the response to 15 (x EP 130 had reached its plateau, a dose
of PGF2a was added. A typical result is shown in Figure
G.15. The contractile effect of PGF2a was opposed by
15 <x EP 130.
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PGF^ (ng/ml)
10 50 15 a EP 130 PGFga
1 Hg/ml 100 ng/ml
Figure G.15 Rat colon preparation: interaction of 15 a EP 130
with PGF„ . The figure shows 15 a EP 130 at 1 ug/wl opposes2a
the contractile action of PGF^ .2a
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DISCUSSION
Rat Gastric Fundus Longitudinal Muscle
In agreement with Bennett, Jarosik, Sanger and Wilson
(1980), we have found that the rat gastric fundus contains
PGE2 and TxA2 receptors.
The TxA2 receptor in this preparation has similar properties
to those in the bullock iris sphincter, the dog saphenous
vein and the guinea-pig trachea. In particular, the
contractile activity of 11,9-epoxymethano PGH2 on the
gastric fundus longitudinal muscle is blocked by TxA2
receptor antagonists EP 045 and EP 116. Affinity constants
of 8.2x10® M-^ for EP 045 and 1.8x10® M-^ for EP 116 (see
Table E.12) are similar to values obtained on the above
three preparations. Furthermore, EP 011 and 15-oxo EP 011
show high activity, 20 times more active than
11,9-epoxymethano PGH2, a result similar to that in the
bullock iris sphincter preparation. The further contraction
induced by EP 011 at higher concentration can be attributed
to its PGE2 or/and PGF2a activity (see below). Because of
the existence of TxA2 receptors in the fundus preparation,
TxA2 receptor antagonists (EP analogues) were widely used in
this study when investigating other PG receptors. The other
compound which is widely quoted as being a thromboxane
receptor antagonist is PTA2. PTA2 opposed contraction of the
rat fundus elicited by azo or epoxymethano analogues of
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PGH2, but it showed weak contractile activity which varied
with the preparation used. Nicolaou, Magolda, Smith,
Aharony, Smith and Lefer (1979), and Aharony, Smith, Smith,
Lefer, Magolda and Nicolaou (1980) found that PTA2 potently
antagonized constriction of cat coronary artery and
aggregation of human platelets induced by PGH2 analogues.
Ansell, Caton, Palfreyman, Stuttle, Tuffin and Walker (1980)
obtained a slight stimulation of rabbit aorta and mesenteric
artery, and a weak antagonism of the TxA2-like material
released from guinea-pig lung. More recently, Jones,
Peesapati and Wilson (1982) showed that PTA2 was a partial
agonist on the TxA2 receptor site in rabbit aorta, dog
saphenous vein and guinea-pig trachea preparations. PTA2
caused shape change but not aggregation in washed human
platelets (Jones, Personal Communication). Bennet and Sanger
(1982) have also examined the action of PTA2 on the rat
fundus. They found that PTA2 (0-5 jug/ml) antagonized
submaximal contractions of the rat gastric fundus to
11,9-epoxymethano PGH2. However. they claimed that the
effect was not selective, since contractions to PGE2, PGF2a,
PGI2 and a lesser extent acetylcholine (Ach), were also
reduced. Their findings with the longitudinal muscle of
human stomach were similar to those with the rat gastric
fundus, except that PGI2 relaxes the human preparation and
this response was unaffected by PTA2. In contrast, we have
found PTA2 did not oppose the effect of either PGE2 or PGI2
on the rat gastric fundus or the effect of PGF2a on the dog
iris sphincter. The discrepancy may be due to two factors:
(1) we used indomethacin to inhibit endogenous biosynthesis
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of PGs; (2) in our case the preincubation time with PTA2 was
10-40 min? in their experiments 1 h was chosen. We also used
a higher concentration (1 pg/ml) of PTA2. One can speculate
that PTA2 may inhibit endogenous production of PGs
stimulated by exogenous PGs (this factor was eliminated by
using indomethacin in our study), or when a prolonged period
of preincubation is adopted PTA2 may affect events in the
excitation-coupling chain, since PTA2 also depresses
responses to Ach. In our hands PTA2 appears to exert a
specific action at the TxA receptor in the rat fundus. It
may be a partial agonist rather than a true antagonist.
The isolated rat gastric fundus has commonly been employed
for the detection and assay of PGE-like substances in
biological fluids. Our results show that the PGE2-sensitive
system responds to PGE2, 16,16-dimethyl PGE2 and ICI 80205.
The order of potency is ICI 80205> 16,16-dimethyl PGE2>
PGE2, consistent with the results from the bullock iris
sphincter experiments. ICI 80205 and 16,16-dimethyl PGE2 are
slightly more active in this preparation than in the iris
sphincter relative to PGE2. This is not due to their
TxA2-like activity since TxA2 receptor antagonists do not
affect their potency and maximum response. The additional
contraction elicited by higher concentrations of ICI 80205
may be caused by an action on PGF2a receptor sites (see
later).
In addition to PGE2 and TxA2 receptor sites, we have shown
that a PGF2a-sensitive system may exist in the gastric
fundus. It is characterized by the high activity of
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ICI 81008, a specific PGF2a-like agonist. ICI 81008 is about
15 times more potent than PGF2a. Its lower maximum response
relative to that of PGF2a is probably due to its inactivity
on PGE2 receptor sites^ since we have shown on the bullock
iris sphincter that ICI 81008 is a very weak agonist^ but
PGF2a is capable of acting on the PGE2 receptor system (the
EPMR is about 50, PGE2=1.0). Since the rat fundus is highly
responsive to PGE2 one can expect that PGF2a will interact
with the PGE2 receptor to produce contraction. The
possibility that ICI 81008 might be a partial agonist on the
PGF2a receptor was also considered. This can be excluded
since the response to PGF2a was not opposed by ICI 81008 on
the rat gastric fundus. It is relevant that on the dog and
cat iris sphincter muscle preparations ICI 81008 is a full
agonist on the PGF2a receptor site. Another possibility is
that there may be two subtypes of PGF2a receptors in the rat
gastric fundus: ICI 81008 is a full agonist on one receptor
site and an inactive or an antagonistic agent on the other.
As we have demonstrated^ in the presence of ICI 81008 at a
concentration which gave a maximum response^ PGF2a elicited
additional contractions at concentrations about 50 times
greater than PGE2, similar to the relative potency of PGF2a on
PGE2-sensitive system of the bullock iris sphincter. This
indicates that the additional contraction induced by PGF2a
may be due to activation of PGE2 receptor. And up to now,
there is no evidence which suggests the existence of two
subtypes of PGF2a receptor.
ICI 79939 PGF2a is more active than ICI 81008 in this
preparation in contrast to the dog iris sphincter where
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ICI 81008 is more active than ICI 79939 PGF2a. The high
activity of ICI 79939 PGF2a on the rat gastric fundus can be
explained by its great potency on the PGE2 receptor, but not
on the TxA2 receptor since its activity is not altered by
TxA2 receptor antagonists.
ZK 36374 is more active than PGI2 on the rat gastric fundus,
relative to PGE2,
Although^ZK 36374 produces slightly higher maximum responses
on the gastric fundus than on the bullock iris
sphincter, in most cases it gives a lower maximum response
than PGE2, and opposes the response to PGE2, a profile
similar to its activity in the bullock iris sphincter. This
suggests a partial agonist action on the PGE2 receptor site.
The higher maximum response to ZK 36374 on the gastric
fundus could however be explained by the presence of PGI2
receptor in the tissue. This is supported by the finding
that PGI2, although it is a much weaker agent, does elicit a
higher maximum response in the rat gastric fundus than in
the bullock iris sphincter relative to PGE2, and in some
an
cases it gives^ even higher maximum response than PGE2.
Furthermore, it has been shown that rat gastric fundus
microsomes can generate PGI2 (Gryglewski, Bunting, Moncada,
Flower & Vane, 1976); this seems to imply that the rat
gastric fundus has PGI2 receptor sites. It is unlikely that
ZK 36374 and PGI2 act on TxA2 or PGF2a receptor sites, since
(1) their actions on the rat gastric fundus are not blocked
by TxA2 receptor antagonists, and (2) both PGI2 and ZK 36374
are very weak on PGF2a receptor sites as shown in the dog
and cat iris sphincter studies. An alternative explanation
165
is that the rat gastric fundus has a larger PGE2 receptor
reserve than the bullock iris sphincter, which allows
ZK 36374 and PGI2 to give higher maximum responses.
Bennett, Jarosik, Sanger and Wilson (1980) have found that
trimethoquinol (50 ng/ml) reduced contraction of the rat
stomach muscle to PGD2, PGF2a, PGI2, 11,9-epoxymethano PGH2
and PGEl but not PGE2. Therefore, the effect on PGE2 and
PGEl may differ, although both are reported to have similar
binding sites in this tissue (Miller & Magee. 1973). Since
PGEl has both PGE2- and PGI2-Iike activity: a full agonist
on the PGE2 receptor and a partial agonist on the PGI2
receptor, the inhibition of PGEl-induced contraction by
trimethoquinol could be due to the depression of the
PGI2-Iike activity. However, since there is certain evidence
suggesting the existence of PGEl receptors, and the
existence of PGI2 receptor in the rat gastric fundus has not
been proved, we had better leave the question open until
selective PGI2 or PGE2 antagonists are available. The
existence of a PGEl receptor we will consider in the General
Discussion Section.
Bennett and Sanger (1982) showed that PTA2 opposed PGF2a and
PGD2 to different extents. Does this suggest the existence
on the cat iris sphincter (P39)
of PGD2 receptors? As we have demonstrated, PGD2 could haveA
PGF2a-like activity; it is about 35 times less active than
PGF2a. Bennett. Jarosik, Sanger and Wilson (1980) have shown
that PGD2 was about 5 times less active than PGF2a on the
rat gastric fundus. However in our study, following prolonged
treatment of the preparation with PGF2a and ICI 81008, PGD2
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showed an activity 170 times less potent than PGF2a. If
there were PGD2 receptor sites, it would appear that PGF2a
and ICI 81008 could desensitize them.
Guinea-oiq Ileum
The isolated guinea-pig ileum is another preparation which
has commonly been used for bioassay of PGs (Eliasson, 1957;
Bergstrom, Eliasson, von Euler & Sjovall/ 1959; Eliasson,
1959; Anggard & Bergstrom, 1963; Bergstrom & von Euler,
1963; Horton, 1963; Horton & Main, 1963; Anggard, 1966;
Horton & Main, 1965; Pike, Kupiecki & Weeks, 1967).
Several studies have demonstrated that PGE series are
released from the guinea-pig ileum (Botting & Salzmann,
1974; Botting, 1977; Kadlec, Masek & Seferna, 1978;
Yagasaki, Takai & Yanagiya, 1980). In fact PGE2 is the most
potent contractile compound among the naturally-occurring
PGs. Like PGEs, PGI2 is synthesized by human and animal
intestinal tracts (LeDuc & Needleman, 1979; Bennett, Hensby,
Sanger & Stanford, 1981; Whittle, 1981) and contracts the
guinea-pig ileal longitudinal muscle (Moncada, Gryglewski,
Bunting & Vane, 1976a; Sirois, Borgeat & Jeason, 1981). In
this study, we have found PGI2 is fairly active, and
ZK 36374 showed a higher activity relative to PGE2 in this
preparation than in the bullock iris sphincter. This
indicates that there may be PGI2 receptor in the guinea-pig
ileum preparation.
Intrigued by the finding that the effect of PGs on the
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guinea-pig ileum could be inhibited by cholinergic
antagonists, we tried some other neurotransmitters receptor
antagonists in an attempt to differentiate PGE2 and PGI2
receptors. As shown in Table G.7, methysergide had little
effect on response to PGE2, but inhibited response to PGI2,
and mepyramine enhanced the action of PGE2 but did not
affect response to PGI2. Cyproheptadine and dibenamine
inhibited both PGE2 and PGI2, but to slightly different
extent.
Cyproheptadine is believed to be a potent antagonist of the
actions of 5-HT, and also has antihistamine and
antibradykinin activity. It has been found that in addition
to its receptor antagonist activities, cyproheptadine
inhibits the release of insulin and glucagon from rat
pancreas (Joost, Beckmann, Holze, Lenzen, Posner &
Hasselblatt, 1976; Richardson, 1976; Donatsch^ Lowe,
Richardson & Taylor, 1980), reduces the spontaneous
contraction of the rat uterus (Sadovsky, Dora, Pfeifer,
Polishuk, Rachaminoff & Sulman, 1973) and suppresses
mechanical and electrical activity in guinea-pig taenia coli
(Lowe, Matthews & Richardson, 1981). These effects are
antagonized by high calcium. Cyproheptadine also decreases
calcium uptake into strips of guinea-pig taenia coli (Lowe,
Matthews & Richardson, 1981). Recently, Riccioppo Neto
(1983) has found that cyproheptadine decreases action
potential duration and plateau amplitude of the action
potentials on canine cardiac Purkinje and ventricular muscle
fibres; these effects were readily antagonized by increase
in the extracellular calcium concentration. The effect of
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cyproheptadine on action potential characteristics of
Purkinje fibres is similar to those described for verapamil
and D 600 (Kohlhardt, Bauer, Krause & Fleckenstein, 1972;
Cranefield, Aronson & Wit, 1974; Rosen, Ilvento, Gelband &
Merker, 1974). He suggests that cyproheptadine reduces
inward calcium current via the slow channel, and at higher
concentration cyproheptadine might also be exerting
depressant effects on the fast inward sodium current.
Furthermore, Ganatra, Dhumal, Bhatt and Sachdev (1979)
reported that cyproheptadine non-selectively blocked the
responses to PGEl, PGF2a as well as Ach and 5-HT at
concentrations from 10 ng to 1 ^pg/ml in rat stomach strip,
rabbit uterus, guinea-pig ileum and rabbit jejunum. All
these findings indicate that cyproheptadine may be a calcium
channel blocker. Thus, the inhibitory effect of
cyproheptadine on the guinea-pig ileum preparation may be
associated with its calcium channel blocking activity.
Apperley, Humphrey & Levy (1976) observed that
cyproheptadine was weak in blocking noradrenaline-induced
contractile response in the rabbit aorta and ear artery.
This is probably .due to noradrenaline - mobilization of
intracellular as well as extracellular calcium pools in
those two preparation, as suggested by Deth and van Breemen
(1974, 1977), and Manzini, Maggi and Meli (1983).
Dibenamine, a haloalkylamine, has many pharmacological
actions in addition to alpha-adrenoceptor blockade. It has
antagonistic action against histamine, 5-HT, Ach
(muscarinic), angiotensin and bradykinin. Thus, it is hard
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to tell through which antagonism dibenamine produces the
inhibitory effect on both PGE2 and PGI2. However one can at
least say that it is not due to antagonism on histamine
receptors since mepyramine did not oppose PGI2 action.
Atropine has an affinity constant of 10^ for Ach
receptor in the guinea-pig ileum. We used the concentration
of 0.02 pM. In work by Kennedy, Coleman, Humphrey, Levy &
Lumley (1982) atropine at 0.8 |iM, 40 times higher than the
concentration we used, was chosen. They showed that relative
to PGE2, PGI2 was far less potent in their study than in our
experiments. This may indicate that PGI2 may be a powerful
Ach releasing agent, and the concentration of atropine we
chose was not high enough to block all activity of the
released Ach. This idea is supported by more recent findings
of Gaion and Trento (1983). They have demonstrated that
PGl2-induced contractions were inhibited by atropine and
potentiated by physostigmine. Tetrodotoxin as well as low
temperature abolished and beta-bungarotoxin reduced the
effect of PGI2, and in the presence of tetrodotoxin PGI2
failed to affect the response to a sub-maximal concentration
of Ach. They suggest that PGI2 releases Ach from intramural
nerves possibly by increasing the excitability of
cholinergic cell bodies. Since PGI2 was very active (its
threshold concentration was less than 1 nM), it is probable
that PGI2 receptors exist on the intramural cholinergic
nerves of the guinea-pig ileum. It is still unknown whether
there are PGI2 receptors in the guinea-pig ileal
longitudinal muscle itself. Therefore dibenamine may inhibit
the response to PGI2 by antagonising the released Ach, since
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it has antagonistic action on the muscarinic receptor.
.Guinea-pig Colon
PGD2 is synthesized enzymatically in the gut and the brain
of mammals. It has been found that PGD2 has a distinct and
interesting profile of biological activity of its own. PGD2
is a potent vasopressor agent in the sheep, being 70 times
more potent than PGF2a (Jones, 1976) . This action is not
blocked by EP 045 (Jones, Personal Communication). PGD2
potently inhibits aggregation of human, sheep and horse
platelets, and it has been suggested that PGD2 acts on a
different receptor than do PGI2 and PGEl. Recently, Ishizawa
and Minowa (1982) have shown that both PGD2 and PGF2a were
active in the guinea-pig colonic longitudinal and circular
muscle. In particular, the contractile action of PGD2 was
more potent than that of PGF2a in the circular muscle. In
the hope of finding a PGD2-sensitive preparation to
characterize the PGD2 receptor we tried both these
preparation. Unfortunately, we have found that these
preparations are sensitive to other PGs as well. One thing
we need to mention is that PGE2 consistently displayed
contractile activity in our study, while Sanger and Bennett
(1980) showed that PGE2 relaxed guinea-pig colonic circular
muscle, and only in some cases did it cause contraction
alone or preceeding the relaxation.
Rat Colonic Longitudinal Muscle
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The rat colonic longitudinal muscle is sensitive to PGF2a
(Jones, Personal Communication) . 15 oc EP 130 showed a
partial agonist activity in this preparation, which is





Actions of Prostanoids on the Rat Platelets
Re/e.e^-c/ Ff 3 rJr - 37o
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Platelets, which are circulating pieces of megakaryocyte
cytoplasm are excitable. The most familiar excitable
responses are adhesion and aggregation. Both of them are
involved in haemostasis and its pathological aberration,
thrombosis. The processes of adhesion and aggregation are
simplest to quantitate in vitro. Aggregation is presently
more frequently studied than adhesion. The most commonly
used method for studying the aggregation process is based on
the light transmission method first described by Born
(1962), and subsequently reviewed by O'Brien (1971), Attar,
McLaughlin and Masaitis (1973) and others.
Platelet activation is a sequence of morphological and
functional changes, with pseudopod formation,
centralisation of the contractile proteins, accompanied by
the. formation and secretion of a variety of substances. The
secretion reaction consists of the release of intragranular
materials (5-HT, ATP, ADP» calcium, the various metabolites
of arachidonic acid, platelet-activating factor (PAF),
lysosomal enzymes and mitogenic substance) to the
extracellular medium (Holmsen & Weiss, 1979). The
aggregating agents include ADP, adrenaline, collagen,
thrombin, PAF, calcium ionophores and prostanoids.
It has been suggested that prostanoids, ADP and PAF can
cause platelet aggregation directly and indirectly (by
Ca-
releasing each other) while ionophores, thrombin and collagen\ '
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aggregate platelets by release of ADP, PAF and prostanoids.
Since the concentration of adrenaline required to induce
platelet aggregation by itself is greater than that normally
found in the circulation, it may act synergistically with
other aggregatory agents.
The turbidometric method has been extensively used to
observe the aggregatory process in vitro. The addition of an
aggregating agent to an opalescent stirred suspension of
platelets results in platelet aggregation and an increase in
light transmission through the platelet suspension. The
activation of platelets can be divided into three steps:
shape change, primary wave and secondary wave. A weak
stimulus induces only shape change visualized by a small
deflexion in the direction opposite to the aggregating wave,
indicating a decrease in light transmission. This change
reflects an internal transformation. Using electron
microscopy it is found the discoid shape of platelets is
lost and the cells become irregularly spherical with
multiple spiny pseudopods. The circumferential bundle of
microtubules and the enclosed organelles shift centrally.
The primary wave reflects a loose platelet-platelet
attachment- Change in platelet shape and the primary
aggregation are reversible. The secondary wave of
aggregation occurs with higher concentrations of agonist and
represents largely irreversible aggregation mediated by
released ADP, PGs and PAF from platelet granules.
Platelet shape change does not require the presence of
external calcium ions, since it occurs in the presence of
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high external concentrations of a chelating agent EDTA
(Born, 1970) or in calcium-free medium (Rink, Smith & Tsien,
1982). This indicates that intracellular calcium may be
is associated with
involved. In fact; shape change induced by ADP^an increase in the
internal free calcium concentration, measured
spectrophotometrically using the calcium-indicator murexide,
though no (45)Ca is taken up from extracellular sources (Le
Breton & Feinberg, 1974). By employing low concentrations of
chlortetracycline as a fluorescent probe for membrane-bound
calcium, a redistribution of calcium away from membrane
sites during the shape shange was shown (Le Breton,
Dinerstein, Roth & Feinberg, 1976) . It is proposed that the
local increase in calcium ions restricted to the
submembranous region initiates the breakdown of the
circumferential ring of microtubules (Borisy, Olmstead,
Marcum & Alen, 1974) and causes local activation of the
contractile system giving rise to the pseudopods and spikes
observed in the course of shape change. For this reason it
is assumed that the release of calcium from the internal
surface of the platelet membrane is responsible for the
shape change.
The primary wave may require a lower cytosol calcium
concentration than the secondary wave the induction of
the release reactionj and may involve a different pool of
calcium ions (Malagodi & Chiou, 1974; Charo, Feinman &
Detwiler, 1976; Le Breton & Dinerstein, 1977).
The secondary wave is calcium-dependent (Feinman & Detwiler,
1974). Since the dependency on external calcium is variable,
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the internal calcium stores are thought to be mobilized for
the release reaction. The dense tubular system (White? 1972;
Kaser-Glanzmann, Jakabova, George & Luscher, 1978)
(analogous to the sarcoplasmic reticulum of muscle),
mitochondria and alpha-granules have been postulated to be
the source of calcium released at this stage. The external
calcium may play a role as trigger calcium to release
calcium from the intracellular calcium stores.
Recently, it has been shown that the diacylglycerol compound
l-oleoyl-2-acetyl-glycerol (OAG), 12-O-tetradecanoyl phorbol
-13-acetate (TPA), collagen and thrombin evoke aggregation
and release reaction without elevation of intracellular free
calcium above the basal level of 0.1 Jil\, suggesting the
existence of alternative triggers for platelet secretory
exocytosis (Rink, Smith & Tsien, 1982).
Platelets possess prostaglandin synthetase activity.
Needleman, Moncada, Bunting, Vane, Hamberg and Samuelsson
(1976) have shown the existence of TxA2 synthetase in both
human and horse platelet microsomes. Raz and Aharony (1978)
have demonstrated PGH2-to-PGE2 isomerase activity in
platelets treated with imidazole to remove TxA2 synthetase
activity. PGD2 is also synthesized and released in
sufficient quantity to affect platelet function (Oelz, Oelz,
Knapp, Sweetman & Oates. 1977). And it has been found that
serum albumin has PGH2-to-PGD2 isomerising activity (Hamberg
& Fredholmj 1976).
It has been shown that PGI2 is synthesized in the cells of
the blood vessel wall (Moncada, Gryglewski, Bunting & Vane,
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1976a, 1976b); platelets lack the enzyme PGI2 synthetase.
The prostaglandins and their analogues exert powerful
effects on platelets. PGI2, PGEl and PGD2 inhibit the
aggregation of platelets in vitro. The mechanism is thought
to be activation of adenyl cyclase. leading to increased
cyclic AMP levels. PGI2 is 30-50 times more potent than PGEl
for this effect. PGE2 exerts variable effects on platelets:
it is a potentiator of the secondary aggregation wave at low
concentrations (below 1 juM) and an inhibitor at higher
concentrations. TxA2 is a very powerful inducer of platelet
aggregation and the platelet release reaction.
It has been suggested that platelets possess PGI2 and TxA2
receptors (Whittle, Moncada & Vane, 1978; Needleman, Minkes
& Raz, 1976; Needleman, Raz, Minkes, Ferrendelli & Sprecher,
1979). The existence of TxA2 receptors is further confirmed
by blockade of the effect of TxA2-like agonists by a
specific TxA2 receptor antagonist EP 045 (Jones, Wilson,
Armstrong, Peesapati & Smith, 1983). PGEl is
thought to interact with the PGIg— receptor. (Whittle,
Moncada & Vane, 1978; Miller & Gorman, 1979).
There is some evidence suggesting that PGD2 has its own
receptor, distinct from that of PGI2, on platelets. PGEl and
PGI2 inhibit the aggregation of platelets of all mammalian
species studied whereas PGD2 is inactive in the rat, and
relatively inactive in the rabbit and cat (Smith, Ingerman,
Kocsis & Silver, 1974; Jones, Wilson & Marr, 1979). Miller
and Gorman (1979) showed that there was no
cross-desensitazation between PGI2/PGE1 and PGD2. N-0164,
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sodium p-benzyl-4- (1-oxo -2- (4-chlorobenzyl) -3
phenytpropyl) phenyl phosphonate, abolishes the inhibition of
platelet aggregation caused by PGD2, but had no effect on
the inhibition caused by PGEl and PGI2. Binding studies with
prostanoid radio-ligands give further support to this
hypothesis. The ability of PGs to displace bound (3H)-PGI2
from the high-affinity site is PGI2>> PGE1>> PGFla,
6-keto PGFla> PGD2, PGE2, PGF2a (Siegl, Smith, Silver,
Nicolaou & Ahern, 1979); for (3H)-PGD2 binding, the potency
is PGD2>> PGEl, PGI2, PGE2, TxB2 and PGF2a (Siegl, Smith &
Silver^ 1979, 1980). Schafer, Cooper, O'Hara and Handin
(1979), and Cooper and Ahern (1979) showed essentially
identical results with those of Siegl et al., except for the
fact that PGI2 was a more potent competitor for (3H)-PGE1
binding than PGEl. Those species whose platelets are
sensitive to PGD2 are those whose plasma is most active in
converting endoperoxides into PGD2 (Whittle, Moncada & Vane,
1978) .
It has been suggested that human platelets have a different
type of TxA2 receptor than smooth muscle does (Needleman,
Minkes & Raz, 1976; Needleman, Raz, Minkes, Ferrendelli &
Sprecher, 1979; Maclntyre, Salzman & Gordon, 1978;
Fitzpatrick, Bundy, Gorman & Honohan, 1978; Ohuchida,
Hamanaka & Hayashi, 1981). Since few TxA2 analogues have
been tested on rat platelets, we have used them to
characterise the "thromboxane" receptor present. The ability
of thromboxane receptor antagonists to block these effects
was also studied. We have found that PGE2 potentiates the
aggregatory action of EP 011 and 11.9-epoxymethano PGH2; for
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comparison^ human platelets were also studied.
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METHODS
Human blood was withdrawn from the antecubital vein of
healthy volunteers into ACD anticoagulant (10 ml/50 ml
blood) and centrifuged at 200 x g for 20 min. ACD contains
disodium hydrogen citrate (1.5 H2O) 2.0 g and glucose 3.0 g
per 100 ml distilled water. Platelet-rich-plasma (PRP) was
collected. Rat blood were collected in ACD (lml/9 ml blood)
with heparin 10 u/ml from cannulated abdominal aorta during
ether anaesthesia and centrifuged at 200 x g for 20 min.
Rat platelets were left at room temperature for 2-3 hours to
allow them to stabilize. Platelet aggregation was monitored
optically using an aggregometer manufactured by H. Upchurch
& Co. Ltd. and changes in light transmission were recorded
on a potentiometer recorder (Servoscribe Is).
Citrated PRP was added to Krebs solution and 0.9% NaCl
solution in a 2.5 ml glass cuvette to make a final volume of
1 ml. The formulae are in Table P.l.
Cuvettes and iron rods (for stirring) were siliconized with
2% dichloro- dimethylsilane in toluene and washed twice with
methanol. After incubation for 2 min (unless otherwise
stated) at 37°C with constant stirring (1000 rev/min), the
aggregating agent was added in 0.1 ml 0.9% NaCl solution.
Inhibitory or enhancing drugs in 0.1 ml 0.9%NaCl solution
were added 2 min prior to the addition of the aggregating
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Table P.l The recipes for testing platelet aggregation
Amount of PRP Krebs 0.9% NaCl Agent
Human(ml) 0.5 0.3 0 .1 0.1
Rat (ml) 0 .3 0.4 0.2 0 .1
agent (replacing 0.1 ml 0.9% NaCl solution).
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Rat PRP was pre-incubated at 37°C for 30 min with 1 pg/ml
(final concentration) 5-hydroxy-(side chain)2-
ri4C]-tryptamine which is incorporated into platelet dense
bodies. PRP (0.3 ml) was diluted with 0-4 ml Krebs solution
and 0.2 ml 0.9% NaCl solution. 2 Min after the addition of
an agonist to the stirred platelet samples, 200 pi samples
were withdrawn into 1.5 ml Eppendorf tubes. Release was
terminated by the addition of 0.8 ml ice-cold 0.4% w/v EDTA
in 0.9% NaCl and immediate centrifugation (15000 x g, 20°C,
30 s) in an Eppendorf centrifuge. Subsamples (0.5 ml) of
cell-free supernatant were transfered into scintillation
vials containing 10 ml of scintillant (2 parts PCS and 1
part toluene). Radioactivity was counted in a Philips PW
4540 liquid scintillation counter. It gave a value of cohnts
per minute (CPM) for each sample. The increase in
supernatant radioactivity above control was calculated and
expressed as a percentage of the radioactivity released by





On rat platelets at concentrations from 0.01-1.0 jjM, ADP
elicited a typical pattern of platelet aggregation: a shape
change at the lowest effective concentration (0.01-0.05 ^uM) ,
a modest reversible clumping of platelets ("primary
aggregation") at higher concentrations (0.05-0.2 pM), and a
more intense irreversible aggregation at 0.2 pM and above at
which the primary and secondary aggregation response merged
(Figure P.l). It was often difficult to find out the narrow
range of intermediate concentrations where primary and
secondary responses are kinetically distinct, resulting in
biphasic aggregation patterns.
EP 011, the most active agent among all prostanoids that
induced platelet aggregation, gave a different pattern of
response from that of ADP: reversible aggregation was
difficult to produce and the transition into a secondary
wave was marked (Figure P.2). EP 011 induces a shape change
in rat platelets at concentrations of 20-100 ng/ml, the
biphasic aggregation at 100-200 ng/ml and the merged
aggregation response at higher concentrations.
11,9-Epoxymethano PGH2, 9,11-azo PGH2, 15-oxo EP 011, CTA2,
PTA2 and 16,16-dimethyl PGF2a were also tested. Responses
were determined in the following way. Adding 0.1 ml 0.9%
NaCl increased light transmission to a new level, which was
1
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Figure P.l Aggregation of rat platelets in vitro:
ADP produces a shape change and a reversible aggregation at low
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Figure P.2 Aggregation of rat platelets in vitro:
EP Oil produces a shape change at low concentrations and
irreversible aggregation at higher concentrations. At 100 ng/ml
EP 011 induces a biphasic aggregation.
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taken as a zero level; the decrease in light transmission
due to platelet shape change produced by a prostanoid after
a 2 min period was measured and expressed as a percentage of
the maximum shape - change response. For aggregation, the
response was taken as the clear increase in light
transmission above the basal level 2 min after adding the
agent. Log concentration-response curves for shape change
and aggregation were plotted.
The threshold concentrations of each prostanoid for shape
change and aggregation were determined and the results of
these studies are shown in Table P.2. 15-oxo EP 011y CTA2
The relative
and PTA2 produced shape change only. ^ potencies of
prostanoids were measured, EP 011 was taken as a standard
(for CTA2, 11,9-epoxymethano PGH2 was taken as a standard).
The results are summarized in Table P.3. If a full agonist
such as EP 011 is added 2-5 min after treatment with 15-oxo
EP 011, PTA2 or CTA2 at 1 jig/ml, its aggregating activity is
inhibited (Figure P.3). When a concentration of EP 011 which
produced a shape change similar in extent to that of 15-oxo
EP 011, PTA2 or CTA2 was used, the action of a further dose
of EP 011 was not opposed.
Effects of TxA2 Receptor Antagonists
EP 045, EP 092 and EP 116 blocked responses to EP 011,
15-oxo EP 011, and PTA2. The irreversible aggregatory action
of arachidonic acid (75 ^g/ml) was also blocked. Log
concentration-response curves for a full agonist or a
partial agonist were constructed in the presence of fixed
concentration of an antagonist. EP 116 vs. EP 011, EP116 vs.
186
Table P. 2 Threshold concentrations of prostanoids for rat platelet
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(110±18, n=4)
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Threshold concentrations of a prostanoid indicate the concentrations
which produced 5% of its own maximum response.
Values in parentheses indicate meanis.e..
- denotes that no aggregation occurred at concentration up to 10
yg/ml for CTA2 and PTA2, and up to 5 Mg/ml for 15-oxo EP 011.
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Table P. 3 Relative activities of prostanoids on rat platelet in vitro
Compound Equipotent molar ratios
(EP 011=1.0)
shape change aggregation
9,11-azo PGH2 3.1 5.7 11 5.6
11,9-epoxymethano
pgh2 6.3 9.1 13 29 29
(17+4.9, n=5)
27 33
(±) 15-oxo EP Oil 71 120 140 170 200 320
(170±35, n=6)






The standard agonist EP Oil was racemic. For CTAg 11,9-epoxymethano
PGH2 was used as a standard agonist.









EP Oil 200 ng/ml in the
presence of 1 yg/ml
15-oxo EP Oil
i
Figure P.3 Rat platelets: interaction of 15-oxo EP Oil with
EP Oil. 15-Oxo EP Oil produces a shape change only and opposes
the action of EP Oil. In trace 3, EP Oil was added 5 min after
15-oxo EP Oil treatment.
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15-oxo EP 011 and EP 045 vs. PTA2 were studied. With all of
the analogues examined approximately parallel shifts to the
right of the agonist concentration-response curve were
produced. Dose-ratios are shown in Table P.4. From the
Gaddum-Schild equation affinity constants were obtained:
9.4x10^ (shape change), 8.0x10®, (aggregation) for
EP 116 vs. EP 011; 7.8xl06 M-1, 9.8xl06 K~1 and 5.8xl06 M"1
(shape change) for EP 116 vs. 15-oxo EP 011 at 100 ng/ml,
200 ng/ml and 500 ng/ml EP 116, respectively; 2.1x10® M~^
(shape change) for EP 045 vs. PTA2.
Effects of PGI2, PGEl and PGD2.
11;9-Epoxymethano PGH2 was used as a shape change inducer.
PGI2 at 5 ng/ml or PGEl at 20 ng/ml inhibited 100 ng/ml
11,9-epoxymethano PGH2-induced shape change. PGD2 at
concentrations up to 1 jjg/ml produced no effect.
Effects of PGE2 Analogues.
PGE2 at concentrations up to 2 ^ig/ml produced neither shape
change nor aggregation responses, but it enhanced the
aggregatory action of EP 011; 11,9-epoxymethano PGH2 and
9,11-azo PGH2. Using EP 011 (50 ng/ml) as a shape change
agent, the threshold concentration for PGE2 to convert the
shape change into an irreversible aggregation response was
found to be 50 ng/ml. Increasing the concentration of PGE2
did not produce greater enhancement. Table P.5 lists the
combination of the concentration of the thromboxane mimetic
which gives a near maximal shape change together with the
minimal concentration of the PGE analogue which will convert
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Table P. 4 Effects of TXA2 antagonists on shape change and aggregation






ep 116 500 ep Oil 12
ep 116 100 15-oxo ep Oil 2.8
ep 116 200 15-oxo ep Oil 5.4
ep 116 500 15-oxo ep Oil 7.6
ep 045 5000 pta2 2.8
►100
EP Oil and 15-oxo EP Oil were racemic.
* indicates the full dose-response curve for EP Oil in the presence of
EP 116 was not established; the dose-ratio was quantified related to
the response at 5% maximum response level of EP Oil in the absence of
EP 116.
Table P. 5 Combinations of minimal concentrations of PGE2 analogues
and threshold concentrations of TxA2 analogues which transformed

















EP 011 and ICI 80205 were racemic. Except for 9,11-azo PGH2 the
experiments were conducted on the same batch of rat platelets.
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their shape change response into an irreversible aggregation
wave. 16,16-dimethyl PGE2 was more potent than PGE2? but
similar to ICI 80205. Typical full dose-response curves for
shape change and aggregation responses induced by EP 011 in
the presence and absence of a fixed concentration of PGE2
are shown in Figure P.4. Below the threshold concentration
of EP 011 mentioned above, PGE2 had little effect on the
shape change induced by EP 011, but above that concentration
PGE2 transformed shape change into aggregation or
potentiated aggregative responses. PGE2 had little effect on
both shape change and aggregation produced by ADP.
Effects of PGE2 on release of f!4C]-5-HT<
In order to investigate the mechanism behind the enhancement
by PGE2 of EP 011 induced aggregation a set of experiments
was performed on release of F14C]-5-HT. The results are
shown in Figure P.5. With EP 011 alone shape change was not
associated with secretion of 5-ht, but resulted in uptake of
the labelled 5-HT; the irreversible aggregation wave was
accompanied by secretion of fl4C]-5-HT in rat platelets. In
the presence of 50 ng/ml PGE2^ there was a marked increase
in secretion of 5-HT during aggregation induced by EP 011.
PGE2 also potentiated secretion of f14C1-5-HT induced by
llr9-epoxymethano PGH2.




a calcium channel blocker, was tested on rat
against EP 011. Verapamil at 10-100 pM partially
irreversible platelet aggregation induced by
1
Concentration (ng/ml)
Figure P.4 Rat platelets: potentiating effects of PGE2 on the
aggregating response to EP Oil. The figure shows the dose-respon¬
se curve for EP Oil acting alone (open circle) and the correspon¬
ding curve (solid circle) in the presence of 50 ng/ml PGE2. PGE2































Concentration (ng/ml) (log scale)
Figure P.5 Rat platelets: potentiation by PGE2 of the
release of (^4C)-5-HT induced by EP 011. The open circle
indicates EP 011 acting alone and the solid circle indi¬
cates EP 011 acting in the presence of 50 ng/ml PGE2-
PGE2 was added a min before adding EP 011.
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EP 011 (Figure P.6) .
Increasing the calcium concentration by 1, 2 and 10 mM above
that present in the citrated PRP - Krebs mixture did not
affect the shape change or aggregation response to EP 011.
Higher concentration (>10 mM) of calcium chloride itself
produced platelet shape change.
Effects of Indomethacin
Rat platelets were preincubated with indomethacin for 25-35
min before adding an aggregating agent. Indomethacin at 100
/JM inhibited the aggregation induced by arachidonic acid(AAV
The results are shown in Figure P.7. Effects of indomethacin
on the aggregating response to EP 011 were inconsistent. In
one set of experiments, indomethacin at 100 uM inhibited
aggregation produced by EP 011, transforming irreversible
aggregation into reversible aggregation; in another set of
experiments indomethacin at 100 jjM had no influence on
EP 011 induced aggregation.
Human
Human PRP was freshly prepared. The sensitivity to TxA2
analogues was markedly decreased when platelets was left
overnight. Doses of 11,9-epoxymethano PGH2 tested were 100,
200, 300 and 500 ng/ml. Reversible aggregation was seen with
100 and 200 ng/ml, and irreversible aggregation with 300
ng/ml and above. PGE2 inhibited the aggregation induced by
11.9-epoxymethano PGH2 (Figure P.8).
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EP Oil EP Oil 1 yg/ml in the presence
1 jag/ml of 10~4 M verapamil
Figure P.6 Rat platelets: inhibitory effect of verapamil
on the aggregating response to EP Oil. The figure shows
EP Oil acting alone (left), and in the presence of
verapamil 10~4 M (right). The platelets were pre-incubated
with verapamil for 5 min before adding EP Oil in the
experiment shown on the right panel.
i
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AA AA 75 pg/ml in the presence
75 (jg/ml j_ncjomethac^n ^o-4 M
mr
Figure P.7 Rat platelets: inhibitory effects of
indomethacin on the aggregating response to AA.
The figure shows AA 75 pg/ml acting alone (left)
and in the presence of indomethacin (right). The
platelets were pre-incubated with indomethacin
10~4 M for 30 min before adding AA.
AA: Arachidonic acid
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11,9-Epoxymethano PGH2 11,9-Epoxvmethano PGH2 300 ng/ml
300 ng/ml in the presence of 100 ng/ml PGE2
Figure P.8 Human platelets: inhibitory effects of PGE2 on the
aggregating response to 11,9-epoxvmethano PGH2- The left panel
shows 11,9-epoxymethano PGH2 300 ng/ml acting alone. The right
panel shows 11,9-epoxymethano PGH2 300 ng/ml acting in the
presence of PGE2 100 ng/ml; the platelets were pre-incubated
with PGE2 for 2 min before adding 11,9-epoxymethano PGH2-
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However, in another group of experiments PGE2 and
16,16-dimethyl PGE2 at 100 ng/ml potentiated the aggregation
response elicited by 11,9-epoxymethano PGH2 and EP 011
(Figure P.9). EP 011 was about 5 times more potent than
11,9-epoxymethano PGH2 in inducing aggregation in human
platelets. PTA2 at 10 pg/ml did not show any response,but
opposed EP 011-induced aggregation. 15-Oxo EP 011 at 5 jig/ml





11,9-epoxvmethano PGH2 500 ng/ml
in the presence of PGE2 100 ng/ml
Figure P.9 Human platelets: potentiating effects of PGE2 on the
aggregating response to 11,9-epoxvmethano PGH2. The left panel
shows 11,9-epoxymethano PGH2 500 ng/ml acting alone. The right
panel shows 11,9-epoxymethano PGH2 acting in the presence of
PGE^ 100 ng/ml; the platelets were pre-incubated with PGE2 for
2 min before adding 11,9-epoxymethano PGH2-
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DTSCnSSTON
There are several lines of evidence suggesting that the TxA2
receptor of human platelets is different from that of smooth
muscle:
(1) Both TxA2 and TxA3 are vasoconstrictor (TxA2> TxA3)
whereas only TxA2 induces platelet aggregation and TxA3
inhibits aggregation (Needleman, Minkes & Raz, 1976;
Needleman, Raz, Minkes, Ferrendelli & Sprecher, 1979).
(2) 15-0xo EP 011 has no effect on human platelets, but it
is a full agonist on smooth muscle (Jones, R.L., Personal
communication).
(3) CTA2 is a full agonist on smooth muscle yet only causes
shape change and antagonises human platelet aggregation
induced by AA or 11.9-epoxymethano PGH2 (Jones, R.L.,
Personal communication).
(4) The sodium salt of rac- 9,11:11,12- dideoxa-
9,11:11,12- diepithio TxA2 (both ring oxygens in TxA2 are
replaced by sulphur atoms) contracts the rat aortic
preparation but has no effect on human platelet aggregation
(Ohuchida, Hamanaka & Hayashi, 1981).
(5) 9,11-epoxyiminoprosta- 5,13- dienoic acid (9,11-EIP) is
a TxA2 antagonist in human platelets, but has intrinsic
agonist properties for smooth muscle, contracting the rat
aorta strip (Fitzpatrick,Bundy, Gorman & Honohan, 1978).
Our results suggest that the TxA2 receptor in rat platelets
differs both from that in smooth muscle and from that in
human platelets. It seems to represent a new type of TxA2
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receptor.
The differences between rat platelets and smooth muscle are
evident: CTA2 and 15-oxo EP 011, which are full agonists on
the smooth muscle preparations we have used, show partial
agonist activity on rat platelets.
In the rat platelets, CTA2 caused shape change only and
opposed the effect of EP 011, indicating partial agonist
properties. In this aspect, rat platelets resemble human
platelets. However, 11.9-epoxymethano PGH2 and 9,11-azo PGH2
are much weaker relative to EP 011 in rat platelets than in
human. Considering that EP 011 might trigger the synthesis
and release of endogenous PGE2 or TxA2, indomethaein was
used. The results are inconsistent. Thus we can not draw any
conclusions at the present stage. As we have suggested
previously EP 011 may have PGE2-like activity. However,
since the minimal concentration for PGE2 to potentiate
EP 011 action is 50 ng/ml, EP 011 at the concentrations we
used is unlikely to have enough PGE2-like activity to
enhance its own TxA2-like activity. Furthermore,
15-oxo EP 011, which had no effect on human platelets and
was a full agonist on smooth muscle, showed partial agonist
activity on rat platelets. The ability of TxA2 receptor
antagonists to block both shape change and aggregation
induced by EP 011 and 15-oxo EP 011 indicates that their
effects are receptor-mediated.
As we have shown in the Addendum (see Figure Add.5), rat
platelets can convert AA into TxB2, a TxA2 metabolite, which
is confirmed by the work of Chang and Tai (1983). This
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appears to imply that the receptor on which EP 011 and
15-oxo EP 011 act is a type of TxA2 receptor.
It has been suggested that there are distinct "endoperoxide"
and "thromboxane" receptors. Maclntyre and Gordon (1977),,,
and Smith, Ingerman and Silver (1977) proposed that
exogenous PGG2 and PGH2 stimulate platelets directly by
interacting with their own receptor since
11,9-epoxymethano PGH2 and 9,11-azo PGH2, which they assumed
were stable PGH2 analogues, aggregated platelets, and PGG2
and PGH2 induced platelet aggregation in PRP without
significant production of TxA2. Furthermore, in 1978
Maclntyre and Willis found that contractions of rabbit aorta
induced by PGH2, but not TxA2, were suppressed by
tr imethoquinol at 10 jag/ml; pre-incubation of platelet
microsomes with tr imethoquinol (10-100 jig/ml) for up to 4
min (at 0°C) did not suppress production of TxA2-like
from PGH2
activity. Therefore, they suggested that there were distinct
A
endoperoxide and TxA2 receptors in vascular tissue, and that
the former is more susceptible to inhibition by
trimethoquinol. More recently, Lampugnani and de Gaetano
(1983) have reported that whilst aspirin induced a parallel
from AA,
suppression of shape change and TxB2 generation^ dazoxiben,
a selective TxA2 synthetase inhibitor, completely prevented
TxB2 formation but did not modify shape change. They have
suggested that PG endoperoxides are effective mediators of
shape change. However, these suggestions are not convincing
since it has been found 11,9-epoxymethano PGH2 is a
selective TxA2 mimetic (Coleman. Humphrey, Kennedy, Levy &
Lumley, 1981), and PGG2 and PGH2 can be active agonists on
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the TxA2 receptor since they are structurally similar to
TxA2. It is going to be a very difficult task to
differentiate these two receptors because of the
of PGH2 andTxA2
evanescent natur^. Thus, it is uncertain whether the
receptor in rat platelets is TxA2 or PGH2 receptor. Anyhow,
it is a different type of receptor from that of smooth
muscle or human platelets.
It was thought that the weak activity of
11,9-epoxymethano PGH2 on rat PRP was due to insufficient
calcium in the milieu, but increase in calcium concentration
made no improvement. Inspired by the findings that PGE2
potentiates human platelet aggregation induced by a
TxA2-like substance (Weiss, Willis, Kuhn & Brand, 1976), we
studied the interactions of PGE2 analogues with TxA2
analogues. We have found that PGE2, 16,16-dimethyl PGE2 and
ICI 80205 potentiate aggregation of rat platelets induced by
TxA2 analogues. As shown in the results, PGE2 facilitates
the release of 5-HT by EP 011. It is believed that the
aggregation and release reaction require extracellular
calcium, and we have shown that verapamil, a calcium channel
blocker, inhibits aggregation induced by EP 011. Thus, PGE2
may produce the potentiation by helping EP 011 manoeuvre
extracellular calcium. Alternatively, PGE2 may have an
intracellular acting point to facilitate the release of
calcium from intracellular stores by trigger calcium which
enters the cell due to activation of TxA2 receptor by
EP 011. Thus, in rat both TxA2 and PGE2 are important in
platelet aggregation.
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In contrast to the work by Ashida and Abiko (1979), who
reported that PGE2 enhanced the aggregating action of ADP,
we have found PGE2 has little effect on the response to ADP.
Aspirin inhibits aggregation induced by ADP (Tuong, Ferrand,
Aubert, Loubrie & Tuong, 1982), which indicates ADP can
stimulate endogenous synthesis of prostanoids, probably
TxA2. In our study, the platelets were left for 2-3 h for
stabilization, which might attenuate the synthesis of TxA2
stimulated by ADP. If this is true, the PGE2 potentiating
effect on ADP-induced aggregation in the study of Ashida and
Abiko may be produced through endogenously synthesized TxA2.
As we mentioned in the introduction, platelet shape change
is caused by release of membrane or receptor-bound calcium.
PGE2 does not affect the shape change induced by low
increased
concentrations of EP 011. During shape change the^uptake of
5-HT is possibly due to the increase in platelet size, and
PGE2 had little effect on the 5-HT movement. This seems to
indicate that PGE2 does not enhance the release of membrane
or receptor-bound calcium induced by activation of TxA2
receptor. It is known PGI2, PGEl and PGD2 inhibit platelet
aggregation by increasing the cyclic AMP level in platelets,
and cyclic AMP acts as a calcium antagonist by enhancing
calcium uptake into the platelet calcium storage sites in
the dense tubular system (Kaser-Glanzmann, Gerber & Luscher,
1979), or cyclic AMP prevents membrane or receptor-bound
calcium release. This may explain the PGI2/PGE1 inhibition
of rat platelet shape change. PGD2 failed to produce the
inhibition since rat platelets lack PGD2 receptors.
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The cold-induced shape change seems to be mediated via a
different mechanism since PGEl can not prevent it (Zucker &
Peerschke, 1980).
In human platelets PGE2 produced varied results: it may
inhibit or enhance aggregation elicited by TxA2 analogues.
It is possible that the PGE2 receptor mediates both
potentiation and inhibition, and the outcomedepends on the
dominant effect which varies with donors.
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ADDENDUM
Metabolism of AA to TxA2 bv Rat Platelets and Bullock Iris Sphincter
Basic Principles of GC/MS.
GC/MS consists of two parts: gas chromatography and mass
spectrometry. The gas chromatography column is a tube
containing the solid (support) on which the liquid phase is
coated. A mixture of two or more components is vapourised
into the column through which an inert gas (carrier) is
flowing. Because of the relative retention characteristics,
partitioning of the mixture between the gas and liquid
phases results in a separation of the individual components
with time. The separated components then pass into the mass
spectrometer. Electron bombardment of the components in a
high vacuum chamber give rise to charged particles. The ions
are accelerated by a potential (V) and made to move in a
curved trajectory by electric and magnetic fields. The
( R)
radius of curvature^ of these ions is determined by their
mass-to-charge (m/e) ratio and the strength of magnetic
field (H) such that m/e = H^R^/2V and only ions of a
particular m/e will be focussed at the collector (detector)
for particular values of H and V.
In gas chromatography, carrier gas flow rates of 30 ml/min
are normally used. If the carrier gas, as well as the
individual components of the mixture, were put into mass
spectrometer, the ionisation process would become very
*
AA = arachidonic acjd
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inefficient due to collisional effects and sensitivity would
suffer. Therefore, a major part (90%) of the carrier gas
(usually Helium) has to be removed selectively prior to
entry into the source. This is achieved by the use of a
molecular separator.
Identification of a compound relies on the detection of one
or more representative ions appearing at the appropriate
retention times.
The quantification of prostanoids by GC/MS can be most
accurately conducted by using stable isotopes as internal
standards. For this purpose, prostanoids are synthesized
that contain four or more deuterium atoms in
non-exchangeable positions of the molecule, for example,
3 ,3,4,4-tetradeutero TxB2. A defined amount of the
deuterated internal standard is added to the biological
sample and passes through all steps of the work-up
procedure. The deuterated prostanoids behave nearly
identically to the endogenous prostanoid in the biological
sample on extraction, derivatization and chromatography. In
the final steps of analysis, the mass spectrometer can
discriminate between the endogenous prostanoid and the
internal standard, the mass of which is dependent on the
number of incorporated deuterium atoms (for 3,3,4,4- (2H)4-
TxB2, the difference is four mass units). The ratio of
protium peak height to deuterium peak height is determined
over the range of a standard curve and the concentration of
TxB2 in the sample is determined from the ratio of protium
to deuterium in the sample.
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The GC/MS data were obtained by using a Pye Unicam 204 gas
chromatograph coupled to a VG micromass 70-70F mass
spectrometer. The gas chromatograph was equipped with a
spiral column (either 1.5mx4mmor3m x 4 mm) packed
with 3% OVl in 100-200 mesh Supelcopart (Supelco, Inc.). The
temperature of the column was fixed between 250-270°C, the
separator temperature was 250°Cr the ion source temperature
250 ° C, the basic accelerating voltage 4 KV and the electron
energy 22 or 70 eV. Helium was used as the carrier gas with
a flow rate of 30 ml/min.
Perivatisation of TxB2
Samples must be derivatised to be both volatile and
thermally stable. Derivatisation provides suitable ions in
the mass spectrum for detection and assay by GC/MS. However,
the ion must not coincide with a column bleed peak (Figure
Add.l), but should be reasonably close in mass to minimise
the loss in sensitivity which occurs as the voltage jumps
from the column bleed peak to the ion, throughout the assay.
The column bleed peak is used as a reference to provide
accurate switching between monitored peaks.
Diazomethane was generated from diazald (N-methyl-
N-nitroso- p- toluene- sulphonamide, Aldrich), ethanol and
potassium hydroxide (KOH), and displaced with ether-vapour-
saturated nitrogen into a tube containing cold diethyl
ether. An appropriate amount of TxB2 (UpJohn Co., Kalamazoo)
in ethylacetate was dispensed into an Eppendorf tube and
blown dry. The TxB2 was taken up in a few drops of methanol
207 281 355 A29
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This mass spectrum gives the GC-MS background peaks.
The prominent ions contain silicon and are derived from
the septum, column stationary phase and separator.
igure Add.l Mass spectrum of column bleed peaks.
211
ethereal of
(Rathburn Chemicals), 0.3-0.4 ml^ diazomethane added, and
left for 5 min before being blown dry on a heating block and
desiccated. Butoxyamine hydrochloride, 3-5 drops (5 mg/ml)
in pyridine was then added. The Eppendorf tube with the
mixture in it was sealed and kept at 60°C for 90 min. The
pyridine was blown off using a heating block and the tube
desiccated in a vacuum chamber before 20 ^ul BSTFA
(Sigma) (N,O-bis (tr imethylsilyl) trif luoroacetamide) was
added and this was sealed and incubated at 60°C for 15 min.
TxB2 methyl ester, butyloxime, TMS ether was injected in the
BSTFA into the GC/MS and from the total ion chromatogram the
retention time and a full mass spectrum of the ions formed
as the molecule splits were obtained. The m/e = 301 ion is
the base peak, i.e. the most abundant ion formed (Figure
Add.2). The m/e =301 ion was chosen as a suitable ion to
monitor since it is formed in large amounts, being the base
peak, and is suitably close in mass to the 281 column bleed.
Both of these factors help to increase the sensitivity of
the assay.
Since deuterated TxB2 was not available, 11-deoxy PGEl was
selected as an internal standard to account for losses in
the derivatization and chromatography steps. The mass
spectrum of 11-deoxy PGEl methyl ester, butyloxime, TMS
ether showed the m/e =280 ion to be the base peak (Figure
Add.3). Again this ion is close in mass to the 281 column
bleed. The m/e =280 ion could be formed by loss of the
W-chain (-71) and the (x-chain (-144) or by the loss of the
butyloxime (-73) and the oc-chain (-142). Since the m/e = 280
ion is also the base peak of 11-deoxy PGEl, methyl ester,methyloxime,
TMS ether, it
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Figure Add.2 Fragmentation of TxB2 Me, BuOx, TMS
by GC-MS.
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Figure Add.3 Fragmentation of 11 deoxy PGE1 Me,
BuOx, TMS by GC-MS.
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must be achieved by loss of the oxime (-31) and the <x-chain
(-142). 11-Deoxy PGEl methylester, butyloxime, TMS ether has
a shorter retention time than the corresponding TxB2
derivative.
Multiple Ion Detection Assay
Amounts of TxB2, 0 ng, 10 ng, 20 ng, 40 ng, 60 ng and 80 ng
were dispensed into Eppendorf tubes. 40 ng 11-deoxy PGEl was
added to each tube. The drugs were methylated using
diazomethane, as above mentioned, and dried. The methylated
drugs were oximated using butoxyamine hydrochloride at 60 ° C
for 90 min before being taken to dryness on a heating block
and desiccated. 20 j:l BSTFA were added to each tube. The
tubes were kept at 60°C for 15 min and 5 ^ul aliquots were
injected into GC column.
The program used for multiple ion detection (MID) is set up
as shown in Table Add.l.
Table Add.l. GC-program for assay of TxB2 by MID
Channel Ion Exact mass (g) MID voltage
1 2 80 280.20965 9.8000
2 281 281.05169 9.7706
3 301 301 . 201 90 9.1170
The instrument was tuned into the 281 colunm bleed, and
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electronically locked on, to facilitate its use as a
reference peak. The machine was focussed on each MID voltage
for 0.1s in turn, the MID voltage regulating the
accelerating voltage. The responses were recorded using a
recorder (Rikadenki Mitsui Electronics (U.K.) Ltd.) while
each standard was run. The ratios of peak heights of 301/280
ions were determined. Typical traces are shown in Figure
Add.4 with the standard curve.
Samples to be tested were diluted to give a peak within the
range of peak heights produced by 0-20 ng TxB2 and processed
in the same way as the standard TxB2.
Arachidonic acid (Grade 1, Sigma), 10 mg/ml in methanol
(Rathburn Chemicals), was stored in ampoules at -40°C until
use.(AA)
Extraction of TxB2 from Rat PRP
Rat PRP was prepared as before and incubated in a waterbath
at 37 0 C. 2.5 ml of rat PRP was incubated for 3 min at 37°C
with 75 jug/ml palmitic acid, then 100 jig/ml AA (final
concentration) was added to the PRP and allowed to act for
30 s before the reaction was quenched by the addition of 500
|il 2m HC1 which gave a pH of about 3. The sample was
extracted twice with ethyl acetate (Rathburn Chemicals) and the
extract
extracts taken into a pear-shaped flask. The ethyl acetate was taken
to dryness using a rotary evaporator.
The sample in the pear-shaped flask was taken up in 2.5 ml
absolute alcohol and transferred to a stoppered test tube.
The remains of the sample in the flask were washed out with
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gain of 100 on both the 301 ion and the 280 ion
TxB2 (ng) 20 15 10 2.5
id
10 20
dose of TxB2 (ng)
Figure Add.4 Typical GC-MS traces for the TxB2 standard
curve.
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2.5 ml distilled water which was added to the alcohol. 5 ml
of benzene (BDH Chemicals, Analar quality) was added to the
tube. This resulted in an ethanol: water: benzene (1: 1: 2)
partition. The tube contents were mixed, then spun in a
bench centrifuge to ensure a clear separation between the
two layers. The upper benzene layer was removed using a
pasteur pipette, and discarded. The ethanol-water layer
was transferred back to the original pear-shaped flask and
the test tube washed out with a further 2.5 ml ethanol which
a solution,
was transferred again to the flask to give^67% ethanolic^ The
solution was taken to dryness on the rotary evaporator as
before.
The sample was taken up in 2 ml methanol and 10 fjl of
usually,
an, 8-fold dilution was derivatized as for standards and
assayed on the GC/MS along with the standards.
For studying the production of TxB2 in the bullock iris
sphincter, the preparation was set up as before. 50 ji 1 AA
(2mg/ml) was added into a 10 ml organ bath, containing
sugar-salt solution. AA produced contraction. After 5 min
the bath solution was collected and 2M HC1 was added to give
a pH of about 3. The rest of the work-up of procedure was
the same as for rat PRP.
The results are shown in Figure Add.5. Both rat platelets
and bullock iris sphincter can convert AA into TxB2, which
indicates that they are able to synthesize TxA2. AA 100
jjg/ml was converted by 1 ml rat PRP into 1 ^pg/ml TxB2 in 30
s, a result similar to that from human PRP (0.2-0.8 jjg/ml
TxB2 from 100 ^pg/ml AA) (Jones, R.L., Personal
Rat platelets Bullock iris sphincter
Figure Add.5 TxB2 generation in the rat platelets
and bullock iris sphincter. AA was used as the
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Enhancement by Verapamil of Actions of Prostanoids
on the Rat Anococcygeus Muscle
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The rat anococcygeus muscle was originally described by
Gillespie (1971, 1972) Gillespie & Maxwell (1971). It
consists of parallel bundles of smooth muscles fibres
attached to a tendon from the coccygeal vertebrae. Some of
these fibres end by merging with the longitudinal muscle of
the colon, and other muscle fibres in the male rat continue
to end either in the perineum or by forming the retractor
penis muscle. The anococcygeus muscles are approximately 3
cm long x0.5 cm wide xl30-300 jim thick. Each muscle bundle
contains between two and eight fibres with numerous gap
junctions between fibres possibly representing regions of
electrical continuity. In the narrow tissue clefts between
bundles run the autonomic nerves within Schwann cell
sheaths. Most of them are adrenergic as shown by their
formaldehyde fluorescence, by the presence of dense-cored
vesicles within their varicosities, by the ability to
enhance these dense cores with 5-HT and their disappearance
after chronic treatment with 6-hydroxydopamine or reserpine.
Recently varicosities containing larger, electron-opaque
vesicles have been found contributing up to 40% of the total
and most probably representing the inhibitory nerves
(Gibbins & Haller, 1979). A third type of varicosity with
mainly clear vesicles accounted for less than 5% of the
nerve profiles and may represent a true cholinergic
innervation, which does not seem an important neural control
as neither contractile nor inhibitory responses to nerve
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stimulation are influenced by atropine. The origin of these
contractile and inhibitory nerve in the spinal cord has been
identified: the contractile nerve is characteristically
sympathetic arising in the upper lumbar outflow; the
inhibitory equally characteristic, arising from the sacral
cord between L5 and S3 (Gillespie & McGrath, 1973). Both are
interrupted by ganglia as judged by the action of ganglion
blocking agents in vivo.
Its structural arrangement makes the rat anococcygeus muscle
an ideal smooth muscle preparations since it fulfils the
following criteria:
(1) The preparation consists of a thin layer of smooth
muscle cells. This arrangement minimizes the problem of drug
access.
(2) Many smooth muscle preparations are derived from
circular or helical tissue which introduces difficulties in
the recording and interpretation of mechanical responses. As
the smooth muscle cells of the rat anococcygeus are arranged
longitudinally, this problem does not arise.
(3) The tissue is densely innervated which is an ideal
arrangement for studies of noradrenergic transmission.
The preparation has attracted additional interest because it
possesses non-adrenergic and non-cholinergic (NANC) nerves
mediating inhibitory response as mentioned above.
It
The electrical properties of the muscle and its response to
nerve stimulation have been examined in the isolated
preparation. The resting membrane potential is high, about
62 mV, and stable, corresponding to the absence of
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spontaneous mechanical activity. Nerve stimulation produces
graded depolarizations without spike potentials and these
give rise to graded contractions. Guanethidine blocks the
adrenergic nerve, depolarises the muscle and raises tone. In
the presence of guanethidine nerve stimulation produces
mechanical inhibition but little or no hyperpolarization.
The responses are different from the large
hyperpolarizations produced in the guinea-pig taenia coli by
stimulating the non-cholinergic and non-adrenergic nerves,
suggesting that the transmitter might also be different.
The muscle is contracted by alpha-adrenergic agents,
dopamine, muscarine, 5-HT, vasopressin, PGEl, PGE2 and
PGF2a. Beta-adrenergic agents and histamine have no effect
on this preparation. The action of ATP is unclear. Little
work had been done on prostanoid action in the rat
anococcygeus muscle. An attempt-was therefore made to define
the nature of any prostanoid receptors present. It has been
suggested that prostanoids can release calcium from
intracellular stores in smooth muscle(Kirtland & Baum, 1972;
Malmstrom & Carafoli, 1975; Tsuyoshi & Develin, 1979; van
Breemen, Aaronson, Loutzenhiser & Meisheri, 1980;
Loutzenhiser & van Breemen, 1981; Brandt, Andersson,
Edvinsson & Ljunggren, 1981; Shimizu, Ohta & Toda, 1980). In
order to study the relationship between PG actions and
calcium movement on this preparation, calcium channel
blockers were tried against PGs. Unexpectedly, calcium
channel blockers potentiate, rather than inhibit, the action
of PGs.
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For convenience, the term "calcium antagonists" will be used
here to mean both calcium channel blockers and calmodulin




Rats were killed by a blow on the head and bled. The abdomen
was opened along the mid-line and the pelvis split. The
colon was then cut through at the pelvic brim and the pelvic
portion pulled forward. The anococcygeus muscles were
separated from surrounding connective tissue, tied and
dissected out. The muscle was mounted under 50 mg tension in
a 5 ml bath containing Krebs solution at 37®C ( unless
otherwise stated). The solution was bubbled with 95%C>2 +
5%C02. Changes in tension were measured isometrically with a
Grass force displacement transducer (FT 03C) and displayed
on a Grass Polygraph. In those experiments when the response
to field stimulation was examined the muscles were encircled
by a pair of ring platinum electrodes embedded in a plastic
tube. A Grass S44 stimulator and timer were used to generate
1 msec pulses at supramaximal voltage at the frequencies
given in the text. Responses were measured on a Devices
recorder. Pulse trains of 30 s were applied every 4th. min ,
In experiments where sympathetic denervation was required
6-hydroxydopamine HBr (250 jjg/ml) was added into the organ
bath and was washed out after 3 hours. If contractions
elicited by adding tyramine (10 yaM) were still present, the
preparation was incubated for a further 3 hours with the
same amount of 6-hydroxydopamine.
Chromatography of urine and hemolysate
Sephadex G50 Fine gel powder (5 g) (Pharmacia Uppsala,
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Sweden) was allowed to fully swell in excess distilled
water. The Sephadex was added to the water slowly and
stirred gently. This formed a dilute slurry which was left
to settle. The gel part sank, leaving a clear layer on top.
The upper layer was poured off and an equal volume of 4 mM
Tris-HCl pH 7.4 was added to form a slurry by stirring
gently. The upper layer was poured off and fresh buffer was
added again. The procedure was repeated until the upper
layer achieved a pH of 7.4. Hibitane 0.002% was added to the
slurry to prevent microbial growth.
Plastic pipettes (10 ml) were shortened to 8 cm lengths
and fitted with a small plug of quartz wool in the pointed
end. Each column was packed with the G50 Fine slurry which
4 mM Tris-HCl buffer(PH7.4)
had been degassed. 2 ml of^eluent was pipetted onto the top
5 o rn
of the column ^ and flow rate estimated by measuring the
volume of eluent collected in 1 min. It was about 0.5
ml/min. The column gave a good separation between serum
albumin labelled with coomassie blue and procion red.
Urine or hemolysate (1 ml) was laid gently on the drained
bed surface and allowed to drain into the bed. The sample
which remained on the bed surface and on the column wall was
washed into the bed with 1 ml of Tris-HCl buffer eluent,
which was allowed to drain away. Then the column was
refilled with eluent and samples were collected every 5 min.
All the procedures were carried out at room temperature. The
swelled gel was stored at 4°C.
Measurement of noradrenaline
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The method used was HPLC and electrochemical detection on a
carbon paste electrode (Dr. A.G. Watts, unpublished method).
The experiments were done with his help.
Owing to the poor solubility of nifedipine in water, 10 mM
stock solution of the drug was prepared in absolute ethanol,
and diluted 10-fold with distilled water. Because of the
known photosensitivity of the dihydropyridines, the




The preparation had neither spontaneous activity nor tone.
It contracted to PGE2 and 11?9-epoxymethano PGH2. The
threshold concentration for contraction was about 15 ng/ml
for both PGE2 and 11,9-epoxymethano PGH2. In Krebs solution
11,9-epoxymethano PGH2 gave a maximum increase in tension of
about 5 gram, but PGE2 showed a much lower maximum response.
Since the preparation was very readily desensitized by high
concentrations of PGE2 and 11,9-epoxymethano PGH2,
experiments in this study were carried out with low
concentrations of prostanoids. Responses to prostanoids
plateaued after 4-10 min remained steady for 2-4 min and
then faded gradually. Atropine 1 pM, phentolamine 1 pM and
indomethacin 1 pM did not antagonize responses to
prostanoids.
The TxA-receptor antagonists EP 045, EP 092 and EP 116
blocked the action of 11,9-epoxymethano PGH2, but not those
of PGE2 and noradrenaline. The antagonist was allowed 10 min
contact with the tissue before addition of the agonist. Dose
ratios are shown in Table A.l together with the calculated
affinity constants.
Some other TxA2 mimetics were also tested. They were EP 011?
15-oxo EP 011, 9,11-azo PGH2, CTA2 and PTA2. EP 011 and
15-oxo EP 011 were about 20 and 10 times more potent than
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EP 045 2.6 x 10~7 2.3 2.3 2.4 4.9±0.14
(n=3)
X 106 M~1
EP 092 1.2 x 10~7 1.8 2.7 2.8 1.2+0.25
(n=3)
X 107 M'1
2.4 x 10~7 4.3 6.7 10 2.5+0.67
(n=3)
X 107 M'1
EP 116 4.5 x 10~8 4.6 4.8 4.9 8.3+0.18
(n=3)
X 107 M~1
11,9-epoxymethano PGH^ was used as standard agonist.
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11j9-epoxymethano PGH2, respectively. 9,11-Azo PGH2 had a
potency similar to 11,9-epoxymethano PGH2. CTA2 and
9,11-epoxymethano PGH2 behaved as partial agonists (Figure
A.l). PTA2 at 2 pg/ml produced no contractile effect^ but it
antagonized the action of 11,9-epoxymethano PGH2 and in
certain cases it potentiated the action of PGE2 (Figure
A.2 p 231 .")
Subthreshold concentrations of PGE2 analogues enhanced the
contractile effect of TxA2 mimetics. An attempt was made to
quantitate this enhancement by calculating a pP2 value. pP2?
analogous to pA2, is the negative logarithm of the molar
concentration of a potentiating drug which increases the
response of half the dose of agonist to that of an initial
submaximal dose. The pP2 values of ICI 80205, 16,16-dimethyl
PGE2 and PGE2 for potentiation of 11f9-epoxymethano PGH2
action are listed in Table A.2 p232.
As with the bullock iris sphincter preparation, ZK 36374 was
a partial agonist on PGE2 sites on the anococcygeus muscle .
It opposed the contractile effect of PGE2 (Figure A.3), but
enhanced the contractile effect of 11,9-epoxymethano PGH2.
ICI 81008 produced contractile response with a low maximum
(<100 mg), and it did not affect responses to PGE2 or
11,9-epoxymethano PGH2. PGF2a was much weaker than PGE2, but
gave a higher maximum than ICI 81008, and enhanced response





Concentration (ng/ml) (log scale)
Figure A.l Rat anococcygeus muscle preparation: partial agonist
action of CTA2; log concentration-response curve for 11,9-epoxy-
methano PGH^ acting alone (open circle) and the corresponding
curve (solid circle) in the presence of 1 jjg/ml CTA2 (solid square).
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Figure A.2 Rat anococcygeus muscle preparation:
interaction of PTA2 with PGE^- In the presence
of PTA2, the response to PGE£ was potentiated,
which is shown as the spike contraction.
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Table A. 2 pP2 values of PGE2 analogues for potentiation of the contractile
action of 11,9-epoxvmethano PGH2 on the rat anococcvgeus muscle prepara¬
tion .
Compound pP2 (meanis.e.)
ti) ICI 80205 9.010.22, n=4
16,16-dimethyl PGE2 8.4±0.13, n=4
PGE2 7.6l0.040, n=3




Concentration (ng/ml) (log scale)
Figure A.3 Rat anococcygeus muscle preparation: interaction
of ZK 36374 with PGE2; log concentration-response curve for
PGE2 acting alone (open circle) and the corresponding curve






The effect of verapamil on the response to PGs was studied.
Verapamil was allowed 5 min contact with the preparation
before adding agonists. Surprisingly, verapamil (1.0-50 ^aM)
enhanced the contractile effects of 11,9-epoxymethano PGH2,
9,11-azo PGH2, PGE2 and PGF2a (Figure A.4), but not
ICI 81008. In contrast, contractions elicited by
noradrenaline, potassium or carbachol were inhibited by
verapamil. Indomethacin (1.0 jaM) , atropine (1.0 jiM) or
phentolamine (1.0 |iM) had no effect on the enhancement.
6-Hydroxydopamine was used in vitro to produce sympathetic
denervation chemically. This procedure was without effect on
the potentiating action of verapamil on 11,9-epoxymethano
PGH2. pP2 values for control and treated preparations were
5.03 and 5.23, respectively.
Some other drugs were also tested for the potentiating
activities. The results are listed in Table A.3.
Difficulties were encountered with the dissolution of
pimozide. It could be dissolved in 40% acetic acid to make a
10 mM stock solution. High concentration (0.1 mM) of
pimozide in this form elicited contraction and potentiated
the action of 11 .9-epoxymethano PGH2. 40% acetic acid
diluted appropriately gave similar effects. Pimozide was
also dissolved in 50% alcohol with 5-6 drops IN HC1 to made
10 mM stock solution. The solution was added to the organ

















Table A.3 p?2 values (mean+s.e., n=4) for potentiation of the contractile
action of 11,9-epoxvmethano PGH2 on the rat anococcvgeus muscle prepara¬
tion .

























this case the vehicle had weak inhibitory effect and
pimozide produced no effect. Nifedipine and flunarizine
showed minimal potentiation at 10 and inhibited
11 j 9-epoxymethano PGH2-produced contractions at 100 jiM.
Xylocaine at 100 inhibited contraction due to
11j9-epoxymethano PGH2.
The potentiating activities of some drugs on response to
PGE2 are shown in Table A.4.
Both noradrenaline and carbachol contracted this
preparation. With noradrenaline which produced tonic
responses at concentrations higher than 1.0 |iM, verapamil,
D 600, nifedipine and trifluoperazine produced inhibitory
effects. The pA2 values were 6.10( + s.e.0.07, n=7) for
verapamil, 5.0 9( + s.e.0 .063, n = 7) for D 600 , 4 .6 8( ±
s.e.0.32, n=4) for nifedipine and 5.16( + s.e.0.26, n=3) for
trifluoperazine.
It is noteworthy that after the development of contraction
induced by 11, 9-epoxymethano PGH2, addition of 100 ^iM
verapamil would cause dual response: an increase in tension
followed by decrease in tension (Figure A.5).
Effect of low temperature on the enhancement.
In a series of experiments, the bath temperature was set at
12°C. At this low temperature PGE2 activity was reduced
remarkably, but the potentiating activity of PGE2 was
unchanged. The pP2 value was 8.06 ( + s.e.0.17, n=3) for
potentiating 11 ; 9-epoxymethano PGH2. On the other hand the
potentiating activities of other drugs were reduced to a
Table A.4 pP2 values for potentiation of the contractile action of PGE2























FigureA.5Ratanococcygeusmusclep eparation:addingver pamil10"M̂test blished submaximalresponset11,9-epo y ethanoPGH2producesad iti nalcontraction(l ft). Thesameeff ctiseenwith10~4Mv rapamil,xceptthcontrac onfadesafterb ut 5min(right).
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great extent. The pP2 value of verapamil for potentiation of
11 -9-epoxymethano PGH2 was 4.22 and the pP2 value of
chlorpromazine for potentiation of PGE2 was 4.70.
Effect of calcium on the enhancement .
The sensitivity of the preparation to 11,9-epoxymethano PGH2
was found to be little affected by changes in external
calcium concentration over the range 0.6-5.0 mM, but
preincubating the preparation in a nominally calcium free
solution for 30 min reduced the maximum response by about
90%. The potentiating activity of verapamil against
11,9-epoxymethano PGH2 was measured in Krebs solution with
different calcium concentrations. The results are shown in
Table A.5. In the absence of calcium in the bathing medium,
verapamil still enhanced the contraction to
11,9-epoxymethano PGH2, albeit to a limited extent.
In the absence of calcium noradrenaline at higher
concentrations produced contractile response and the
response was not affected by 1.0-20 verapamil, but
suppressed by 100 yjM verapamil (Figure A.6).
Effects of Trypsin on Prostanoids and lto£adx.e.naJJji£ Actions.
A fixed concentration of 11,9-epoxymethano PGH2 or
noradrenaline was added to obtain a response. Following
wash-out trypsin 40 jig/ml was added into the organ bath,
kept for 2-4 min and washed out. Then the preparation was
challenged with the same amount of 11,9-epoxymethano PGH2 or
noradrenaline. The results are shown in Figure A.7a and b
241
Table A.5 pP2 values of verapamil against 11,9-epoxvmethano PGH2 at
different calcium concentrations on the rat anococcvgeus muscle.









Verapamil (M) 10 ^ 2x10 ^ 10"^
Figure A.6 Rat anococcygeus muscle preparation: effects of verapamil
on the response to noradrenaline in the absence of calcium.









Figure A.7a Rat anococcygeus muscle preparation: effects




4xl0~6 M 40 ug/ml 4xl0"6 M
Figure A.7b Rat anococcygeus muscle preparation:
effects of trypsin on the response to noradrenaline.
NA = noradrenaline, W = wash.
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Pretreatment of the preparation with trypsin diminished
responses to 11,9-epoxymethano PGH2, but not to
noradrenaline.
Effect of Sodium Azide
Noradrenal ine Action ,
In the presence of
11,9-epoxymethano PGH2 and
markedly. When NaN^ was
11, 9-epoxymethano PGH2 and
(HaH.3) on Prostanoid and
10 jjM NaN^ contractions to
to noradrenaline were inhibited
washed out sensitivity to both
noradrenaline was restored.
IlLine .cLUd. HeffglYSakg Prostanoid an<j
Noradrenaline Action.
It was discovered by chance that rat urine collected from
rat bladder, augmented contractile action of
11,9-epoxymethano PGH2. Carnosine and urea were tested. The
former substance at 200 showed no effect, the latter at
4% w/v produced inhibitory action on 11,9-epoxymethano PGH2-
contracted preparation,
p 224
Chromatography^was then used to effect a crude separation of
the elements in rat or human urine. The yellow-coloured
fraction (YCF) in both rat and human urine showed
potentiating activity.
Rat red blood cells, obtained after rat PRP was collected in
rat platelet experiments were also examined. The intact red
blood cell produced no effect^ but the hemolysate enhanced
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contraction due to 11,9-epoxymethano PGH2. Again the
hemolysate was chromatographed. The red-coloured fraction
(RCF) in the hemolysate possessed potentiating activity.
Purchased hemoglobin (containing MHb 75%) and methemoglobin(MHb)
showed the same potentiating activity. Their pP2 values were
4.19( ± s.e.0.11, n=3) for hemoglobin (molecular weight
64,500) and 4 .11( + s.e.0.081, n = 3) for methemoglobin. Hemin
was dissolved in 80% alcohol to make 10 mM solution and
further diluted with 0.9% NaCl. Hemin at concentrations less
than 10 produced no effect, at 100 ^pM it showed solvent
effect.
RCF, YCF, hemoglobin and methemoglobin produced no effect on
response to noradrenaline.
Effects of Calcium Channel Blockers on Contractions due to
High Potassium .
In this series of experiments 118 mM NaCl in Krebs solution
was replaced by equal molar concentration of KC1. The high
potassium elicited a biphasic contraction of the rat
anococcygeus muscle. Immediately after addition, a large
contraction corresponding to an increase in tension of about
5.0-7.0 G was seen. The response peaked at 2-4 min, then
faded to a lower level, followed by a second rise in tone
(tonic contraction). The preparation was allowed 2-3 hours
to achieve a stable tone with wash-out from time to time.
The wash-out gave rise to a fall in tone. Between wash-outs,
the bath solution was collected, and its noradrenaline
content was measured. It was estimated that the output of
noradrenaline was approximately 15 ng/mg wet tissue/min at
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the beginning and 0.05 ng/mg wet tissue/min after 2 hours.
Noradrenaline which remained in the tissue after the 2 hour
incubation was 1 ng/mg wet tissue. When the tone became
stable, the experiments was conducted as follows; calcium
was withdrawn from the high K+ Krebs solution, and after the
muscle tone had returned to a basal level, calcium was added
cumulatively to the organ bath to give dose-dependent
contractions. Following wash-out, a calcium channel blocker
was added and 10 min later another calcium
concentration-response relationship was established. It
should be mentioned that there was a small rise in tension
resistant to the calcium removal.
The contractile response to calcium in the presence of high
K+ was highly reproducible. Figure A.8 shows calcium
concentration-response curve alone and in the presence of a
fixed concentration of verapamil. Increasing the
concentration of calcium overcame the blockade produced by
verapamil. Higher concentrations of calcium were not tested
since the bathing solution become cloudy with concentrations
of calcium more than 10 mM.
The
. calcium-produced contraction was blocked to greater
extents as the concentration of calcium channel blocker was
increased. These results are shown with different
concentrations of calcium in Figure A.9. Verapamil was the
most potent blocking agent among the calcium channel
blockers tested. pA2 values were 6.30 for verapamil, 6.15
for D 600, 6.00 for trifluoperazine, 5.00 for nifedinpine
and 4.00 for flunarizine. Trifluoperazine, phentolamine and
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Tension (g)
Calcium concentration (mM) (log scale)
Figure A.8 Rat anococcygeus muscle preparation: effects of
verapamil on the contractile response to calcium in the presence
of high potassium. Open circle indicates calcium acting alone,
solid circle indicates calcium acting in the presence of 5 x 10~7
-
M verapamil, and solid square in the presence of 10 M verapa¬



















































Figure A.9 Rat anococcygeus muscle preparations: effects of calcium channel
blockers on calcium-induced contraction in the presence of high potassium.
The response to a concentration of calcium in the presence of different
concentrations of a calcium channel blocker was compared with the response
to the same concentration of calcium in the absence of the calcium channel
blocker. Calcium channel blockers were allowed 10 min contact with the
tissues before adding calcium. Control experiments were performed first,
and the control tension increase was taken as 100%.
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propranolol also blocked the potassium-produced contraction.
Figure A.10 shows responses to calcium in the presence and
absence of a fixed concentration of trifluoperazine in
comparison with calcium channel blockers. Trifluoperazine
was less active than D 600 in inhibiting high
potassium-produced contraction.
and II rJ^EjaoxymeJUiana ££Ml m Field
Contractile response to field stimulation.
Field stimulation produced contractile responses both at
frequencies of 5 Hz and 20 Hz. Since field stimulation at 20
(for 30 s , every 4th min )
Hz gave higher contraction this frequency was chosen
A
for studying the contractile response due to field
stimulation. The response was invariably potentiated by
subthreshold concentrations of 11,9-epoxymethano PGH2
(Figure A.11) and the potentiation was not affected by
atropine. The action of PGE2 on the response to field
stimulation was variable. In some cases subthreshold
concentrations of PGE2 inhibited the response, but in other
cases potentiated it (Figure A.12).
In order to find out whether the prostanoids act
postsynaptically or presynaptically, effects of the
prostanoids on noradrenaline were investigated.
both
Subthreshold concentrations of ^PGE2 and 11,9-epoxymethano
PGH2 augmented responses to noradrenaline (Figure A.13a & b).






































Figure A.10 Rat anococcygeus muscle preparations:
Comparison of potency of calcium antagonists. The experiments were
conducted in different preparations with different calcium channel
blockers. The response to a calcium antagonist was compared with its
own control on the same preparation. The control experiments were done
first. The control tension increase was taken as 100%. Calcium
antagonists were allowed 10 min contact with the tissues before adding
calcium. All experiments were done in high potassium Krebs* solution
containing 2.0, 4.5 or 9.5 mM calcium. V = verapamil, D = D 600,







Figure A. 11 Rat anococcygeus muscle preparation:
potentiating effects of 11,9-epoxymethano PGH^











Figure A.12 Rat anococcygeus muscle preparation: inhibitory
effects of pge2 on the response to field stimulation at 20
Hz and 30 v.
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4"
W I 0.1 g
NA (M) 10"5 10"5 10"5 10~5
pge2 pge2
20 ng/ml 40 ng/ml
Figure A.13a Rat anococcygeus muscle preparation: potentiating effects
of PGE2 on the response to noradrenaline. NA = noradrenaline, W = wash.
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4'
—1 T 0.1 g
W
NA (M) 10"5 10"5 10"5 TO"5
11,9-epoxymethano
PGH2 20 ng/ml
Figure A.13b Rat anococcygeus muscle preparation: potentiating effects
of 11,9-epoxymethano PGF^ on the response to noradrenaline.
NA = noradrenaline, W = wash.
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For investigating effects of prostanoids on inhibitory
at 110 V
responses to field stimulation a frequency 5 Hz^was chosen.
Tone was provided with PGE2, 11,9-epoxymethano PGH2 or
guanethidine.
In calcium free Krebs solution neither contractile nor
relaxant responses to nerve stimulation could be seen. At
low temperature (12°C) the inhibitory response was markedly
reduced.
In this study guanethidine at 20 juM abolished the motor
response to field stimulation without raising the resting
tone of the muscle. If guanethidine was applied initially at
a concentration of 40 jjM the anococcygeus muscle showed a
rise in tone and responses to field stimulation became
biphasic initially, progressing to purely inhibitory
responses as the tone continued to rise (Figure A.14).
Phentolamine 1.0 jiM inhibited the contractile responses to
field stimulation partly.
With PGE2 the field stimulation gave a relaxant response and
verapamil (10 jiM) did not block the response (Figure A.15).
When tone was provided with 11,9-epoxymethano PGH2, the
field stimulation caused either a contractile response or a
biphasic response. inhibition followed by contraction or
contraction followed by inhibition. Atropine at 2.0 ^iM or
indomethacin at 2.0 failed to block the contractile
component (Figure A.16a). Adding guanethidine 20 or phento-
tolamine 20 yjM converted the contractile or biphasic re¬





Figure A.14 Rat anococcygeus muscle preparation:
responses to field stimulation at 5 Hz and 120 V
when tone was provided with 40 jjM guanethidine.
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Figure A.15 Rat anococcygeus muscle preparation: the effect of vera¬
pamil on the inhibitory response to field stimulation at 5 Hz and 110








Indomethacin 2 x 10 M
Figure A.16a Rat anococcygeus preparation: the effect of indomethacin
on responses to field stimulation at 20 Hz and 50 V when tone was








Figure A.16b Rat anococcygeus muscle preparation:
the reversal by guanethidine of responses to field
stimulation at 5 Hz and 110 V when tone was provided
with 11,9-epoxymethano PGH^.
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Chlorpromazine at 10 pM, and promethazine at 10 pM had no
effect on the inhibitory response produced by the field
stimulation in the presence of guanethidine or
11,9-epoxymethano PGH2, but propranolol 100 jiM and verapamil






11,9-epoxymethano PGH2 11.9-epoxymethano PGH2
140 ng/ml 70 ng/ml
Chlorpromazine
10"5 M
Figure A.17a Rat anococcygeus muscle preparation: the effect of
chlorpromazine on the inhibitory response to the field stimulation
at 5 Hz and 110 V when tone was provided with 11,9-epoxymethano









Figure A.17b Rat anococcygeus muscle preparation: the effect of verapamil
on the inhibitory response to the field stimulation at 5 Hz and 110 V when
tone was provided with 11,9-epoxymethano PGH2. W = wash.
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Figure A.17c Rat anococcygeus muscle preparation: the effect of
propranolol on the inhibitory response to field stimulation at 5




The rat anococcygeus muscle contains PGE2 and TxA2
receptors, and probably PGF2a receptors.
The PGE2 receptor system is characterized by the high
activity of PGE2, the partial agonism of ZK 36374 and the
potentiating action of PGE2 analogues on the response to
11;9-epoxymethano PGH2. The order of potency for the
potentiation is ICI 80205> 16,16-dimethyl PGE2> PGE2, as
found in the bullock iris sphincter and rat gastric fundus
for contractile activity.
The TxA2 receptor sites are sensitive to 11^9-epoxymethano
PGH2 and susceptible to blockade by TxA2 antagonists. Unlike
in the bullock iris sphincter, CTA2 was weaker than
11,9-epoxymethano PGH2 and showed partial agonism at
thromboxane receptors in the rat anococcygeus muscle. PTA2
showed no contractile effect on its own and blocked the
action of 11.9-epoxymethano PGH2. PTA2 may not be a pure
antagonist on this preparation since it could potentiate the
action of PGE2.
It is probable that there exists a third group of prostanoid
receptor PGF2a receptor sites. ICI 81008, a specific
PGF2a mimetic, showed properties distinct from PGE2, PGF2a
and 11,9-epoxymethano PGH2. It did not potentiate
11} 9-epoxymethano PGH2 and its contractile action was not
augmented by verapamil. Although PGF2a potentiated response
to 11j9-epoxymethano PGH2 and its action was enhanced by
verapamil, this could be explained by







In order to understand the unexpected effect of calcium
antagonists at the rat anococcygeus muscle, it is useful to
present a synopsis of normal cellular calcium metabolism
first.
A 100 years ago Sidney Ringer discovered the vital role of
calcium in the maintenance of cardiac contractility. Since
then it has been found that intracellular free calcium plays
a role as the regulator for numerous different types of cell
function throughout the animal and plant kingdoms.
Not all these cell functions and their regulatory mechanisms
are so well worked out as is the case with muscular
contraction, where contraction is both triggered and
modulated by the amount of free calcium within the cell.
However, calcium is known to be involved in blood clotting
and coagulation, cellular adhesion and integrity and
membrane stability, bone and teeth formation, enzyme
activity, control of certain aspects of cyclic nucleotide
metabolism, mediation of some actions of prostaglandins,
glandular and other cellular secretory formation, neuronal
transmission, in cell transformation and division, in
transducing sensory signals, in the production of free
radicals by activated polymorphs, in coupling energy
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production from intermediary metabolism to energy needs and
in the control of membrane ion permeabilities, gravitropism
in plants, and undoubtedly many more physiological
functions. Calcium also mediates the pharmacological and
toxicological actions of numerous drugs and chemicals.
However the messenger function of calcium has been
appreciated only comparatively recently ( Kretsinger,1971 &
1976; Cheung, 1980, 1982 & 1983). This messenger function
for calcium is made possible by three key features of
cellular calcium regulation: (1) In the resting state the
intracellular concentration of ionized (free) calcium is
within the range 0.05-0.5 ^jUM whereas that of the
extracellular fluid is 1-10 mM. On electrical or chemical
stimulation, the intracellular free calcium is increased by
one to two orders of magnitude. (2) There exist within the
cell specific calcium-binding proteins with dissociation
— 7 — S
constants for calcium of between 10 ' and 10 M and which
serve as intracellular calcium receptors. (3) Within the
plasma membrane and intracellular organelles,
calcium-specific entry, exit, release, and uptake processes
exist. These processes function both to generate the
elevated levels of calcium during excitation and to restore




Cellular calcium is distributed among several extracellular
and intracellular compartments. Most cells are surrounded by
an extracellular coat of proteins and mucopolysaccharides
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called the glycocalyx, which can bind large amounts of
calcium (Chambers, 1940; Burgos, 1960; Brandt, 1962; Gasic &
Gasic, 1962; Bennet, 1963; Cook et al., 1965; Borle, 1968;
Howell & Tyhurst, 1976). Calcium is also bound to the
phospholipids and to the structural proteins of the cell
plasma membrane (Tobias et al, 1962; Carvalho et al., 1963;
Koketsu et al., 1964; Palmer et al., 1970; Quinn & Dawson,
1972; Duffy & Schwarz, 1973). 50-90% of the cell calcium is
bound extracellularly depending on the tissue (Borle, 1968;
van Rossum, 1970; Claret-Berthon et al., 1977; Muriarty,
1977; Tupper & Zorgniotti, 1977). Within the cells, the
intracellular calcium storage pools contain widely different
amounts of calcium: the cytosol, the nucleus, the
mitochondria, the endoplasmic or sarcoplasmic reticulum,
inner aspect of the plasma membrane, and possibly secretory
vesicles. Mitochondria contain 3 times as much calcium as
the microsomes derived from endoplasmic reticulum or
sarcoplasmic reticulum. About 60% of the intracellular
calcium is sequestered in these two subcellular organelles
while only 10% is left in the supernatant or cytosolic
fraction. 50% or less of the mitochondrial calcium is
exchangeable. The unexchangeable fraction could possibly
reflect the sequestration of calcium in mitochondria as
calcium phosphate precipitates (Peachey, 1964; Greenawalt et
al., 1964; Weinbach & von Brand, 1968; Zadunaisky et al.,
1968; Lehninger,1970; Matthews et al., 1970; Martin &
Matthews, 1970; Sutfin et al., 1971; Ruigrok & Elbers, 1972;
Sayegh et al., 1974) or as organic-inorganic complexes
(Barnard & Afzelius, 1972; Bonucci et al., 1 973),
Importance of Cytosolic Ionized Calcium
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The cytosolic calcium activity is the most important
aspect of the metabolism of cellular calcium. It is the
ionized calcium that regulates the cell functions sensitive
to calcium. The regulation of intracellular ionized calcium
is clearly of central importance to cell function. It is
indeed essential for cell viability. Calcium is not
distributed passively across the plasma membrane. There is a
large electrochemical gradient between the exterior and
interior of the cell which makes the distribution of free
calcium across the cell membrane far from equality but
a proportionately much higher calcium concentration in
extracellular fluids. The maintenance of this uneven
distribution indicates the existence of specific active
mechanisms for the extrusion and sequestration of
intracellular calcium to maintain intracellular calcium
homeostasis.
Calcium Withdrawal and Its Storage,
Several mechanisms for the active transport of calcium out
of the cell, across the plasma membrane, have been
described; (1) an ATP-dependent calcium efflux mediated by a
calcium-sensitive, magnesium-dependent ATPase (CaMgATPase)
that derives its energy from the hydrolysis of ATP; (2) an
efflux of calcium in exchange for extracellular sodium ions
(Na-Ca exchange) that derives its energy from the sodium
electrochemical gradient established across the plasma
membrane by the enzyme Na-K-ATPase; (3) an efflux of calcium
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in exchange for an extracellular calcium ion (Ca-Ca
exchange) that derives its energy from the calcium
electrochemical gradient.
ATP-dependent calcium efflux and its relation to the enzyme
CaMgATPase have been extensively studied in erythrocytes,
where the only possible controller of the intracellular free
calcium concentration is the ATP-dependent calcium transport
across the plasma membrane, which is catalyzed by
CaMgATPase. However, most other cells of tissues, for
example, kidney (Parkinson & Radde,1971; Kinne-Saffran &
Kinne,1974; Moore et al., 1974; Gmaj et al., 1979),
intestine (Kurebe, 1978, 1979; Ghijsen & van Os, 1979),
brain (Ohashi et al. , 1970; Blitz et al., 1977; Rahamimoff &
Abramovitz, 1978), nerves (DiPolo, 1976; Baker, 1976),
skeletal muscle (Sulakhe et al., 1973; Casteels et al.,
1973), smooth muscle (Thorens, 1979), exhibit some kind of
ATP-dependent calcium transport across their plasma membrane
or some CaMgATPase activity. The enzyme is inhibited by
lanthanum, ethacrynic acid, mersalyl, chlorpromazine and
ruthenium red; it is not inhibited by ouabain, oligomycin,
sodium azide, fluoride or caffeine (Schatzmann &
Vincenzi,1969; Vincenzi, 1971; Weiner & Lee, 1972;
Schatzmann, 1975; Quist & Roufogalis, 1975; Hinds et al.,
1978). Many investigators have found that an activator
protein called calmodulin stimulates the CaMgATPase activity
from two- to fourfold. Calmodulin also acts as the
calcium-dependent regulator of a host of biochemical and
physiological events. Low- and a high-affinity binding sites
of CaMgATPase for calcium have been detected (Schatzmann &
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Rossi, 1971; Quist & Roufogalis, 1975, 1977; Gopinath &
Vincenzi, 1977; Scharf & Foder, 1978). Scharf and Foder
(1978) presented evidence that the enzyme exists in two
different and reversible states: (a) a resting state with
low affinity for calcium (Kca=30 ^iM) , a Hill coefficient of
1, a low maximum velocity, and (b) an active state with high
affinity for calcium (Kca=l ^iM) , a Hill coefficient greater
than 1, suggesting a positive cooperativity of calcium
activation, and a high maximum velocity. The resting state
corresponds to the enzyme free of the activator protein
calmodulin, whereas the activator would be bound to the
enzyme in the active state. Scharf and Foder (1978) also
showed that the shift from resting to active state occurs
when the enzyme is exposed to increasing calcium
concentrations in the presence of calmodulin. It has been
found that calmodulin is not the only activator of
CaMgATPase, the ATPase purified from the erythrocyte
membrane can also be stimulated by a number of acidic
phospholipids, by polyunsaturated fatty acid, and by a
limited proteolytic treatment.
In 1958, Luttgau and Niedergerke (1958) reported that frog
hearts depolarized in high-KCl media can be made to contract
or to relax, respectively, by reducing or increasing the
proportion of Na in the surrounding fluids. Reuter and Seitz
(1968) were the first to suggest an exchange diffusion
counter transport by which calcium could be transported out
of the cells in exchange for Na against a large
electrochemical gradient without direct metabolic energy
coupling.
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An extracellular calcium-dependent calcium efflux has been
reported by many investigators (Blaustein & Hodgkin, 1969;
DiPolo, 1974; Blaustein, 1974, 1977; Blaustein et al., 1974;
Blaustein & Russell, 1975; Baker & McNaughton, 1976, 1978;
Baker, 1978). Since calcium influx is also stimulated by
raising intracellular calcium (Blaustein & Russell, 1975;
DiPolo, 1979), Blaustein proposed that this represents a
Ca-Ca exchange mediated by the same carrier as the
Na-dependent calcium efflux, sodium and calcium competing
for the same carrier site.
The uptake of intracellular free calcium by intracellular
calcium stores is an important factor that maintains
intracellular calcium homeostasis with the exception of
erythrocytes. Calcium pumps exist in sarcoplasmic reticulum,
endoplasmic reticulum, mitochondria, and plasma membrane.
Although the affinities for calcium, Kca, are not very
different, the velocity of the plasma membrane transport
system is smaller than in microsomes and several orders of
magnitude less than in mitochondria and sarcoplasmic
reticulum, suggesting that calcium transport across the
membrane may be comparatively ill-suited to control the "set
point" of the cytosolic calcium activity. Since the
mitochondrial inhibitor azide causes a rapid rise in
intracellular free calcium it is likely that mitochondria
play an important role as a controller of cytosolic calcium
(Simonsen & Christofferson,1979). The cytosolic exchangeable
calcium pool changes little when the extracellular calcium
concentration is altered between 0.7 and 2.5 mM, most of the
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gain or loss in cell calcium is seen in the mitochondrial
calcium pool.
In fact more than 40% of the total cell calcium is stored in
mitochondria, constituting the largest calcium compartment
explained
of the cell. The mitochondrial calcium transport is j on
chemiosmotic theory. During equ ilibrium - state oxidative
phosphorylation the proton electrochemical potential
difference (<apH+) generated by proton extrusion linked to
the respiratory chain is utilized to drive a
proton-translocating ATPase in reverse, so that a net
synthesis of ATP occurs. The proton electrochemical
potential difference has both electrical and concentrative
components, and the extrusion of H+ results in the buildup
of a membrane potential (positive outside the matrix) and a
pH gradient (acid outside the matrix).
A/Ph+=a^-^0 aPh
where is the membrane potential (positive when the matrix
is negative) and ApH is the transmembrane pH gradient
(positive when the matrix is acidic). Calcium can be
transported across the inner membrane by a uniport
mechanism, i.e. as uncompensated calcium ion. The driving
force for calcium accumulation is by definition the calcium





Since A ^ is in the range 150-180 mV, it follows that the
gradient of free calcium across the inner membrane could in
theory attain values of 105-10® if this were the only means
for transporting calcium across the inner membrane.
It has been proposed that there is a high-affinity
calcium-binding site in mitochondria which reflects the
active site of the carrier molecule with an affinity
constant Kca of 0 .025 jjM (Reynafarje & Lehninger, 1969;
Lehninger et al., 1978). Lanthanum is a competitive
inhibitor of calcium transport into mitochondria, presumably
competing with calcium for the same site on the carrier
molecule. And indeed several investigators have isolated
from mitochondria a glycoprotein with affinity for calcium
(Sottocasa et al., 1971, 1972; Gomez-Puyou et al., 1972;
Kimura et al., 1972; Tashmukhamedov et al., 1972).
Some findings have indicated that except in erythrocytes and
in skeletal and cardiac muscle fibers, mitochondria are the
main controllers of the cytosolic calcium activity
(Lehninger, 1964; Bygrave,1967, 1978; Borle, 1973; Mela,
1977; Carafoli & Crompton, 1978b). However, there are
objections against the major role of mitochondria in
controlling cytosolic free calcium: (a) the affinity of
mitochondria for calcium is simply too low (Kca>l ^jM); (b)
calcium cycling across the inner mitochondrial membrane
appears to be negligible at the physiologic cytosolic free
calcium concentration (0.5-3.0x10"^ M) (Scarpa, 1975; Scarpa
et al., 1978; Brinley, 1978; Brinley et al., 1978). Several
lines of evidence suggest that mitochondria do play a
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important role in cellular calcium metabolism. First, the
major part of the cell calcium is found in mitochondria.
Second, when a cell is taking up calcium (during calcium
loading or in tracer experiments) the major part of the load
is taken up by the mitochondria in liver, kidney, muscle,
salivary glands, synaptosomes and in the squid axon. Third,
Rose and Lowenstein (1975) showed that intracellular
microinjections of calcium in the giant salivary gland cells
of chironomus were rapidly buffered by an energy-dependent
process and did not increase the cytosolic ionized calcium
monitored with aequorin. However, when cyanide or ruthenium
red were injected before calcium, there was a large and
diffuse increase in aequorin luminescence, indicating a
large rise in cytosolic free calcium. Since ruthenium red
inhibits mitochondrial calcium uptake without affecting
calcium transport by microsomes or by the plasma membrane
(Ash & Bygrave, 1977; Blaustein et al., 1978), these
experiments suggest that mitochondria are the principal
controllers of cytosolic free calcium in these salivary
gland giant cells. In fact, the mitochondrial calcium
transport system has high maximal velocity and capacity to
sequester calcium. In spite of a Kca that is one order of
magnitude larger than the cytosolic calcium activity the
rate of calcium transport of mitochondria is so high that
even at physiologically low calcium concentrations, its
transport capacity or rate of cycling is significant and
predominates over the plasma membrane calcium transport
system. Another important consideration is the relative mass
and the relative surface area of mitochodria transport
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system. Work by Weibel et al. (1969) showed that the surface
of the inner mitochondrial membrane was 21 times greater
than the plasma membrane surface in the rat liver.
Furthermore, the mitochondrial calcium uptake increases more
than that of plasma membrane with increasing cytosolic free
calcium. Experiments have shown that in liver, kidney,
adipocytes, nerve terminals, and smooth muscle the rate of
calcium uptake and the capacity of calcium sequestration of
mitochondria exceed by least one order of magnitude those of
endoplasmic reticulum and of plasma membrane (Carafoli &
Tiozzo, 1967; Batra & Daniel, 1971; Batra 1973, 1974; Moor
et al., 1974; Wikstrom et al., 1975; Vallieres et al., 1975;
Bruns et al., 1976; Janis et al., 1977; Malmstrom &
Califoli, 1977; Ash & Bygrave, 1977; Farber et al., 1977;
Bygrave & Trauter, 1978). Therefore, the importance of
mitochondria in controlling intracellular calcium
homeostasis in these tissues must be considered.
In skeletal muscle the sarcoplasmic reticulum is recognized
to be the principal controller of the cytosolic calcium.
Detail of calcium transport in skeletal muscle has been
studied using the reconstituted vesicles or microsomes from
fragmented sarcoplasmic reticulum. In the muscle microsomes,
calcium transport is stoichiometrically coupled to ATP
hydrolysis: for each ATP hydrolyzed, 2 calcium atoms are
carried across the membrane in a process that Mg-dependent.
The active transport mechanism is the Mg-dependent
Ca-activated ATPase that catalyzes the formation of a
phosphoprotein intermediate. The sarcoplasmic reticulum
affinity for calcium is in the same order of magnitude as
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the Kca of the plasma membrane, endoplasmic reticulum and
mitochondria. Its important kinetic property is the great
velocity of the transport process reflected by a Vm that may
exceed 1 ^imol mg-1 prot. min--1-. Thus, it is accepted that
skeletal muscle sarcoplasmic reticulum can lower the
cytosolic calcium activity below 10~® M.
In heart muscle, the sarcoplasmic reticulum is probably not
the only controller of cytosolic calcium activity. The
existence of calcium channels makes this tissue more
dependent on the extracellular calcium concentration and on
calcium influx and efflux through the plasma membrane. In
addition, many investigators have suggested that
mitochondria may play a role in the control of free calcium
in heart muscle (Chance, 1965; Patriarca & Carafoli, 1968;
Harigaya & Schwartz, 1969; Carafoli & Azzi, 1972; Carafoli
et al., 1972; Lehninger, 1974; Affolter et al.f 1976;
Carafoli & Crompton, 1978a; Lentz et al., 1978; Nayler et
al., 1979). Others doubt it because of the mitochondrial
high Kca and their slow transport velocity compared with
that in sarcoplasmic reticulum (Solaro, 1972; Scarpa &
Graziotti, 1973; Scarpa, 1975; Tsokos et al., 1977). Tsokos
et al. (1977) suggested that, although mitochondria may not
play a significant role in the rapid uptake of calcium
promoting relaxation of myofibrils, the possibility still
remains that they participate in regulating the steady-state
calcium levels and the resting tension of the myofibrils.
Calcium Sources and Mobilizationr
There may be as many as three different sources of calcium
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for contraction: (1) extracellular calcium,(2) Calcium bound
to receptors,and (3) calcium released from intracellular
calcium stores, which are present on the inner surface of cell
membranes,ih mitochondria and endoplasmic or sarcoplasmic
reticulum.
The entry of the extracellular calcium can be (a) by passive
diffusion down the concentration gradient, (b) in exchange
for internal sodium or other ions and (c) operated by two
types of ion channel in the cell membrane: the
voltage-dependent calcium channel (VDC) and the
receptor-operated calcium channel (ROC). The
voltage-dependent channels have been defined as those
activated by membrane depolarization (electrical or high
potassium), while the receptor-operated channels are those
associated with membrane receptors and are activated by
specific agonist-receptor interaction. It is not known if
the channels themselves are different structures or if the
association of ligand receptors with voltage-dependent
channels changes their voltage dependence and sensitivity to
channel antagonists and make them receptor-operated
channels. In any smooth muscle several different stimulants
may have their own receptors, each receptor type operating
its own ion channels with their particular ionic
selectivity. It is easy to appreciate how the maximal
contractile responses to various stimulants may not be the
same, because the increase in intracellular free calcium
concentration produced by different stimulants is unequal.
The process of release of calcium from intracellular stores
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(mitochondria and sarcoplasmic or endoplasmic reticulum)
needs to be triggered by calcium from other sources. Trigger
calcium may come from the extracellular source either
through voltage-dependent ion channels or through ROCs. It
may also be dislodged from a bound site associated with the
receptor. At low concentrations of stimulants the action
potential (AP) is the important source of trigger calcium in
cells that generate APs. In cells that do not readily
generate APs, calcium entering through ROCs is the main
source of trigger calcium, and this source is also
quantitatively the most important in cells that normally
generate APs when high concentrations of stimulants are
applied and AP discharge is abolished. A voltage-dependent
opening of calcium ion channels in smooth muscle cells not
normally generating APs may be a minor source of trigger
calcium when these are depolarized by stimulant drug
application. The relative extent of intracellular and
extracellular sources is dependent on the tissue, stimulant,
species, the environment of the calcium channels, and the
effect of other calcium regulating mechanisms (Bolton, 1979;
Casteels, 1980; Danniel, Crankshaw & Kwan, 1979; Putney,
1978; van Breemen, Aaronson, Loutzenhiser & Meisheri, 1980).
Calcium £haimgi. Blockers
The ubiquitous role of calcium in cell regulation and the
diversity of processes controlling cellular calcium
concentration indicate the importance of identification of
the sources and routes of calcium mobilization. Several
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approaches have been used to examine fundamental processes
at the
of calcium ion metabolism ^ cellular level and to estimate
the relative importance of different calcium stores for the
mechanism of activation. One approach is to use agents that
selectively antagonize the pathways of calcium utilization.
Considerable attention has been paid in recent years to two
major groups of compounds the calmodulin antagonists
and the calcium channel blockers.
The description of calcium channel blockers owes much to the
original investigations of Fleckenstein who first observed
that verapamil mimics the cardiac effects of calcium
withdrawal (Fleckenstein, 1964). Since the original studies
with verapamil, a large number of additional structures have
joined this class of calcium channel blockers.
The calcium channel blockers are a structurally and
pharmacologically heterogeneous group of drugs. The obvious
structural heterogeneity suggests that more than one site
O _i_
and mechanism of action exist. The inorganic cations Mn^ ,
Co^+and La^+ apparently act as general antagonists and are
effective in a wide variety of calcium-dependent processes
(Bolton, 1979; Mikkelsen, 1976; Parod & Putney, 1980;
Rosenberger, Ticku & Triggle, 1979; Triggle & Swamy, 1980).
This nonselectivity of action probably arises from a general
ability of these cations to substitute for calcium at
calcium-binding sites. It is possible that these cations
occupy the cation coordination site of calcium channels and
either block channel function or actually enter the cell
(Fukuda & Kawa, 1977; Hagiwara, 1975), where they can
28 1
substitute for or block calcium binding at the intracellular
calcium receptors.
The organic calcium channel blockers are generally
competitive with calcium, but it is clear that they lack the
widespread calcium-blocking properties of the inorganic
cations and important differences in activity can be
seen among the various structural classes of these
compounds. They are grossly divided into three classes in
terms of the binding of the labelled calcium antagonist to
the calcium channel. Those which compete according to the
law of mass action for an interaction at one binding site
(Hill slope=1.0), are designated Class I, to which all of
the 1,4-dihydropyridines, for example, nifedipine and
nimodipine, belong. Those which compete in a more complex
manner, suggesting interaction at multiple sites (Hill
slope<1.0), are termed as Class II and include verapamil and
D 600 ( the methoxy derivative of verapamil). There is a
third class of calcium channel blocker, of which diltiazem
is representative. It stimulates the binding of
tritium-labelled nimodipine by decreasing the Kd value.
Class II drugs, verapamil and D 600, are the most
intensively studied organic calcium blockers. The specific
mechanism of action of these drugs in blocking calcium entry
is known. Extracellular calcium can enter the cell by
passive diffusion, ion exchange and calcium channels, as
mentioned above. Only the pathway which involves the inward
movement of calcium through the voltage-dependent channels
has been shown to be sensitive to verapamil (Fleckenstein,
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1977; Kohlhardt, Bauer. Krause & Fleckenstein, 1972). For
this reason, the term "slow channel blocker" more accurately
describes their mode of action; the term "slow" refers to
the relatively slow rate of opening of these channels
compared with that of the channels which are responsible for
the influx of sodium during the rapid depolarization phase
of the action potential in the heart. The slow channels also
admit some sodium ions, and verapamil and D 600 inhibit the
sodium as well as the calcium transporting capacities of
these channels (Kass & Tsien, 1975). It is now known that
high concentrations of verapamil affect the fast inward
sodium current (Bayer, Kalusche, Kaufmann & Mannhold, 1975).
In addition to the blockade of the slow inward calcium
current in cardiac tissue, they serve as competitive
antagonists against extracellular calcium in smooth muscle
and are potent inhibitors of smooth muscle contractile
activity produced by potassium depolarization (Hashimoto,
Nakagawa, Nabata & Imai, 1978; Imai, 1979; Reimer, Dorfler,
Mayer & Ulbrecht, 1974). They are also potent antagonists of
some agonist-induced mechanical events, and there is a
reasonably good correlation between this activity and the
dependence of the response on extracellular calcium (Farley
& Miles, 1978; Harris, Swamy, Triggle & Waters, 1980; Jetley
& Weston, 1980; Rosenberger, Ticku & Triggle, 1979;
Schumann, Gorlitz & Wagner, 1975; Shimizu, Ohta & Toda,
1980) .
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Actions of Calcium Antagonists and Ponsiilo Heoiiaiiiomo
In this study it has been found that verapamil enhanced the
contractile activity of prostanoids on the rat anococcygeus
muscle. This is not due to release of noradrenaline by
prostanoids, since the potentiating activity is not altered
by sympathetic denervation with 6-hydroxydopamine or the
presence of phentolamine. Several other stimulant actions of
verapamil are known. On frog sartorius muscle verapamil
produced contraction (Bondi, 1978). In rat diaphragm muscle
verapamil increased the transmitter release from motor nerve
terminals (Nishimura,Asai & Urakawa, 1982). Verapamil
potentiated the response of the rat vas deferens to single
pulse field stimulation (French & Scott, 1981). On rat
kidney cortical slices verapamil stimulated the
p-aminohippurate (PAH) uptake (Matsushima & Gemba, 1982). On
the mouse leukemia cells, verapamil and diltiazem, but not
nifedipine, causes a 3-fold enhancement of the frequency of
transfer of the cloned gene for herpes simplex virus
thymidine kinase (Akiyama, Ona & Kuwano, 1983).
It has been suggested that verapamil inhibits the membrane
calcium pump and the associated activation of the
calcium-sensitive ATPase (Mas-oliva & Nayler, 1980;
Publicover & Duncan, 1979). In addition, Johnson et al.
(1982), Bostrom et al. (1981) and Motlib, Vaghy, Johson and
Schwartz (1982) showed that verapamil, D 600, diltiazem,
felodipine and nisoldipine (nifedipine analogues) can bind
to the hydrophobic binding sites of calmodulin. It is now
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known that calmodulin plays a pivotal role in many cellular
functions (Cheung, 1980). In the calcium-transport system,
the CaMgATPase activity of erythrocytes is enhanced by
calmodulin (Jarret & Penniston, 1977; Waisman, Gimble,
Goodman & Rasmussen, 1981; Niggli, Penniston &
Carafoli,1979). In addition to erythrocytes, calmodulin
stimulates the calcium-transport system of the plasma
membranes of most cell types, e.g. cardiac muscle (Caroni &
Carafoli, 1981) and adipocytes (Pershadsingh, Landt &
McDonald, 1980) by a direct interaction with CaMgATPase. It
is proposed that verapamil might produce the potentiation by
inhibiting CaMgATPase through binding to calmodulin.
Raess and Vincenzi (1980) reported that in the presence of
calcium? antipsychotic drugs could bind to calmodulin and
thereby inhibit calmodulin-stimlated CaMgATPase activity.
the
This inhibition is related to the binding of^drugs to
hydrophobic regions of calmodulin which are exposed by
calcium-induced conformational changes. Phenothiazines and
substituted-
N-yiaphthalenesulfonamides have been widely used as tools to
demonstrate the calmodulin-dependent process in isolated
enzyme systemrand at the level of intact cells (Weiss,
Prozialeck, Cimino, Barnette & Wallace, 1980; Nishikawa,
Tanaka & Hidaka, 1980).
A number of calmodulin antagonists were then tested in this
and
study. Most of the phenothiazines tested propranolol
—... ' produced enhancement of the action of
prostanoids on the rat anococcygeus muscle preparation.
Since CaMgATPase can also be stimulated by a limited
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proteolytic treatment, trypsin was tested. It inhibited
the response to 11;9-epoxymethano PGH2, which appeared to
support the idea that the membrane CaMgATPase played a
important role in regulating intracellular free calcium in
the rat anococcygeus muscle. For these reasons, it was
assumed that those calcium antagonists produced their
enhancement by binding to calmodulin and preventing
CaMgATPase from pumping calcium out of the cell. Thus,
intracellular free calcium which is essential for
contraction would be increased. These findings seemed to
support our above assumption.
However there is evidence against this hypothesis. The order
of pP2 values for the calmodulin antagonists differs from
the Ki values for the displacement of
tritiated-trifluoperazine from calmodulin (Weiss,
Prozialeck, Cimino, Barnette & Wallace, 1980). Pimozide,
which is the most potent compound in displacing
tritiated-trifluoperazine produced no enhancement on the rat
anococcygeus muscle preparation. Tetracaine, a local
anesthetic, inhibits the specific calmodulin-dependent
of
stimulation erythrocyte CaMgATPase. However, xylocaine,
which is a compound structurally similar to tetracaine,
inhibited the response to 11.9-epoxymethano PGH2.
Nifedipine, a structural analogue of felodipine has been
shown to have little potentiating effect (Bostrom et al.,
1981). Furthermore. Epstein, Fiss, Hachisu and Andrenyak
(1982) showed that verapamil was a weak inhibitor against
calmodulin-sensitive forms of cyclic AMP phosphodiesterase.
And verapamil does not antagonize the calcium stimulation of
2.86
aortic myosin light chain kinase or ATPase, which are
presumed to be mediated through calmodulin (Kanamori, Naka,
Asano & Hidaka, 1981).
CaMgATPase can also be stimulated by acidic phospholipids
and polyunsaturated fatty acids (Niggli, Adunyah, Penniston
& Carafoli, 1981; Niggli, Adunyah & Carafoli, 1981; Stieger
& Schatzmann, 1981). It has been reported that calmodulin
antagonists can interact not only with calmodulin but also
with phospholipids and inhibit phospholipid-stimulated
phosphodiesterase (Kanno & Sasaki, 1982; Adunyah, Niggli &
Carafoli, 1982), and calmodulin antagonists may even have a
direct interaction with the CaMgATPase (Vincenzi, Adunyah,
Niggli & Carafoli, 1982). However, at low temperature
(12°C), where CaMgATPase will completely lose its activity
(Duncan, 1976), verapamil and chlorpromazine were still
capable of potentiating responses to prostanoids, although
higher concentrations were needed.
It is suggested that verapamil also blocks sodium channels
(Shigenobu, Scheider & Sperelakis, 1974). The increase in
the sodium gradient and stimulation of NaK-ATPase activity
can not explain the stimulatory action of verapamil, since in
the presence of ouabain the PAH accumulation was still
stimulated by verapamil (Matsushima & Gemba, 1982).
Caffeine in high concentrations produces smooth muscle
contraction. Its niechanism is not known. Kurebayashi & Ogawa
(1981) reported that the amount of calcium release by
chlorpromazine from the loaded fragmented sarcoplasmic
reticulum of bullfrog skeletal muscle was increased by a.1,
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rise in calcium concentration and decreased by procaine or
an increase in magnesium concentration, and that
chlorpromazine may act in a way similar to caffeine. However
their further experiments showed chlorpromazine evoked
tension by a different mechanism: calcium release by
chlorpromazine from fragmented sarcoplasmic reticulum loaded
with calcium in the presence of carbamylphosphate was
markedly decreased during the initial phase; in the presence
of carbamylphosphate, p-Y-methylene adenosine triphosphate,
a nonhydrolyzable analogue of ATP, does not potentiate the
calcium releasing action of chlorpromazine. These are in
contrast to the action of caffeine. And the action of
chlorpromazine in the presence of caffeine was difficult to
explain by the assumption that they might act on the same
site. Other workers have shown verapamil elicited
contraction through a different way from caffeine.
Elimination of extracellular calcium partially depressed
verapamil-induced contraction without significantly blocking
caffeine-induced contraction and sarcoplasmic reticulum
calcium release (Frank, 1962; Luttgau, 1963; Putney &
Bianchi, 1974). And caffeine-induced contraction is totally
inhibited by procaine while verapamil induced contraction is
only partially inhibited by procaine (Bondi, 1978).
These unsatisfactory explanations urged us to look for other
possibilities. It is known that phenothiazines possess some
unusual properties. Caroni & Carafoli (1981) reported that
phenothiazines caused leakage of the plasma membrane of
cardiac muscles. N-(6-aminohexyl)-5-
chloronaphthalene-l-sulfonamide (W-7), triflupromazine and
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trifluoperazine induced renin release from isolated
glomeruli in a dose-dependent manner (Kawamura & Inagami,
1983). Naccache, Molski, Alobaidi, Becker, Showell and
Sha'afi (1980) reported that trifluoperazine induced the
release of lactate dehydrogenase from rabbit peritoneal
neutrophils. In saponin-treated guinea pig peritoneal
macrophages, chlorpromazine, trifluoperazine, W-7 and
N-(6-aminohexyl)-1- naphthalenesulfonamide inhibited calcium
uptake and released accumulated calcium (Hirata, Suematsu &
Koga, 1983). On fragmented sarcoplasmic reticulum from
bullfrog skeletal muscle/ chlorpromazine caused calcium
release and inhibited calcium uptake (Kurebayashi & Ogawa,
1981). Hirata, Suematsu and Koga (1982) found that addition
of 100 juM phenothiazines caused leakage of the endoplasmic
reticulum membrane and released more than 50% of the calcium
taken up by the endoplasmic reticulum. Trifluoperazine
inhibited calcium uptake and produced sudden release of
calcium from sarcoplasmic reticulum vesicles of rabbit
skeletal muscle, and inhibited calcium accumulation by rat
cardiac sarcoplasmic reticulum in situ (Ho, Scales & Inesi,
1983). Sulfhydryl agents can release calcium from isolated
rabbit sarcoplasmic reticulum vesicles, and chlorpromazine
acts synergistically with the sulfhydryl agents (Bindoli &
Fleischer, 1983). Chlorpromazine was found to make the
contractile system more sensitive to calcium ion in fast
twitch smooth muscle in a skinned fiber preparation and the
main site of action was interpreted to be on the calcium
release mechanism (Meissner & Fleischer, 1971).
Verapamil and D 600 showed similar properties. They caused
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calcium release from frog sartorius muscle (Bondi, 1978). At
the frog neuromuscular junction^ verapamil and D 600 at high
concentration caused the release of calcium from
intracellular calcium stores and raised intracellular free
calcium (Publicover & Ducan, 1979), and they suggested that
verapamil generates tension by a mechanism other than
depolarization. Furthermore, verapamil inhibits calcium
binding in preparations of isolated cardiac sarcoplasmic
reticulum (Nayler & Szeto, 1972; Watanabe & Besch, 1974;
Mas-Oliva & Nayler,1980) and calcium uptake by isolated
rabbit skeletal muscle sarcoplasmic reticulum (Balzer,
1972). Pang and Sperelakis (1983) have proved that verapamil
enters and accumulates in the cardiac and smooth muscles,
and internal verapamil concentration at steady state for
both cardiac and smooth muscle is much higher than the drug
concentration in the medium. Nayler, Mas-Oliva & Williams
(1979) have shown verapamil binds to isolated rabbit cardiac
sarcolemmal fragments and particularly to
carbohydrate-containing residues. Lullmann, Timmermans &
Ziegler (1979) have reported that verapamil was accumulated
by isolated left atria of the guinea pig. The uptake was
enhanced by electrical stimulation of the muscle. The
accumulation of verapamil by cardiac tissue has also been
confirmed by Keefe and Kates (1982), who found a
myocardial/plasma concentration ratio of 6.2 following
intravenous administration of verapamil into anesthetized
dogs. These facts indicate that those drugs may produce
their stimulatory action by acting on intracellular calcium
stores inhibiting calcium uptake by and releasing
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calcium from sarcoplasmic reticulum and mitochondria.
The release of calcium from sarcoplasmic reticulum can be
by
triggered by calcium from other sources or^ nerve impulses
which propagated into the sarcoplasmic reticulum. This
calcium uptake into the sarcoplasmic reticulum is an
ATP-dependent process representing the operation of a
CaMgATPase located in the membrane. Calmodulin has been
reported to stimulate calcium transport in the sarcoplasmic
reticulum of cardiac muscle (Katz & Remtulla, 1978; LePeuch,
Haiech & Demaille, 1979), and calmodulin has been found in
endoplasmic reticulum of both lobster muscle and rat liver
(Carafoli, Niggli, Malstrom & Caroni, 1980). Therefore, it
was considered that calcium antagonists might bind to
calmodulin in sarcoplasmic reticulum and inhibit CaMgATPase,
so that the intracellular free calcium would be increased.
However, Pershadsingh, Landt & McDonald (1980) found that,
although calmodulin stimulated calcium transport in plasma
membrane vesicles of adipocytes prepared from rat epididymal
fat pads, it did not stimulate calcium transport in
endoplasmic reticulum-enriched adipocyte microsomes. So, it
of
appears that the calmodulin stimulation^calcium transport
occurs in plasma membranes but probably not in endoplasmic
reticulum, and that the sarcoplasmic reticulum of cardiac
muscle was an exception, perhaps due to the existence of a
special protein, phospholamban, in cardiac < sarcoplasmic
reticulum (LePeuch, Haiech & Demaille, 1979). Thus, whether
calmodulin would stimulate calcium transport in the
cytoplasm is controversial. Recently, Hirata, Suematsu and
Koga (1983) obtained new evidence supporting the idea that
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calmodulin does not enhance either the maximal capacity for
calcium uptake or the apparent affinity for calcium of
calcium accumulation by the endoplasmic reticulum of guinea
pig peritoneal macrophages, under the condition of saponin
treatment in the presence of sodium azide, an inhibitor of
mitochondrial calcium uptake. They also discovered that
phenothiazine inhibition of calcium uptake
required a higher concentration than did inhibition of
calmodulin stimulation of phosphodiesterase activity (Levin
& Weiss, 1977; Raess & Vincenzi, 1980). The order of potency
of inhibition of phosphodiesterase activity by various
calmodulin antagonists was not applicable to inhibition of
calcium uptake. Furthermore, inhibition of calcium uptake by
phenothiazines was not reduced by the addition of excess
calmodulin (Shenolikar, Cohen, Cohen, Nairn & Perry, 1979).
And the inhibition of calcium uptake by calmodulin
antagonists was not modified by changes in the concentration
of either Mg-ATP or free calcium , both of which are
important factors in calcium uptake. Therefore, the
inhibitory effect on calcium uptake by calmodulin
antagonists does not seem to be due to a specific effect on
endogenous calmodulin.
Another possibility is that these drugs inhibit calcium
uptake of mitochondria or enhance the calcium release.
Hirata, Suematsu and Koga (1982) demonstrated that
substitute*-'
phenothiazines and N-naphthalenesulfonamides at low
concentration had an inhibitory effect on the calcium uptake
of the mitochondria of the guinea- pig macrophage. This
inhibition is probably not due to a specific antagonist
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effect of these drugs on calmodulin: (1) exogenously added
calmodulin did not affect calcium uptake by the
mitochondria, in terms of both the capacity and the apparent
affinity for calcium, (2) exogenously added calmodulin did
not affect the inhibitory effect of phenothiazines, (3)
almost complete inhibition by phenothiazines and
N-naphthalenesulfonamides occurred; if the inhibition of
calcium uptake by these drugs is due to specific effects on
calmodulin, all of the mitochondrial calcium uptake would be
dependent on the activation of calmodulin. Furthermore.
Carafoli, Niggli, Malmstrom & Caroni (1980) reported that
calmodulin was either absent in liver mitochondria, or
present only in negligible amounts, and the mitochondrial
calcium uptake of liver and heart was not affected by the
exogenous addition of calmodulin. Both verapamil (Appel,
1962) and phenothiazines (Carey, Hirom & Small, 1976) are
lipophilic substances and at appropriate pH they will become
cationic detergents to produce surface activity and disturb
the ordered phospholipid bilayer structure of membrane. It
has been proved that phenothiazines preferentially bind to
phosphatidylserine on the inner half of the lipid bilayer
(Carey, Hirom & Small, 1976). Therefore, calcium antagonists
may produce their inhibition of calcium uptake and release
of calcium by their detergent-like activity.
Since the proton efflux in the inner membrane of
mitochondria supplies the energy for mitochondrial calcium
uptake, as mentioned before, any drugs which can affect
mitochondrial metabolism or membrane permeability will
change calcium release from or uptake into mitochondria. The
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following studies of the effect of chlorpromazine on
mitochondria with respects to respiratory activity and
potassium metabolism may help to explain the mechanism for
the potentiating effect produced by calcium antagonists.
Chlorpromazine inhibits respiratory activity by acting on
different substrates, causes membrane de-energization
(Byczkowski & Korolkiewicz, 1978; Byczkowski, 1977; Chazotte
& Vanderkooi, 1981), and increases the mitochondrial
membrane passive permeability to monovalent cations
(Byczkowzki & Borysewicz, 1976, 1979; Byczkowzki, 1983).
Depending on the external potassium concentration,
chlorpromazine caused the passive shrinking or swelling of
mitochondria due to efflux of potassium from their matrix in
hypopotassium medium or influx of potassium into the matrix
in hyperpotassium medium. It is generally believed that
prior to transport into the mitochondrion, potassium cations
bind temporarily to fixed superficial anionic sites such as
phospholipids which, in addition, may serve as cation
exchangers with the inner mitochondrial membrane
(Byczkowski, Salamon, Harlos & Porter, 1981). Chlorpromazine
(0.25 mM) produced partial neutralization of the surface
potential of intact mitochondria. Byczkowzki (1983)
postulated this neutralization may be caused by
electrostatic interaction of the nitrogen atom of
chlorpromazine molecule, positively charged at pH 7.2, with
negatively charged binding sites at the surface of inner
mitochondrial membrane. Moreover, the lipophilic portion of
chlorpromazine molecule is able to interact with lipid phase
of the membrane (Byczkowski, 1977) and even form a
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charge-transfer complex (Szent-Gyorgyi, 1960). As a
consequence of electrostatic and lipophilic interaction of
chlorpromazine with the inner mitochondrial membrane and
subsequent dearrangement of the lipid phase the activation
of endogenous permeability to osmotically active potassium
occurred. Perhaps, both mechanisms are essential for
chlorpromazine action, since surface potential
neutralization alone by spermine or other polyamines
(Byczkowski & Porter, 1981; Byckowski, Zychinski & Porter,
1982) caused no increase of mitochondrial membrane passive
permeability of osmotically active cations, although the
polyamines counteracted effects of chlorpromazine. On the
other hand, purely lipophilic agents derivatives of
DDT, known for their interaction with lipid bilayer
(Byczkowski, 1973, 1977), not only inhibited the
carrier-mediated potassium transport in mitochondria
(Chefurka, Zahradka & Bajura, 1980) but also reversed the
effect of chlorpromazine (Byczkowski, 1977, 1978). More
recently, Vale, Moreno and Carvalho (1983) have pointed out
that the inhibitory effect of chlorpromazine and
trifluoperazine on the respiration-dependent and
ATP-dependent calcium uptake by rat liver mitochondria is
due to direct action of the drugs on the electron carrier
system of the respiratory chain. Therefore, it is possible
that phenothiazines affect both potassium and calcium
metabolism through the same mechanism the inhibition of the
respiratory chain.
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Prostanoids, Calcium and Calcium Antagonists
In some tissues, e.g. rat uterine horn, PG-induced
contraction requires extracellular calcium: the withdrawal
of calcium fromthe bathing medium abolishes the contraction
(Harbon, Vesin & Do Khac, 1975; Paton & Daniel, 1967). On
the other hand, it has been reported that
11,9-epoxymethano PGH2 produces a submaximal contraction of
rabbit aorta in the absence of extracellular calcium which
is .sustained for many hours, and it has been proposed the
11,9-epoxymethano PGH2-induced contraction is the result of
mobilization of calcium from one of the intracellular
calcium stores (van Breemen. Aaronson, Loutzenhiser &
Meisheri, 1980; Loutzenhiser & van Breemen, 1981). Brandt,
Andersson, Edvinsson and Ljunggren (1981) found that on
human cerebral arteries potassium-contracted vessels relaxed
almost completely, while PGF2a-contracted arteries were
relaxed by only 60% when calcium antagonists were added.
Shimizu, Ohta and Toda (1980) have also shown that in dog
cerebral arteries, verapamil relaxed potassium-contracted
arteries more then PGF2a-contracted vessels. Godfraind,
Miller and Socrates Lima (1983) reported that the
contraction induced by PGF2a in the rat aorta is partially
dependent on intracellular calcium. In calcium-free
solution, depolarization with 100 mM potassium failed to
produce a contraction of rat aorta, but PGF2a (3 jjM)
stimulated a contraction equal to about 23% of maximal
elicited in normal physiological solution. More recently
Heaslip & Rahwan (1982) have demonstrated that in rat aorta
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the persistent contraction induced by 11,9-epoxymethano PGH2
under calcium-free conditions is not diminished by
nifedipine, but is blocked by 2-n-butyl-3-dimethylamino-
5,6-methylenedioxyindene (bu-MDI). bu-MDI is a tertiary
amine with predominantly intracellular calcium antagonistic
properties (Rahwan & Witiak, 1979; Rahwan, Faust & Witiak,
1977; Rahwan, Witiak & Muir, 1981; Rahwan & Gerald, 1981;
Piascik, Johnson, Potter & Rahwan, 1981; Burchfield & Rail,
1981). In further support of this contention is the finding
by Heaslip & Rahwan (1982) that quaternary-bu-MDI, which in
all likelihood has very limited access to the intracellular
compartment, is incapable of diminishing the contractile
response of the aorta to 11,9-epoxymethano PGH2 elicited in
the absence of extracellular calcium. In addition, Grosset &
Mironneau (1977) have shown in uterine smooth muscle from
pregnant rats that PGEl increase the late outward current;
it has been suggested in several other preparations that the
increase in the intracellular calcium concentration could,
in turn, lead to an increase in the outward current (Meech &
Standen, 1975; Bassingthwaighte, Fry & Mcguigan, 1976).
Furthermore, it has been shown in several studies that PGs
may release calcium ions from isolated sarcoplasmic
reticulum (Carsten, 1973) and mitochondria (Kirtland & Baum,
1972; Malmstrom & Carafoli, 1975; Tsuyoshi & Develin, 1979).
These results may be interpreted most easily by assuming
that prostanoids induce the release of calcium ions from
intracellular storage pools into the cytoplasm as well as
admit extracellular calcium ions.
In the present study, the alteration of extracellular
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calcium concentration over the range 0.6-5.0 mM did not
affect 11f9-epoxymethano PGH2 activity on the rat
anococcygeus muscle preparation. However, in the
calcium-free solution the maximum response to
11,9-epoxymethano PGH2 was markedly reduced. This seems to
accord with the above observations that PGs can not only
manoeuvre extracellular calcium but also intracellular
calcium. However, verapamil and D 600 enhanced the actions
of PGs instead of depressing them, even in the absence of
calcium in the bathing medium. This raises a question: Do
PGs really require extracellular calcium for contraction in
this preparation? If so, why do calcium channel blockers
fail to block PGs action? if notr what role does the
extracellular calcium play in PG-induced contraction?
Possible assumptions could be that (1) interaction of PGs
with their receptors needs extracellular calcium, (2)
extracellular calcium may help PG transport into the cell,
if PG receptors located inside the cell, or (3) PGs release
an
membrane-bound calcium, which comes from ^extracellular
source, to trigger further release of calcium from
intracellular calcium stores.
From a search of the literature, only one example of a
similar potentiating effect has been found. D 600
potentiates the contractile response to PGE2 in the uterine
smooth muscle of pregnant rats (Grosset & Mironneau, 1977).
In another group of experiments, Reiner & Marshall (1976)
showed D 600 neither enhanced nor inhibited PGF2a-induced
tonic contraction in the uterine smooth muscle of pregnant
rats, but it is noteworthy that in their study a high
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concentration of PGF2a (10 pM) was used. It is possible that
this was a supramaximum concentration and no further
increase in tension was attainable.
Receptor-response coupling can be altered (1) by compounds
interacting with membrane receptors, (2) by action on the
chain of events between the binding of an agonist to its
receptor and the activation of actomyosin-ATPase which
follows, or (3) by acting on the effectors, i.e. muscle
filaments. Calcium antagonists may produce their enhancement
by acting on any of these points.
Obviously, calcium antagonists give the enhancement not by
interacting with the effectors, since calcium antagonists
do not potentiate contractions due to high potassium
or noradrenaline. With high potassium, one may argue that
high potassium-induced contraction requires extracellular
calcium and calcium antagonists block the channels, so the
enhancement can not be seen. But in the absence of calcium
in the bath solution, noradrenaline was able to cause
contraction and the contraction was not blocked by
verapamil, suggesting the release of intracellular calcium
by noradrenaline.
Drugs may increase the level of cytoplasmic free calcium by
enhancing the influx of extracellular calcium, by mobilizing
intracellular calcium, or by preventing sequestration or
efflux of cytosolic calcium. It is likely that calcium
antagonists act on intracellular calcium stores,
particularly mitochondria, since the mitochondrion in smooth
muscle is an important regulator and calcium antagonists are
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capable of releasing calcium from it.
Now the question is where and how PGs act. One could assume
that (1) PGs can act directly on mitochondria by binding to
their receptors in/on mitochondria to release calcium, or
eUKer
(2) PGs release calcium from mitochondria^ by means of
"trigger calcium" which is released by PGs from other
calcium sources, or by means of other second messengers.
Our results suggest that contraction induced by PGs in the
rat anococcygeus muscle is a receptor-mediated process,
since (1) PG-induced contraction is antagonized by specific
receptor blockers or partial agonists, (2) the order of
potency for ICI 80205, 16,16-dimethyl PGE2 and PGE2 to
enhance contraction by 1179-epoxymethano PGH2 in rat
anococcygeus muscle is the same as that for their
contractile activities on other preparations, and (3) the
order of potency of several TxA analogues is similar to
that in other smooth muscle preparations. But these findings
may not fit in with an action on intracellular organelles.
Several investigators have tried to prove PGs can bind to
and release calcium from mitochondria (Kirtland & Baum,
1972; Malmstrom & Carafoli, 1975; Tsuyochi & Develin, 1979;
McNamara, Roulet, Gruetter, Hyman & Kadowitz, 1980).
Malmstrom and Carafoli (1975) pointed out that the
concentrations of PG necessary to demonstrate calcium
release from liver mitochondria are much greater than those
required for pharmacological actions; they concluded the
PG-induced liver mitochondrial calcium release did not
reflect a physiological situation. On the other hand,
3 00
Somlyo, Somlyo, Devine, Peters & Hall (1974) found that 39%
of the mitochondria in rabbit mesenteric vein are within 100
nm of the cell membrane. McNamara et al. (1980) assumed
there was a relative high concentration of PGs in the
vicinity of the mitochondria. At these high concentrations
the surface active properties of PGs may affect the
mitochondria. It has been shown that PG molecules will
aggregate at an interface and will reduce the surface
tension of water at 10 jjg/ml. Since micelle formation can
not be detected, orderly packing of the PG molecules at an
interface does not seem to occur. It is possible that
sufficient PG could enter the lipid layers of mitochondrial
membrane and thus disrupt the close aligment of the natural
components.
McNamara and his colleagues (1980) have compared the order
of potency for mechanical contraction in bovine
intrapulmonary vein with the order of potency for releasing
calcium from the mitochondria fraction of the same tissue.
11;9-Epoxymethano PGH2 is at least 1,000 times more active
than PGA2 and other PGs in producing an increase in tension
while PGA2 is the most potent calcium-releasing agent in
mitochondria and 11/9-epoxymethano PGH2 released only about
half as much calcium as PGA2. PGA2 can be formed by
spontaneous dehydration of PGE2. In PGE2-sensitive
preparations PGA2 has been found to be very weakly active
relative to PGE2. It is generally considered that it is
unlikely that PGAs occur naturally in mammals. These
findings seem to support the idea that PG release of calcium
from mitochondria is not a receptor-mediated process. Since
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it is believed that mitochondria originate from a different
source than the rest of the cell, and have their distinct
genetic system, we can not exclude the possibility that PGAs
might be synthesized in the mitochondria and play a certain
role in biological activity. PGA-series have been found in
the Florida sea whip, Plexaura homomalla, and in varieties
of P. homomalla collected from various locations in the
Caribbean area in surprisingly large amounts.
In fact, it has been found that prostaglandin synthetase
activity is present in mitochondrial membrane subfractions
from rabbit kidney medulla (Erman, Azuri & Raz (1983). Both
outer and inner membrane fractions of the medullary
mitochondria catalyzed PGE2 biosynthesis from arachidonic
acid. The specific activity of prostaglandin synthetase in the
outer membrane is 9-10 fold higher than in the inner
membrane. Rao and Mitra (1982) have reported that a variety
of intracellular organelles, as well as outer cell-membranes
of bovine corpora lutea, contain PGEl and PGF2a binding
sites; mitochondria free from lysosomes do not exhibit
intrinsic PGEl or PGF2a binding. However, the other PGs were
not tested. Thus, up to now, it is uncertain whether PG
receptors exist in mitochondria and what role PGs may play
in the organelle. However, one can assume that PGs might act
on membrane receptors and release membrane-bound calcium as
"trigger calcium" or PGs may operate a special type of
calcium channel resistant to calcium channel blockers, and
at the same time facilitate the release of calcium from
intracellular calcium stores, since McNamara and his
colleagues (1980) showed that the threshold concentration
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for calcium release by PGA2 and 11,9-epoxymethano PGH2 was
quite low, between 0.04-0.2 and 0.07-0.3 ^aM PG/mg protein,
respectively. Calcium antagonists may aid j . the
tKe
facilitation. Since^effect of noradrenaline, which also can
mobilize intracellular calcium, was not potentiated by
calcium antagonists, it is reasonable to assume that the
"trigger calcium" may pass through a special route to reach
mitochondria, and noradrenaline utilizes intracellular
calcium from different sources than PGs.
Most agonists which are thought to act through calcium are
also capable of stimulating the formation of cyclic GMP. It
has been suggested that cyclic GMP may act as a second
messenger. Thus, there is a possibility that PGs may
stimulate sythesis of cyclic GMP, which in turn releases
calcium from mitochondria.
In order to see if inhibition of mitochondrial calcium
uptake can enhance PGs action, sodium azide, which is an
inhibitor of mitochondrial calcium uptake, was used. This
turned out to be unsuccessful, since sodium azide, probably
by inhibiting oxidative phosphorylation, depresses the
contraction induced by 11,9-epoxymethano PGH2. This agrees
with the findings that oxygen deprivation, cyanide, or azide
all depressed PG action (Coceani & Wolfe, 1966; Paton &
Daniel, 1967). Coceane and Wolfe (1966) also found PG action
was diminished by lowering the bath temperature, with which
our results accord. The enhancement of response to
11 ,9-epoxymethano PGH2 by calcium antagonists was attenuated
by lowering the bath temperature, too. Matzushima and Gemba
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(1982) showed a similar case where the PAH accumulation in
the rat kidney cortical slices pretreated at 0*C for 90 min
in the medium containing verapamil was unaffected. This may
suggest that not extracellular (including binding to the
outside cell surface) but intracellular calcium antagonists
taken up from the medium give the potentiating activity. It
further proves that the acting point of calcium antagonists
for the potentiation is within the cell. Evidently, PGE2
analogues achieve their effect in a different way than
calcium antagonists, since the enhancement by PGE2 analogues
was not affected by low temperature.
The interesting findings are that RCF, YCF and hemoglobin
potentiated the response to 11,9-epoxymethano PGH2. The
active principles in the hemolysate and urine may be
hemoglobin and urobilin. The potentiating effect does not
seem to be produced by hemin or urobilin alone, since hemin
at 10 piM produced no effect, and natural urobilin in the
body binds to a polypeptide. It is not clear whether the
effect is due to globins, the polypeptide or their
combinations with pigments.
Currently, there is considerable interest in the
pharmacological properties of hemoglobin (Tanishima, 1980,
1983; Wellum, Irvine & Zervas, 1980), triggered by the
observation that it may be responsible for the prolonged
vasoconstriction of cerebral blood vessels that occurs after
cerebral hemorrhage (Echlin, 1971; Osaka, 1977; Boullin,
1980). And more recently Bowman and Gillespie (1982) have
showed that both the bovine retractor penis (another
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preparation which is claimed to possess NANC nerves) and the
rat anococcygeus muscle contract in the presence of blood
hemolysate (hemoglobin) and the hemolysate blocks the
relaxation of both the bovine retractor penis and the rat
anococcygeus to the inhibitory factor extracted from the
bovine retractor penis, and to field stimulation of the
present
inhibitory nerves. In the . study, verapamil and propranolol
opposed the inhibitory response to field stimulation, but
chlorpromazine and promethazine failed to do so. Since
verapamil and propranolol at high concentrations have been
proved to have local anesthetic effect (Hay & Wadsworth,
1982a; Volpi, Sha'afi, Epstein, Andrenyak & Feinstein,
1981)^ they may act by blocking the inhibitory nerves.
There are a number of other possible explanations for the
potentiation produced by calcium antagonists. By binding to
calmodulin, these drugs may activate 15-hydroxyprostaglandin
dehydrogenase which is inhibited by calmodulin, and may
inhibit adenylate cyclase and phosphodiesterase, in turn
the
affecting^intracellular cAMP level. They may affect the
phosphatidylinositol (PI) turnover which leads to a change
in the calcium gating system, Folkert and Schlondorff (1983)
have shown that trifluoperazine increases PI turnover and PG
synthesis in isolated rat glomeruli. They may influence the
PG transport system and increase . the intracellular
concentration of PGs. They may change the affinity of PG
receptors. Narayanan, Lee, Newland and Khandelwal (1983)
found a cytosolic protein fraction from rabbit heart cytosol
which caused marked inhibition (up to 95%) of ATP-dependent
calcium uptake by cardiac sarcoplasmic reticulum. And
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Fournier, Crevat, Ducet and Murisasco (1983) found a
fraction, isolated from urine, which had an ionophorous
activity and affected mitochondrial function by releasing
intramitochondrial calcium. Calcium antagonists might mimic
those substances or affect their activities.
At present we can only make assumptions. Calcium antagonists
have been used as inhibitory tools. Now they have been
discovered to possess new properties: releasing calcium and
potentiating PGs actions. It needs to be found out whether
these properties are restricted to a few tissues or area
universal phenomenon. It may be worth while examining the
ultramicroscopic structure and the components of membranes
of the rat anococcygeus muscle, and finding out whether
there is a second messenger triggering calcium release from
intracellular stores. All the drugs used in this study
possess multiple activities, it should be found out
whether calcium channel blockers, calmodulin antagonists,
and hemoglobin and urobilin produce the potentiation by an
identical or different mechanism(s).
Inhibitory Actions of Calcium Antagonists
The drugs tested for this action were verapamil, D 600,
nifedipine, flunarizine and trifluoperazine. All of them
inhibited contraction due to both noradrenaline and high
potassium.
Noradrenaline.
Results in this study show that noradrenaline manoeuvres
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intracellular calcium as well as extracellular calcium,
since in the absence of calcium in the medium noradrenaline
still caused contraction though ahigher concentration of
noradrenaline was required, and verapamil at 20 jjM had no
effect on the contraction. This is in agreement with work by
Hudgins and Weiss (1968), Hudgins (1969), van Breemen
(1969), and Deth and van Breemen (1974). They have
demonstrated that isolated rabbit aortic strips retain their
ability to contract phasically upon exposure to
noradrenaline, even after being washed in calcium-free
buffers to remove any extracellular calcium. It was proposed
that this noradrenaline-induced contraction is mediated by
the release of intracellular calcium into the smooth muscle
myoplasm (Deth & van Breemen, 1974, 1977).
It is a general belief that contraction elicited by
noradrenaline is mediated by alpha-adrenoceptors.
Alpha-adrenoceptors can be divided into the alpha-1- and
alpha-2-subtypes. Presynaptic alpha-adrenoceptors are almost
exclusively of the alpha-2-subtype. But, both alpha-1- and
can
alpha-2-adrenoceptors ^ occur in comparable numbers at
postsynaptic sites. Stimulation of postsynaptic alpha-1- and
alpha-2-adr enoceptor s by their selective agonists causes
contraction in smooth muscle. Recently, van Zwieten, van
Meel and Timmermans (1983) have shown that vasoconstriction
induced by stimulation of vascular postsynaptic
alpha-2-adrenoceptors, using selective agonists, is reduced
by calcium channel blockers through a noncompetitive
mechanism, while vasoconstriction evoked by selective
excitation of vascular alpha-l-adr enoceptor s remains
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virtually uninfluenced by calcium channel blockers. Similar
results were shown by Muller-Schweinitzer (1983) using
canine saphenous veins where nifedipine inhibited the
venoconstrictor response to the alpha-2-agonist guanfacine,
leaving that to the alpha-l-agonist phenylephrine unchanged.
Since Fleckenstein (1977) hypothesized that the main site of
action of these drugs is on the plasma membrane, these
findings seem to imply that alpha-2-receptor activation
mobilizes extracellular calcium, while contraction induced
by alpha-l-receptor agonists is due to release of calcium
from intracellular stores. This prompted us to assume that
rat anococcygeus muscle has both alpha-1- and
alpha-2-receptor s. However, the same Muller-Schweinitzer
(1983) also found that in saphenous arteries and circumflex
coronary arteries, nifedipine antagonized responses to both
alpha-1- and alpha-2-adrenoceptor stimulation. Obviously, it
is dangerous to subclassify alpha-adrenoceptors using
calcium channel blockers. Fortunately, it has been claimed
that on the smooth muscle cells of the anococcygeus there
are two distinct alpha-adrenoceptors, alpha-1 and alpha-]s ,
exist (Coates, Jahn & Weetman, 1982; Coates & Weetman,
1983). The alpha-Is receptor is characterised by full agonist
activity of Sgd 101/75 on the rat anococcygeus muscle and
abolition of Sgd 101/75 action by benextramine. Also de
Jonge, Mathy, Thoolen, Timmermans, Wilffert and van Zwieten
(1983) have reported in pithed normotensive rats that
alpha-l-adrenoceptor-mediated vasoconstriction consists of
two components: contraction elicited by (-)-phenylephrine
and by methoxamine (alpha-1 agonists) does not need an
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entry of extracellular calcium ions, while contraction
induced by Sgd 101/75 seems governed by an influx of
extracellular calcium. It is unknown whether this is the
case with alpha-1 and alpha-Is receptors in rat anococcygeus
muscle.
It has been demonstrated that D 600, verapamil and
nicardipine, a nifedipine analogue, inhibit specific ligand
(WB 4101 or prazosin) binding to alpha-l-adrenergic receptors
in a competitive manner with IC 50 values in the jjM range
(Blackmore, El-Refal & Exton, 1979; Fairhurst, Whittakar &
Ehlert, 1980; Glossmann & Hornung, 1980; Atlas & Adler,
1981). However, the alpha-l-adrenoceptor ligand WB 4101 also
binds to calcium channels (Atlas & Adler, 1981), so
inhibition of ligand binding to membrane fragments by calcium
channel blockers is not necessarily equivalent to
alpha-adrenoceptor blockade. Hay and Wadsworth (1983) have
reported that certain alpha-adrenoceptor mediated responses
the
in^prostatic half of the rat vas deferens were unaffected by
nifedipine 14.4 pM, even though WB 4101 binding to rat brain
membranes is 50% inhibited by the nifedipine analogue
nicardipine at 4 jjM (Atlas & Adler, 1981). Hay and Wadsworth
(1980 , 1981) also found methoxamine (alpha-1 agonist) and
BaC12-induced rhythmic contractions in rat vas deferens are
inhibited in parallel by nifedipine 2-3 jjM, by verapamil
30-36 jjM or by D 600 14-17 yjM. They assume that the site of
action of the calcium channel blockers is probably not the
alpha-adrenoceptor, but the ion channel, since methoxamine
acts via alpha-adrenoceptors and BaC12 does not. In our
case, nifedipine is very weak, and its pA2 value is close to
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nicardipine IC50 value (4 pM) for displacing WB 4101 bound
to rat brain membranes, which suggests that nifedipine may
bind to alpha-adrenoceptor to produce the inhibition in rat
anococcygeus muscle. However, D 600 (IC50=1.1 pM) was more
potent than nicardipine in displacing WB 4101 binding to the
rat brain membrane (Fairhurst, Whittaker & Ehlert, 1980;
Atlas & Adler, 1981). In rat liver verapamil was very weak
(IC50 = 20 pM) in inhibiting adrenaline binding (Blackmore,'
present
El-Refal & Exton, 1979). In the A study the order of potency
for inhibiting noradrenaline-induced contraction is
verapamil> trifluoperazine> D 600> nifedipine which is not
consistent with the binding data. This indicates that these
calcium antagonists may not bind to adrenoceptors,
supporting the assumption made by Hay and Wadsworth (1983).
It should be pointed out that the order of potency we
obtained is opposite to that of Hay and Wadsworth (1981) for
verapamil; D 600 and nifedipine. Therefore, it would be wise
not to jump to any conclusion at present stage.
Oriowo (1982) found that the removal of calcium from the
bathing fluid completely abolished the response to
noradrenaline in the rat anococcygeus muscle; this is in
conflict with our results. However, in his study, Tyrode's
solution was used, contraction was recorded isotonically,
and most importantly, higher concentrations of noradrenaline
were not tried. He also showed that the contractile effect
of noradrenaline was not affected by dantrolene sodium which
prevents the release of calcium from the sarcoplasmic
reticulum but not from other intracellular storage pools
such as mitochondria (Winkle, 1976). This seems to support
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our early hypothesis that mitochondria are important
regulators in rat anococcygeus muscle.
There is a question: Do calcium antagonists potentiate
response to noradrenaline at all? The ostensible effect of
calcium antagonists could be a mixture of potentiation and
inhibition. The answer seems to be "no". Nifedipine has a
higher affinity for binding to alpha-adrenoceptors than have
D 600 and verapamil, but verapamil showed higher potency for
inhibition of noradrenaline and for potentiation of PGs, and
moreover, RCF, YCF and hemoglobin which can potentiate PGs,
had no effect on the response to noradrenaline.
High Potassium.
The contractile response of smooth muscle to potassium is
considered to depend on calcium associated with
extracellular or surface membrane pools: contractions
induced by a high concentration of potassium are markedly
decreased by the removal of calcium from the extracellular
milieu (van Breemen, Farinas, Gerba & Mcnaughton, 1972; Deth
& van Breemen. 1974; Heaslip & Rahwan, 1982). Calcium flow
into the cell is believed to occur through voltage-dependent
channels in the membrane, these channels can be blocked by
calcium channel blockers (Bolton, 1979).
In agreement with these findings, we have found that
deprivation of calcium from the extracellular milieu or
adding calcium channel blockers decreases the contractile
response to high potassium in rat anococcygeus muscle.
Despite this, we have found that a small tonic contraction
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is resistant to both calcium deprivation and calcium channel
antagonists. It is not clear what causes the residual
response.
There are some difficulties in studying the effect of high
potassium since potassium can cause release of
neurotransmitters from nerve endings. The rat anococcygeus
muscle has a dense adrenergic innervation and it is possible
that the response induced by high potassium is caused by
both potassium and noradrenaline. In order to diminish the
adrenergic effect, several methods were tried. (1) 6-OH
dopamine (50 mg/kg body weight) was injected
intra-peritoneally into rats daily for 4 days. Then the rats
were killed and preparations were set up. When challenged
with tyramine, the preparations contracted markedly, which
indicates that adrenergic nerve endings were still
functioning. (2) Preparations were incubated with a
combination of high potassium and 6-OH dopamine ( 400 jjM) for
one hour. This resulted in a severe damage to
voltage-dependent calcium channels: contraction could not
elicited by calcium up to 10 mM in the presence of high
potassium. (3) When phentolamine was added to the organ
bath, it produced a marked decrease in tension when
the preparation was contracted to high potassium. Reserpine was
not used since it blocks the voltage-dependent calcium
channel (Casteels & Login, 1983). The method we used in this
part of experiment has been mentioned in the results.
In a preparation contracted with high potassium, wash-out
during the initial period decreased the tone by about 20%.
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It is possible that released noradrenaline accounts for this
20% of the contraction. Since the output of noradrenaline in
the bath gradually decreased, and 2 hours later the tissue
contained only a small amount of noradrenaline, it is
assumed that the remaining contraction is mainly due to the
opening of voltage-dependent calcium channels.
In this study the order of potency for inhibiting high
potassium induced contraction has been found to be
verapamil> D 600> trifluoperazine> nifedipine> flunarizine.
It is known that phenothiazines have alpha-adrenoceptor
blocking activity. However, trifluoperazine, one of the
phenothiazines, was more active than D 600 in opposing
noradrenaline-induced contraction, but less potent than
D 600 in inhibiting high potassium-induced contraction.
Furthermore, trifluoperazine was more potent in inhibiting
potassium-induced than nor adrenaline-evoked contraction.
This indicates that the inhibition produced by calcium
channel blockers is due to blocking voltage-dependent
and the
channels, L not due to ^opposing effect of noradrenaline
released by high potassium.
It has been reported that in cardiovascular tissues and
guinea-pig taenia coli nifedipine is about 2 orders of
magnitude more potent than verapamil in blocking contractile
activity produced by potassium depolarization (Andersson,
Edivinsson, Mackenzie, Skarby & Young, 1983; Fleckenstein,
1977; Mikkelsen, Andersson & Lederballe Pedersen, 1979;
Shimizu, Ohta & Toda, 1980; Humphrey & Robertson, 1983;
Imai, 1979; Hashimoto, Takeda, Katano, Nakagawa, Tsukada,
Hashimoto, Shimamoto, Sakai, Otorrii & Imai, 1979; Spedding,
1982). However, our results show that verapamil is more
effective than nifedipine in blocking high potassium-induced
contraction in rat anococcygeus muscle. Nachsen and
Blaustein (1979) showed similar results in rat brain
synaptosomes where verapamil and D 600 were more potent than
nifedipine in inhibiting calcium uptake evoked by potassium
depolarization. Hay and Wadsworth (1982b) have suggested
that receptor-operated calcium channels exist in two
sub-types, one of which is blocked by nifedipine, and both
are blocked by verapamil, D 600 and flunarizine. It is well
known that calcium channel blockers such as verapamil and
D 600 possess different pharmacological characteristics from
the dihydropyridine family. For example, verapamil
non-specifically blocks the fast calcium channel as well as
the slow calcium channel, while nifedipine analogues just
act on the latter (Quirion & Pert, 1982). It is unknown
whether the nifedipine-resistant channel is the fast calcium
channel, but our results indicate that verapamil and D 600
act on a different channel in rat anococcygeus muscle frcm the
nifedipine-sensitive channel in guinea pig taenia coli.
Interestingly, with rat anococcygeus muscle in the presence
of guanethidine nerve stimulation produces mechanical
inhibition but little or no hyperpolarization, while large
hyperpolarizations in the guinea-pig taenia from stimulating
the NANC nerves are seen. It is worth while finding out
whether these findings are related to the differences
between calcium channels in these two tissues.
It is noteworthy that D 600 displayed a biphasic pattern in
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displacing a radiolabelled dihydropyridine compound in
guinea pig brain membranes (Glossman, Ferry, Lubbecke, Mewes
& Hofmann, 1982; Gould, Murphy, Reynolds & Snyder, 1983).
This may indicate the nifedipine-sensitive calcium channels
are not homogenous or that high concentrations of D 600
cause an allosteric effect to facilitate dihydropyridine
binding.
Massingham (1973) and Nguyen Duong and Brecht (1977)
demonstrated in isolated vessels that verapamil, D 600 and
nifedipine relaxed high potassium-induced contractions more
effectively than contractions evoked by noradrenaline. On
the other hand, Mikkelsen. Addersson and Lederballe Pedersen
(1979) reported that in isolated human mesenteric arteries
and veins, verapamil is equally potent in relieving
contractions induced by high potassium and noradrenaline, a
finding that accords with our findings. This appears to
indicate that noradrenaline uses, the same type of calcium
channel qs potassium in the rat anococcygeus muscle.
However, the preparations where the voltage-dependent
calcium channel was damaged by combination of high potassium
and 6-OH dopamine, were still sensitive to low concentration
(1.0 jjM) of noradrenaline, and contractions induced by
noradrenaline were blocked by phentolamine. It may suggests
that noradrenaline has its own calcium channels.
In this study, trifluoperazine inhibited the high
potassium-induced contraction. It has been found that
pimozide and trifluoperazine inhibited potassium-induced
contraction (Spedding, 1982; Gould, Murphy, Reynolds &
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Snyder, 1983). Elias and Boyer (1979) demonstrated that
chlorpromazine (10-50 pM) produced solid gel formation with
filamentous actin and that a high concentration of
chlorpromazine (500 pM) inhibited polymerization of actin.
However,thepA2 value for trifluoperazine to inhibit potassium
ecju.; valeat ~to
induced contraction in our study isAabout 1.0 pM, lower than
the concentrations Elias and Boyer used. Furthermore,
Karaki, Murakami, Nakagawa, Ozaki and Urakawa (1982) have
shown that chlorpromazine may be a voltage-dependent calcium
channel blocker in rabbit aorta (IC 50=2.3 pM) in which the
adventitial layer has been removed to avoid the effects of
endogenous catecholamines^ and in guinea pig taenia coli (IC
50=2.9 pM) . Some other alpha-blockers, rauwolscine and
corynanthine were shown to block voltage-dependent calcium
channels and depress calcium influx (Godfraind, Miller &
Socrates Lima, 1983). It can be concluded that
trifluoperazine inhibits potassium-induced contraction by
acting on voltage-dependent calcium channels in the rat
anococcygeus muscle.
In this study, it was found that propranolol and
phentolamine inhibited potassium-induced contraction. It is
possible that they produced the effect by inhibiting
voltage-dependent calcium channels. It has been proposed
that propranolol is a calcium channel blocker (Rokutanda,
Araki, Sakanashi, 1983).
The depressing effect of the high concentration (l00 pM)of
verapamil on the response to 11,9-epoxymethano PGH2 might be
due to its damaging effect on the contractile mechanism as
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occurs with a high concentration of chlorpromazine.
As we can see, when high concentrations of calmodulin
antagonists and calcium channel blockers are used, the
distinction between these two groups of drugs is obscure:
one group can act on the other group's site. Therefore, we
have been using calcium antagonists to describe these drugs.
It has been postulated that PGE types play an important role
in modulating the activity of the adrenergic nervous system
and vascular reactivity to noradrenaline (Hedqvist, 1977;
Neri Serneri. Masotti, Poggesi & Galanti, 1980; Stjarne,
1978). PGE series reduce the vasoconstrictor response to
sympathetic nerve stimulation in subthreshold concentrations
( Armstrong, Thirsk & Salmon, 1979; Malik, 1978). On the
other hand, Greenberg, Kadowitz, Diecke and Long (1973)
observed that superfused mesenteric arteries and veins
showed greater contractile responses to noradrenaline in the
presence of PGEl and PGE2, and Malik, Ryan and McGiff (1976)
found that PGE2 potentiated noradrenaline vasoconstriction
in rat and rabbit mesenteric arteries.
This study shows that in rat anococcygeus muscle
1179-epoxymethano PGH2 facilitates, but PGE2 reduces, the
release of noradrenaline, a finding which is consistent with
previous work by Al Timini, Bedwani & Stanton (1978); and
both 1179-epoxymethano PGH2 and PGE2 potentiate response to
noradrenaline. The final effect of PGE2 on field stimulation
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depends on the concentration of PGE2 and stimulation
frequency.
The potentiating effect of calcium antagonists on response
to PGs is not due to blocking the inhibitory nerve since
chlorpromazine and promethazine enhanced
11,9-epoxymethano PGH2, but produced no effect on the
inhibitory response when preparations were contracted by
11.9-epoxymethano PGH2. Finally, the inhibitory response
seems to be calcium- and temperature-dependent.
General Discussion
e,r-eynce C\tn.tttmi . PP3JJ'
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Receptor differentiation for PG receptors is a difficult
task, since (1) many pharmacological preparations contain
several different receptors, often giving rise to opposing
actions and one PG can produce both excitatory and
inhibitory responses in the same preparation; (2)
subthreshold concentrations of one PG can potentiate or
inhibit other PG effects; (3) PGs trigger or inhibit release
of other autacoids or neurotransmitters; (4) PGs potentiate
or oppose the actions of other neurotransmitters or
autacoids, particularly when PGs themselves do not produce
visible effects; (5) PGs stimulate synthesis of PGs; (6) PGs
can be metabolized by tissues; (7) certain highly unstable
PGs decay spontaneously in neutral aqueous solution.
In this study we have made some efforts to characterize PG
receptors using certain preparations and a limited number of
available drugs.
PGE2 Receptors.
As has been shown, PGE2 receptors can be divided into two
subtypes: subtype I mediates contraction in the bovine iris
sphincter muscle, the rat gastric fundus and anococcygeus
muscle and the guinea-pig trachea (Jones, R.L., Personal
Communication); subtype II mediates relaxation in the cat
3 1 9
trachea muscle, and vasodepression in the dog hind limb in
vivo. Subtype I receptor is characterized by (1) high
activity of ICI 80205 and 16,16-dimethyl PGE2, (2) partial
agonist activity of ZK 36374, (3) inability of EP 045 and
EP 116 to block the response to PGE2 analogues , and (4) low
activity of ICI 81008, PGD2, 11r9-epoxymethano PGH2 and
PGI2. Subtype II receptor is distinguished by the high
potency of PGE2 but the low activity of 16,16-dimethyl PGE2
and ICI 80205, and the inactivity of both ZK 36374 and PGI2.
At the present stage we cannot say that every subtype I
receptor mediates excitatory effects while every subtype II
receptor mediates inhibitory effects. Indeed, the definition
of receptors on the basis of the type of biological response
produced is totally unacceptable to many pharmacologists. In
fact, data from Hedqvist (1976) showed that in the
superfused guinea-pig vas deferens 16,16-dimethy1 PGE2 was
about 20 times more potent than PGE2 in inhibiting release
of (3H)-noradrenaline induced by transmural stimulation.
However, this effect might not be due to activation of
adenylate cyclase. It has been suggested (Gutman &
Boonyaviroj. 1979) that in adrenal medulla PGE2 inhibits
catecholamine secretion through inhibition of adenylate
cyclase; this causes a fall of cellular cyclic AMP resulting
in reduced release of calcium from intracellular stores and
reduced free cytoplasmic calcium. Another case is:
16,16-dimethy1 PGE2 is 40-100 times more potent than PGE2 in
inhibiting gastric secretion of acid and pepsin and in
preventing the formation of peptic ulcers in laboratory
animals (Main & Whittle, 1975). However, these are in vivo
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experiments and the much slower oxidation of
16,16-dimethyl PGE2 by 15-hydroxy- prostaglandin
dehydrogenase (15-hydroxy-PGDH) is thought to contribute to
its high activity. Furthermore, it has been demonstrated
that exogenous PGE2 analogues produces cytoprotection in the
gastric mucosa by stimulating gastric bicarbonate secretion
(Johansson, Aly, Nilsson & Flemstrom, 1983). And PGE2 also
has a potent central antisecretory action in controlling
gastric secretion (Puurumen, 1983). Apparently, when
differentiating receptors, one should make sure a single
response is observed, and metabolic and penetration factors
are precluded.
PGF2qt Receptor .
ICI 81008 seems to be a selective and highly active PGF2a
mimetic. The high activity of ICI 81008, together with the
low activity of 16,16-dimethyl PGE2 and the weak antagonism
by EP 116, EP 0 92 or EP 045 can indicate the existence of
the PGF2a receptor in a preparation. The .partial agonist
activity of 15-oxo EP 011 may give further support. PGI2 and
ZK 36374 are very weak agonists on PGF2ac receptor sites.
PGD2 can mimic PGF2aj contractile action in reasonable
concentrations. We have not found a suitable isolated
preparation with the PGD2 receptors to test the selectivity
of ICI 81008 on the PGD2 receptor site. However, Jones
(1978) has shown that ICI 81008 is very weak agonist on a
PGD2 receptor system mediating arteriolar constriction in
the sheep in vivo.
One has to keep in mind that the label of selectivity on a
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compound may lead to a pitfall that of the circular
reasoning. Selective agonists are classified according to
tissue response and tissue receptors mediating these
responses are classified with selective agonists. The
potential for a damaging circularity in this matter is
evident. A response to an agonist classified as being
selective for a receptor does not necessarily indicate that
the receptor type exists in the preparation, since this
requires the assumption of absolute selectivity for the
agonist, if other receptors are to be excluded from
consideration. Often selective labels can be misleading, but
corroborating evidence from studies with selective and
the
competitive antagonists can help clarify^issue and break
the vicious circle. Therefore, it is necessary to re-examine
the selectivity of ICI 81008 on different preparations, and
not to draw the final conclusion before a selective PGF2a
antagonist is available.
Analysis with selective antagonists can be of value in
confirming receptor analyses by agonists and, in many cases,
the data may be relatively simple to interpret. However,
mixtures of receptors may lead to complications. For
suppose
example,^ a tissue contains two types of receptor and an
agonist which can act on the two types of receptor is used.
est-.na.tedL of one of -the receptor t^es
The ' Kd value of an antagonist will not conform to the realA A
value. The difference is ascribed to the activation of the
antagonist-resistant receptors by the agonist. It can be
seen from this that the estimate of the potency of the
antagonist depends on the selectivity of the agonist, the
relative importance of the 2 receptor types and the
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selectivity of the antagonist. Thus, there is a danger of a
double circularity in that the results depend not only upon
the selectivity of the agonist, but also upon that of the
antagonist.
Therefore, one has to remember that selectivity is relative
and a receptor agonist or antagonist can act on other
receptors, or even behave as a channel blocker at high
concentrations. It will be wise to use different approaches
to define receptors in a preparation, to re-examine the
selectivity in different preparations and not to stick to
the rigid selective labels.
A given agonist may have a high affinity but low efficacy
for a receptor. For example, impromidine, a selective
histamine H2-receptor partial agonist, is more potent, but
less efficacious than histamine (Parsons & Sykes, 1980).
Other examples of low efficacy with high affinity can be
found in a series of alpha-adrenoceptor agonists related to
clonidine (Ruffolo, Waddell & Yaden, 1980) and dobutamine
a drug with 25 times of the affinity but one-fortieth
of the efficacy of noradrenaline for alpha-adrenoceptors
(Kenakin, 1981). These facts prompted us to suspect that a
different subtype of the PGF2a receptor might exist in the
rat gastric fundus from that in the dog, cat and horse iris
sphincter muscle, and ICI 81008 could behave as a potent
partial agonist on the former preparation. Up to now, there
is no evidence supporting this assumption, and the lower
maximum response of ICI 81008 seems to be due to its weaker
PGE2-like activity compared with PGF2a in a system
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containing both PGE2- and PGF2a-sensitive contractile
systems.
PGI2 Receptor,
According to the limited data available, PGI2 receptors
mediating inhibitory and excitatory effect have similar
properties. ZK 36374 and PGI2 are potent compounds; PGEl is
a partial agonist; PGE2, PGF2a, PGD2 and
11j 9—epoxymethano PGH2 are very weak agonists.
In human PRP, ZK 36374 was 2-5 times as potent as PGI2; in
contrast, in rat PRP, PGI2 was 3-4 times as potent as
ZK 36374 (Casals-Stenzel, Buse & Losert, 1983). This does
not sufficiently indicate that rat platelets possesses a
different type of PGI2 receptor than human platelets do,
since ZK 36374 has PGE2-like activity, and this may affect
its PGl2-like activity on the rat platelets.
Beside its excitatory effect on rabbit iris sphincter and
guinea-pig ileum, PGI2 contracts certain blood vessels
(Table D.l) . Since very high doses of PGI2 had to be
used to elicit the contraction, it is possible that PGI2
acted on other PG receptor sites, for example, PGE2 or PGF2a
receptor sites as in the bullock, dog or cat iris sphincter.
TxA2 Receptors.
It has been demonstrated that 11,9-epoxymethano PGH2 mimics
TxA2. The high activity of 11,9-epoxymethano PGH2 will
indicate the existence of TxA2 receptors in a preparation.
The selective TxA2 receptor antdgonits EP 0 45, EP 0 92 and
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Table d.i Contractile effects of PG12 on certain vascular smooth
muscle.
Preparation Species Effect (yg/ml) Reference
Coronary artery Man Relaxation ( < 0.3) 1
Contraction (> 0.3)
Coronary artery Pig Contraction OA 2
Aorta Rat Contraction ( >0.5) 3
Aorta Rabbit Contraction (> 1.0) 4
Umbilical artery Man Relaxation ( < 0.3) 5
Contraction (> 0.3)
Pulmonary artery Rabbit Variable (0.01-1.0) 6
Basilar artery Dog Relaxation ( < 0.03) 7
Contraction (> 3.0)
Portal vein Rat Contraction (> 0.1) 8
Vena cava Rat Contraction (> 0.5) 8
1. Ginsburg,R., Bristow,M.R., Harrison,D. & Stinson,E.B.(1980) Chest,
78,1 (Suppl.), 180-186. 2. Dusting,G., Moncada,S. & Vane,J.R.(1977)
Eur.J.Pharmac. 45,301. 3.Levy,J.V.(1980) Prostaglandins 19,517-529.
4. Omini,G., Moncada,S. & Vane,J.R.(1977) Prostaglandins 14,625.
5. Pomerantz,K., Sintetos,A. & Ramwel1,P.(1978) Prostaglandins
JJ5,1035-1044. 6. Salzman,P.M., Salman,J.A. & Moncada,S.(1980) J.Pharmac.
Exp.Ther. 215,240-247. 7. Chapleau,C. & White,R.(1979) Prostaglandins
27,573. 8. Levy,J.V.(1978) Prostaglandins 16,93-97.
325
EP 116, are a great help in confirmation.
It has been realized that TxA2 receptors exhibit
considerable heterogeneity. As has been pointed out, human
platelets may have a different type of TxA2 receptor than
smooth muscle does; rat platelets may have a distinct TxA2
receptor from all the others. Moreover, EP 045, EP 092 and
EP 116 are relatively weak in blocking responses to
11, 9-epoxymethano PGH2 in the rat anococcygeus muscle; a
PIS.
case similar to the rabbit aorta (see Table E.12^) . It is
likely that these two preparation have a similar type of
TxA2 receptor. Recently, Burke, Lefer, Nicolaou, Smith and
Smith (1983) have demonstrated the species differences which
exist in the responsiveness of platelets to TxA2 analogues.
The stable TxA2 analogues, CTA2 and PTA2 significantly
inhibited the aggregatory responses to AA or 9,11-azo PGH2
in platelets from man, dog and guinea-pig, while only PTA2
produced significant inhibition in cat platelets. The
aggregatory response of PRP from rabbits was not
significantly blocked by either analogue. Obviously, more
work should be done in this field to differentiate subtypes
of TxA2 receptor and to exclude penetration factors and the
possibility of existence of PG endoperoxide receptors.
PGD2 Receptor.
Little work has been done in this study on the
characterization of PGD2 receptors. The existence of PGD2
receptors is beyond question. It has been reported by Jones
(1976) that in the sheep cardiovascular system, PGD2 has a
distinct receptor. PGD2 is a potent vasopressor agent in the
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anaesthetized sheep, being 19-145 times more active than
PGF2a. Later, Jones (1978) found that the PGD2-sensitive
constrictor system might also exist in the systemic arterial
circulations of the pig, dog, cat, rabbit and rat. He
suggests that 13,14-dihydro-15-oxo PGD2 is a potent and
selective agonist on this system, and 15-oxo PGF2a is more
potent than PGF2a in this system.
The PGD2 receptor system has also been found in the
platelets of man, horse and sheep; activation leads to an
increase in cyclic AMP and inhibition of aggregation. PGD2
receptors may also exist in the brain of various mammals
influencing many neural activities, such as sleep induction
(Ueno, Ishikawa, Nakayama & Hayaishi, 1982; Ueno, Honda,
Inoue & Hayaishi, 1983), body temperature regulation (Ueno,
Narumiya, Ogorochi, Nakayama, Ishikawa & Hayaishi, 1982),
and neuroendocrine function (Kinoshita, Nakai, Katakami,
Imura, Shimizu & Hayaishi, 1982), and probably in the gut
(Ishizawa & Minowa, 1982).
PGA2 Binding Sites.
Tritiated PGA2 was found by Attallahj Payakkapan and Lee
(1974) to have the capacity to bind to a supernatant
fraction of the rabbit kidney. Studies by others confirmed
these findings, but led to the suggestion that this
interaction is one with a soluble enzyme which specifically
degrades prostaglandins (Kuehl, Oien & Ham7 1974) rather
than with a true PG receptor. As has been suggested by
Kuehl, Oien and Ham (1974), the binding site is probably
15-hydroxy-PGDH, an acceptor rather than a receptor.
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Recently, Asano and Ogasawara (1982) have reported that PGAl
and PGA2 are potent inhibitors of (3H)-diazepam binding to
the benzodiazepine receptor (probably a chloride ionophore
linked with GABA receptor) of the membranes of bovine
cerebral cortex while PGBl and PGB2 are less potent and PGD,
PGE and PGF series are inactive. They suggested that PGA
series could be potential candidates as endogenous ligands
of the benzodiazepine receptor. However, as PGAl and PGA2
competitively inhibited (3H)-diazepam binding with quite
high Ki values, 7.1 and 15 pM, respectively, it is difficult
to tell whether the binding site is a PGA receptor.
Furthermore, it has been found that the protein with high
affinity for PGA, present in renal cortical homogenates,
binds PGA covalently through a reactive sulfhydryl group
(Ham, Oien, (Jim & Kuehl, 1975) and that the high affinity
binding protein in human plasma binds PGA non-covalently
(Gueriguian, 1975). These indicate PGA may bind to proteins
rather than PGA receptors.
PGEl Receptor.
The existence of PGEl receptor is questionable. However,
there are several lines of evidence suggesting there may be
a PGEl receptor site distinct from PGE2 and PGI2 receptor
sites.
In male Wistar rats PGI2 is about one order of magnitude
more potent than PGEl or PGE2 in systemic vasodepression
effect; d,L-ll, 15-bisdeoxy PGEl (Figure D. l.p328](Fried,
Santhanakrishnan, Himizu, Lin, Ford, Rubin & Grigas, 1969)
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itself had no effect on mean systemic arterial pressure. It
produced reversible inhibition of PGEl-mediated
vasodepression, while no significant effect was observed on
PGE2 or PGl2-mediated vasodepression (Stinger, Fitzpatrick,
van Dam, Ramwell & Kot, 1980). On the isolated gerbil colon
preparation, d,l-ll, 15-bisdeoxy PGEl is a specific
antagonist of the contractile response to PGEl, and had no
agonist activity or effect on the contractile response to
PGF2a or Ach (Tolman, Partridge & Barris, 1977).
PGs are known to regulate immune responses and fibrous
tissue formation. It has been reported (Das, 1981) that
deficiency of PGEl and/or TxA2 and excess PGE2 seem to
activate B-cells and suppress T-cell function and enhance
fibrosis. Viruses can block the enzyme delta-6-desaturase
necessary for PGEl synthesis and thus depress cell-mediated
immune response. Drugs which cause autoimmune disorders also
seem to block PGEl and/or TxA2 synthesis and enhance PGE2
formation, which may lead to excess auto-antibody formation.
Drugs like colchicine, which can enhance TxA2 formation and
the biological action of PGEl were found to be of benefit in
auto-immune disease in man and animals. But PGI2 action on
the immune system has never been reported. The possibility
that PGEl produces the effect by acting on PGI2 receptor
should be precluded.
As has been mentioned before, trimethoquinol reduced
contraction of the rat gastric fundus to PGEl, but not PGE2
(Bennett, Jarosik, Sanger & Wilson, 1980). This indicates
PGEl may have a different acting site from PGE2.
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In chick ileum, PGEl is more potent than PGE2 for
contraction and SC-19220 lacks effect on the response to
PGEl and PGE2 (Coleman, Kennedy, Levy & Penning, 1980).
Since PGI2 is very active on the preparation and PGEl is
capable of acting on both PGE2 and PGI2 receptors, the
possibility of a synergestic effect between PGI2 and PGE2
should be excluded. Nevertheless, a similar order of agonist
potency to that in chick ileum has been described in a
number of systems in which prostaglandins sensitize
peripheral nociceptors (Tyers & Haywood. 1979).
The above findings suggest there is a PGE receptor system
different from the PGE2 subtype I and II receptors. It
merits further investigations to find out if it is another
subtype of the PGE2 system or a PGEl system.
It has been suggested that prostaglandin receptors may be a
magnesium- and disulfide-dependent protein (Altura & Altura,
1971, 1974; Altura, Altura & Waldemar, 1976; Greenberg &
McGowan, 1981; Greenberg, Kadowitz, Long & Wilson, 1976).
Similar conclusions were obtained by Johnson et al. (see
Bohr, Greenberg & Bonacorrsi, 1978), who showed that the
binding of PGE and PGF to uterine smooth muscle and red
blood cell membranes was diminished by disulfide bond
reduction with dithiothreito I and dithiobisnitrobenzoic
acid. Divalent cations, e.g. calcium or magnesium ions are
also essential for the binding of radiolabelled
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prostaglandins to the membranes of vascular smooth muscle
(Rucker & Schror. 1983).
Structure-Binding and Structure-Activity EeleJtieiLS.lxip.£ (SBJ3 & iLAR)
Soon after the first members of the prostanoid family were
characterized chemically by Bergstrom (1967), and pure
materials were available for biological studies, the
preparation of chemically modified prostanoids or analogues
began. Since then a very large number of PG analogues have
been made by many research groups.
The types of analogues synthesized have expanded as the
number of AA metabolites formed from prostaglandin
synthetase have grown to include the endoperoxides,
thromboxane, and prostacyclin. More recently the
5-lipoxygenase pathway has been further characterized to
cover the hydroperoxy and hydroxy fatty acids and the
leukotrienes. The reasons for preparing the analogues are as
following:
(1) To provide increased metabolic stability and chemical
stability. It became apparent very early that these fatty
acid-based autacoids were usually quite short-lived in vivo
(Samuelsson, Granstrom, Green & Hamberg 1971), although the
half-life of the endoperoxides (5 min) and TxA2 (30 s) were
especially noteworthy (Hamberg, Svensson, & Samuelsson,
1976). The 15-hydroxy prostaglandin dehydrogenase which is
the metabolic enzyme which degrades the prostaglandins to
the relatively inactive 15-keto derivatives is widespread
and largely responsible for the short-lived effects (Anggard
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& Samuelsson, 1966). It is clear that one needs
longer-lasting compounds which can escape the rapid
inactivation in vivo and in vitro for basic experimental
study and clinical use.
(2) To find agents with greater selectivity.
(3) To provide selective receptor antagonists.
(4) To synthesize enzyme inhibitors.
PG Receptor Antagonists,
The use of receptor antagonism to establish the identity of
receptors has developed only slowly in the prostanoid field
since the main organic synthetic effort has been devoted to
the development of long-acting, stable PGE, PGF, and • PGI
analogues. Studies of the actions of natural substances such
as Ach, histamine, and catecholamines have been greatly
aided by the availability of specific, competitive
pharmacological antagonists of these substances, and
isolated smooth muscle preparations are powerful tools for
studying such antagonists. From a pharmacological
standpoint. the optimal antagonist should be specific,
potent, reversible, and possess no agonist activity and have
no activity against PG synthetase.
In the early stage, three main types of substances (Figure
D.2) were used as pharmacological antagonists of the
prostaglandins. The anti-prostaglandin activities of each of
these classes of compounds was first demonstrated on
isolated preparations of gastrointestinal smooth muscle.
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Figure D.2 Chemical structures of 7-oxa-prost-I3-
ynoic acid, di-4-phloretin phosphate and SC-I9220
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and Gringas reported that they had sythesized a series of
7-oxaprostaglandin analogues. Among them compounds with
15-hydroxy substituents were reported to be mixed agonists
and antagonists (Fried, Lin, Mehra, Kao & Dalven, 1971), and
the 15-nor compound with a 13,14-triple bond
(7-oxa-13-prostynoic acid) has become known as the prototype
prostaglandin antagonist of this series. Flack (1970) found
that 7-oxa-13-prostynoic acid was the only
7-oxaprostaglandin analogue out of 15 tested that would
specifically inhibit prostaglandin-induced contractions on
isolated gerbil colon. It did not, however, specifically
inhibit prostaglandin-induced contractions on isolated
guinea-pig ileum (Flack, 1970; Bennett & Posner, 1971),
rabbit jejunum "(Flack, 1 970), or on human stomach, ileum, or
colon (Bennett & Posner, 1971). On isolated rat stomach
strips 7-oxa-13-prostynoic acid produced contraction,
indicating prostaglandin-like agonist activity (Bennett &
Posner, 1971). Prostaglandin antagonism with
7-oxa-13-prostynoic acid has been demonstrated best in
experiments showing inhibition of prostaglandin-stimulated
formation of cyclic AMP, and it has been found to bind
weakly to prostaglandin binding sites that are proposed as
prostaglandin receptors (Bennett. 1974; Sanner, 1974; Sanner
& Eakins, 1976). Baudouin-Legros. Meyer and Worcel (1975)
concluded that the effect of 7-oxa-13-prostynoic acid was
different on proestrous rat uteri than on the metestrous
uteri. They found that on the proestrous uterus the compound
inhibited PGF2a-induced stimulation without reducing the
maximum response, but on the metestrous uterus it reduced
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the maximum response to PGF2a. This may suggest competitive
antagonism on the proestrous uterus and noncompetitive
inhibition on the metestrous uterus. 7-Oxa-13-prostynoic
acid also inhibited spontaneous contractions and those
produced by angiotensin II on the proestrous uterus, thus
indicating either a non-specific inhibitory effect of the
compound or that prostaglandins are involved in these
contractions.
Two non-prostanoid compounds, the polymeric compound
polyphloretin phosphate (PPP) and SC-19220, have also been
noted to attenuate responses to PGs. PPP is a mixture of
polyester polymers that affects the activity of many
enzymes, including hyaluronidase, alkaline phosphatase, and
urease (Eakins & Sanner, 1972). Intra-arterial
administration of PPP blocks changes in ocular membrane
permeability (Beitch & Eakins, 1969), that have been
associated with a mixture of PGs (Eakins & Sanner, 1972).
Unlike SC-19220 and 7-oxa prostaglandin, PPP 200 mg/kg does
block the cardiovascular actions of PGF2a (Villanueva,
Hinds, Katz & Eakins, 1972; Mathe, Strandberg & Fredholm,
1972), yet is ineffective in inhibiting the vasodepressor
actions of PGEl and PGE2 (Nakano, Prancan & Moore, 1971).
Such high doses of PPP significantly decrease systemic
arterial pressure (Mathe, Strandberg & Fredholm, 1972) and
the compound may in fact exert its inhibiting action at
sites other than the PG receptor, such as adenylate cyclase
(Hynie, Cepelik, Cernohorsky, Klenerova, Skrivanova & Wenke,
1975; Kuehl & Humes, 1972).
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Eakins and Karim (1970), using isolated gerbil colon
preparations, found that PPP would specifically inhibit
prostaglandin-induced contractions. It was thought that this
compound inhibited only PGF series, but it was later found
to inhibit contractions produced by PGE also (Eakins, Karim
& Miller, 1970; Park & Dyer, 1973). It did not inhibit
contractions produced by Ach, bradykinin, angiotensin, or
5-HT.
High concentrations of PPP were required to inhibit
prostaglandin-induced contractions on human isolated
gastrointestinal muscle preparations. PPP, like the other
antagonists, did not inhibit the relaxant effect that
prostaglandins have on circular gastrointestinal smooth
muscle (Bennett & Posner. 1971).
Despite its prostaglandin inhibitory effects on most smooth
muscle, PPP has stimulatory activities on some smooth
muscles that are also stimulated by prostaglandins. Thus,
PPP was found to stimulate rather than inhibit contractions
of rat isolated stomach strips (Bennett & Posner, 1971;
Adaiken & Karim, 1973). It also produced contractions or
increased pendular movements of rabbit jejunum (Eakins,
Karim & Miller, 1970). Low concentrations of PPP increased
spontaneous contractions of human isolated jejunum, while
high concentrations inhibited them (Adaiken & Karim, 1973).
Since PPP inhibits metabolism of prostaglandins by
15-hydroxy-PGDH (Marrazzi & Matschinsky, 1972), this may
account for its stimulatory effect on these tissues.
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As mentioned above, PPP is a mixture of different weight
polymers. It has been found that the prostaglandin
inhibitory activity lies in the low molecular weight
fractions, while the enzyme inhibitory activity is generally
associated with the higher molecular weight fractions
(Eakins, 1971; Bethel & Eakins, 1971). The dimer,
di-4-phloretin phosphate, is considerably more active as a
prostaglandin antagonist than is the mixture, polyphloretin
phosphate (Eakins, Fex, Fredholm, Hogberg & Veige, 1973).
Unfortunately. di-4-phloretin phosphate is also a more
potent inhibitor of 15-hydroxy-PGDH (Crutchley & Piper,
1973) .
It is necessary to point out in most of the preparations
stated above PG receptors have not been defined and the
selectivity of these two types of compounds has not been
determined.
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Another compound, SC-19220a, a dibenzoxazepine derivative,
which was initially tested as an anticonvulsant and
analgesic agent (Coyne & Cusic, 1968), specifically inhibits
PGE2 induced contractions of the isolated guinea-pig ileum
at low concentrations (Sanner, 1969; Bennett & Posner,
1971). Since contractions produced by bradykinin, 5-HT and
Ach were not inhibited, the compound was considered to be a
specific PG antagonist. Recently, Kennedy, Coleman,
Humphrey, Levy and Lumley (1982) have made an intensive
study on this compound. They have found that SC-19220 at 300
pM had little or no effect on responses of dog saphenous
vein, rat aorta and guinea-pig lung strip to
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11,9-epoxymethano PGH2 or PGE2; neither did it affect
responses of dog and cat iris sphincter muscles to PGE2 or
PGF2a. Therefore, SC-19220 is devoid of antagonistic actions
in both TxA2 and PGF2a-sensitive preparations. On the other
hand, SC-19220 caused concentration-related parallel shifts
to the right of concentration-response curves for PGEl, PGE2
and PGF2a on guinea-pig ileum and guinea-pig and dog fundus
where PGE2 is the most potent prostanoid. However, others
have reported that in concentrations of greater than 10 jiM,
SC-19220 has actions apparently unrelated to blockade of
prostanoid receptors (Bennett, 1974), and it has been found
that higher concentrations of SC-19220 flattened the curve -f-or
and reduced the maximum contractions (Jones, R.L., Personal
Communication). The inhibition of PG-induced contractions on
rat fundus strips (Bennett & Posner, 1971) is in contrast to
stimulation of this tissue produced by 7-oxa-13-prostynoic
acid and by PPP. The difference is probably due to the lack
of inhibitory effect of SC-19220 on 15-hydroxy-PGDH
that was seen with both 7-oxa-13-prostynoic acid and PPP
(Marrazzi & Matschinsky, 1972).
The above three compounds and their close relatives have
presented several practical problems. For example, excessive
amounts of these antagonists are required to obtain
inhibition of PG action in vitro. Thus, continued efforts
have been made to systematically screen new prostanoid




Several compounds with antagonistic activity against PGF2a
have been reported.
Ceserani, Gandolfi, Longiave and Mandell (1979) suggested
that 20-methyl- 13,14-didehydro PGF2a might be a selective
antagonist of PGF2a on rat uterus preparation; it did not
show any antagonistic activity against the contractions
induced by PGE2, Ach, histamine and 5-HT on guinea-pig
ileum, by BaC12 on duodenum and by PGE2, 5-HT and Ach on rat
uterus. However, we have found that a similar PGF2a analogue
13,14-didehydro PGF2a is an active and full agonist on a
PGF2a-sensitive preparation the dog iris sphincter.
Fitzpatrick, Alter, Corey, Ramwell, Rose and Kot (1978)
showed N-dimethylamine PGF2a (Figure D.3) and
N-dimethylamide PGF2a antagonized the vasoconstrictor
response to PGF2a in the isolated canine lung lobe, but not to
*-
AA. Also Stinger, Fitzpatrick, Corey, Ramwell, Rose and Kot
(1982) found N-dimethylamine PGF2a selectively antagonizes
the pulmonary and systemic vascular responses to PGF2a in
the intact rat in a dose-dependent fashion. The same
strategy, that is, synthesis of the C-l dimethylamine or
dimethylamide which was used for developing the PGF2a
antagonist, was also used for PGI2 but without success; this
is interesting since the strategy has been successfully
extended to PGE series. (Ramwell, Karanian & Foegh, 1982).
Another report from Temesvari-Major, Gruber, Tomoskozi,
Kovacs and Cseh (1980) claimed that a C-8-quaternary
prostanoid could be regarded as an active PGF2a antagonist





Figure D.3 Chemical structures of
and its N-dimethylamine analogue.
in the uterus.
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More work should be done to test the selectivity and potency
of these compounds.
TxA2 Antagonists.
A greater number of TxA2 receptor antagonists have been
synthesized. In 1978, Fitzpatrick, Bundy, Gorman and Honohan
reported that 9,11-EIP (9,ll-epoxyimino-prosta-5,13- dienoic
acid) antagonized platelet aggregation by direct
TxA2-receptor blockade. However, the compound shows agonist
properties on coronary artery and rat aorta, and it also
inhibits PGI2 formation in rabbit lung microsomes and BALB
3T3 cells at 10 pM. Similarly, PTA2 and CTA2 were claimed to
be TxA2 receptor antagonists (Lefer, Smith. Araki, Smith,
Aharony, Claremon, Magolda & Nicolaou, 1980; Nicolaou,
Magolda, Smith, Aharony, Smith & Lefer, 1979), but in
certain cases they showed agonist activity. Roth, Lefer,
Smith and Nicolaou (1982) have synthesized six PTA2
analogues (Figure D.4) and tested their ability to
antagonize CTA2—induced coronary vasoconstriction and TxA2
analogue — induced platelet aggregation. Two of the
derivatives, 5C-15(S) BPTA2 and 5T-15(S) BPTA2 showed high
potency in inhibiting of CTA2 induced vasoconstriction of
cat coronary arteries; 5C-15(S) BPTA2 also antagonized TxA2
analogues-induced human platelet aggregation.
Harris, Phillips. Michel, Goldenberg, Heikes, Sprague and
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Antonaccio (1981) showed SQ. 26536 ^(8(R), 9(S), 11(R), 12 (S) —
9oc- homo- 9,11-epoxy- 5(Z), 13(E)- 15 (S) —
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5T-1 5S-BPTA2: R, = H, R2 =0H
5T-15R-BPTA2: R, = OH. R2 = H
5C -15R -1 5Me-BPTA2: R, = Me. R2 = OH
5C-15S-1 5Me BPTA2: R( = OH. R2 = Me
Figure D.4 Chemical structures of PTAg analogues.
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hydroxyprostadienoic acid) is a TxA2 antagonist on human
blood platelets, while SQ 26538, the 15-epimer of SQ 26536
is an agonist on the platelet TxA2 receptor (Figure D.5).
Coleman, Collington, Geisow, Hornby, Humphrey, Kennedy,
Levy, Lumley, McCabe & Wallis (1981) demonstrated AH 19437
(lac (Z), 2f3, 5<x)- methyl 7 — (2— (4- morpholinyl) - 3-oxo- 5-
(phenylmethoxy) cyclopenyl )~ 5-heptenoate, blocked
11j9-epoxymethano PGH2 action on guinea-pig lung strip, dog
saphenous vein and rat aorta with pA2 values of 6.5, 6.0 and
5.9, respectively. The antagonistic action of AH 19437 was
specific in that at 24 jjM it had little or no effect on
contractile responses of guinea-pig ileum to PGE2 or PGF2a,
chick ileum to PGE2 or dog iris to PGF2a and at 72 jjM had no
lung
effect on responses of guinea-pig^strip to Ach or histamine
or on responses of dog saphenous vein and rat aorta to KC1
or 5-HT (Kennedy, Coleman, Humphrey, Levy and Lumley, 1982).
In this study we have demonstrated that EP 045, EP 092 and
EP 116 are selective TxA2 receptor antagonists without any
intrinsic activity. They have little effect on PGE2 and
PGF2a receptor sites. These compounds will greatly
facilitate study on PG receptors. The possible inhibitory
activity of EP 045 on PGE2 biosynthesis is worthy of further
study.
SBR & SAR for PGF2a ,
It has been assumed that PGF2a assumes a "hair-pin"
conformation (Rabinowitz, Ramwell & Davison. 1971). The
three hydroxyl groups at C-9, 11 and 15 are all in
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COOH
9a . 11a. a*o-HGH2
Figure D.5 Chemical structures of SQ 26538, SQ 26536,
TxA2 and 9,11-azo PGH2.
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alpha-position. Any change from this hair-pin conformation
or changes in chirality or inversion of any one of the
hydroxyl group leads to loss of biological activity
(Andersen & Ramwell, 1974; Andersen, Ramwell, Loevey &
Johnson, 1976). Recently, Andersen, Imamoto, Subramanian,
Picker, Ladner, De, Tyanan, Eggerman, Harker, Robertson,
Oien and Rao (1981) has constrained the analogues of PGF2a
to the hair-pin alignment by covalent bonding between the
terminal portions of the side chains and confirmed the
validity of this model in a series of new PGF syntheses. The
carboxyl group and the hydroxyl group at C-15 in PGF2a are
very important for the binding reaction; conversion of these
groups to hydroxy (1,9,11,15- tetrahydroxyprosta-
5,13-diene) and keto groups (15-keto PGF2a) increased the
dissociation constants 100- and 200-fold, respectively. The
hydroxyl group at C-9 and the double bond at C-5 were of
intermediate importance; conversions to a keto group (PGE2)
and a saturated bond (PGFla) increased the dissociation
constant 50- and 40- fold, respectively. The hydroxyl group
at C-ll and the C-13,14 double bond were relatively
nonimportant for the binding reaction and contractile
activity; 9- and 4-fold increases in dissociation constants
were observed upon oxidation to the ketone (PGD2) and
reduction to a saturated bond (13,14-dihydro PGF2a),
respectively (Powell, Hammarstrom & Samuelsson, 1974, 1975).
SBR & SAR for PGE2 Analogues_
The saturation of either the 5,6-trans or 13,14-cis double
bonds, or removal of the 11-hydroxy group has less effect on
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PGE2 subtype II than subtype I receptor. The presence of the
15(S)-hydroxy group in PGE2 is essential for high activity;
substitution of a methyl group on C-15 with retention of the
(S) configuration does not alter this activity; inversion of
configuration, formation of a methyl ether and oxidation to
a ketone at C-15 all markedly reduce its potency (Jones,
1976). On the PGE2 receptor binding site in the fetal
adrenal gland PGE2 and PGEl are very active, but the
affinities of other PGs (PGF2a> PGA2> 13,14-dihydro- 15-oxo
PGE2> PGD2> 6-oxo PGFla) are 130- to 1300- fold lower
(Karaplis & Powell, 1981b). TR 4752 (2-decarboxy-
2-hydroxymethyl- 15-deoxy- 16 S-hydroxy- 17,17- dimethyl
PGEl seems to have high activity on PGE2 subtype II receptor
but lack activity on PGE2 subtype I receptor (Gardiner &
Collier, 1980). This indicates that TR 4752 may be a
specific agonist on the PGE2 II receptor.
16,16-Dimethylation or 16-aryloxy substitution will increase
the activity on subtype I receptor but decrease the activity
on subtype II receptor. 11-Deoxy PGEl, although weaker than
PGE2 on PGE2 receptor sites, is far weaker than PGE2 on
PGF2a-sensitive preparations.
SAR for PGD2 analogues
Jones (1976) has proposed that compounds with the greatest
selectivity on PGD2 receptor site mediating contraction must
have (1) a D-type ring system, (2) 5,6-cis and 13,14-trans
double bonds and (3) an oxo, (R) hydroxyl or (S) methyl
ether group at C-15.
SBR & SAR for PGI2 Analogues.
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The detailed relationships of SBR and SAR for the PGI2
receptor have been discussed extensively (Blair & MacDermot,
1981; Blair, Hensby & MacDermot, 1980; MacDermot, Blair &
Cresp, 1981; Maclntyre, 1981). The vinyl ether moiety of
PGI2 is critical, and hydrolysis results in total loss of
activity (cf. 6-oxo PGFla). The 5-6 double bond is an
important determinant of activity, since alteration of the
geometry at C-6 to the 5,6(E)-isomer of PGI2, saturation of
the double bond to form 6]B-PGIl or a shift of the double
bond to C-4-5 or C-7-8 results in markedly decreased
activity. ZK 36375, a 5(Z)-stereoisomer of ZK 36374, has
lower affinity than ZK 36374, the 5(E)-isomer of 6a-carba
PGI2 is 30- fold more potent than the 5(Z)-isomer, and the
affinity of 5,6-trans PGE2 is greater than that of the cis
isomer. The higher activity of 5,6-trans PGE2 may be
explained as follows. The Z-configuration of the 5,6-double
bond of PGI2 and the E-configuration of the 5,6-double bond
of ZK 36374 (Rucker & Schror, 1983) are important for
PGI2-Iike activity, and more closely resembles the trans
configuration of 5,6-trans PGE2 than the cis configuration
of the natural isomer PGE2. One interesting anomaly is that
reduction of the 5,6-trans double bond of 5,6-trans PGE2 to
form PGEl increased significantly the binding to the
membrane receptor. The finding that PGEl and PGI2 bind
competitively to the same receptor suggests that the
anomalous affinities (PGI2> 6b-PGIl whereas 5,6-trans PGE2<
PGEl) are not explained by the presence of multiple receptor
types. It has been proposed that the alpha-side chain of
PGEl takes up a conformation that is different from PGE2 and
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more closely resembles PGI2. The affinity for PGE2 is 100
times lower than that for PGEl. The 15-hydroxyl group is an
absolute requirement for high affinity binding since PGE2
has a higher affinity than 15-oxo PGE2 in binding to the
PGI2 receptor, and it holds true for 13,14-dihydro PGE2 and
15-oxo- 13,14-dihydro PGE2. Furthermore, the absolute
configuration at C15 is critical, as the activity of the
natural isomer (15(S)-0H) is lost in 15(R)-PGE2. Some
structure-activity data have been obtained using analogues
of PGI2 or other ring-modified derivatives in which the
6,9 « epoxy linkage is replaced by 5,9 « epoxy, 9k,5
nitrilo, 6,9 k imino, 6,9 « epithio or 6a- carba linkages.
Among them 9-deoxy- 9«,6-nitrilo PGFl is equipotent with
PGI2 as an inhibitor of platelet aggregation, while the
others display reduced or zero activity. Removal of the
C-13-14 double bond has little effect on activity. Addition
of a trans C2-3 double bond augments potency. Transformation
of 15(S) into 15(R) leads to loss of activity. The
17-methylation augments potency. 16-Phenoxy substitution of
the 17 ,1 8 ,1 9,20-tetranor derivatives of PGI^. reduces
PGI2-Iike activity but increases other prostanoid-like
activity.
MacDermot, Blair and Cresp (1981) have reported that
divalent cations regulate the binding of PGI2 to its
membrane receptor. Magnesium increase the binding. Proton
magnetic resonance spectroscopy shows that an upfield shift
of H5 and downfield shift of Hi 5 in the presence of
magnesium ions. They propose that PGI2 may exist in two or
more conformational states with different Kd values in the
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ligand-receptor interaction. The functionally critical
substituents, the vinyl ether moiety and the 15(S)-hydroxy1
group, are adjacent to protons that undergo
magnesium-dependent changes in their electronic environment.
These substituents allow formation of a complex between the
divalent cation and prostacyclin, and the altered
geometry of PGI2 satisfies the geometric constraints of the
PGI2 receptor.
SAR for TxA2 Mi met ICS
11;9-epoxymethano PGH2 seems to be a selective TxA2 receptor
agonist. But its isomer 9,11-epoxymethano PGH2 is only a
partial agonist. 9,11-Azo substituent sustains the spectrum
of TxA2 action. Replacing the epoxymethano group with etheno
or ethano groups results in partial agonism.
C-16-p-fluorophenoxy or C-16-p-chlorophenoxy substitution
changes these compounds into full agonists in smooth muscle.
Substitution of oxygens in the ring of TxA2 with carbon
atoms keeps its full agonist activity in smooth muscle
contraction but results in reduced potency in inducing
platelet aggregation. The pinane structure in the ring will
markedly reduce TxA2-like activity in both smooth muscle and
platelet. The 15-hydroxy group is essential for platelet
aggregation but not for smooth muscle contraction.
Maclntyre, Salzman and Gordon (1978) have suggested the
requirements for dienoic prostaglandins to act on the
TxA2/endoperoxide receptor: (1) the configuration of the
molecule should be such that the side chains are out of
plane with the ring, as they are in the native compounds.
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The chains of PGE2, PGF2a and PGA2 are in plane and thus
they cannot affect the receptor in such way as to produce
aggregation. (2) Certain changes in C-ll, C-15 and C-16 will
achieve the required configuration and will probably
favourably alter lipid solubility characteristics. The
latter conclusion is supported by the effect of modified
PGE2 analogues (e.g. 16,16-dimethyl PGE2)which act as TxA2.
(3) the existence of two rings (bicyclic compounds) appears
to be a strong and perhaps sufficient (although not sole)
stimulus for affecting the site.
Methylation and Aromatic Substitution .
The discussion below is based on data from this study, Andersen,
Imamoto, Subramanian, Picker, Ladner, De, Tynan, Eggerman,
Harker, Robertson, Oien & Rao (1981), Jones, Wilson & Marr
(1979), and Jones, Peesapati & Wilson (1982), unless
otherwise stated.
When the first metabolites of the PGs resulting from
oxidation of the 15-hydroxyl to a 15-ketone by the
dehydrogenase had been characterized (Anggard & Samuelsson,
1966), it was decided to look at the effect of introduction
of a 15-methyl group to prevent this oxidation. These
compounds were synthesized and proved to have full agonist
activity but with an increased biological half-life because
they could not be oxidized to the corresponding 15-ketone
(Bundy, Lincoln, Nelson, Pike & Schneider, 1971). Other
strategies have also been used to prevent the the metabolic
inactivation of the lower side chain by the
15-hydroxydehydrogenase. These have involved the concept of
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steric crowding close to the 15 position by the synthesis of
16,16-dimethyl analogues such as 16,16-dimethyl PGE2
(Magerlein, DuCharme, Magee, Miller, Robert & Weeks, 1973)
which are again not substrates for the enzyme and increase
PGE2-like activity, but reduce PGF2a-like activity.
Methylation at C-15 or C-16 position of PGF2a will increase
PGF2a-like activity. The order of potency for methylated
PGF2a analogues in aPGF2a-sensitive preparation is 15-Me=
16.16-diMe= PGF2a= 18,18-diMe> 17,17-diMe; the order of
potency for methylated PGE2 analogues in PGF2a-sensitive
preparations is PGE2 > 15-Me= 16,16-diMe> 17,17-diMe>
18,18-diMe. Also the methylation will con-fer TxA2-like
activity on the PGE2 and PGF2a compounds.
In complete contrast to PGF2a and PGE2 receptors,
17.17-dimethylation is the best tolerated modification for
retaining PGI2 potency while 16,16-dimethylation is most
disruptive. 17,17-dimethylation actually improves
PGl2-action specificity even for the PGE2 analogue:
17,17-dimethyl PGE2, unlike natural PGE2, is a potent
anti-aggregatory agent. The disruptive influence of
16,16-dimethylation on PGI2-Iike action is also seen in the
PGE2 analogues: 16,16-dimethyl PGE2 is an aggregating
stimulus by itself (Corey, Gordon, Maclntyre & Salzman,
1977), probably through its TxA2-like activity. And
16,16-dimethylation converts PGF2a into an aggregating
agent. The rat liver PGE2 receptor affinities and smooth
muscle activities of the prostacyclins are also consistent
with the hypothesis that 17-methylation enhances
prostacyclin specific activity for both PGE and PGI
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compounds while 16,16-dimethylation enhances PGE2-like
activity, even for prostacyclin structures:
16,16-dimethylation results in aggregatory activity in an
exo-PGl2 analogue structure has been reported (Gandolfi &
Ceserani, 1981). Thus one can predict that removal of the
methyl group at C-16 position of ZK 36374 and replacing it
at C-17 position will decrease its PGE2-like activity and
increase its PGI2-Iike activity.
Another tactic is to substitute the alkyl lower side chain
with aromatic rings such as phenyl or phenoxy residues
(Magerlein, Bundy, Lincoln & Youngdale, 1975; Crossley,
1976). Replacement of the C17-20 unit in PGD2, PGF2af PGE2,
9,11-etheno and 9,11-ethano PGH2 with a p-fluorophenoxy or
p-chlorophenoxy moiety markedly increase TxA2-like activity.
Also these substitutions confer both high PGE2- and
PGF2a-like activity on PGE2 or PGF2a and make PGE2 and PGF2a
more versatile. The 16-m-trifluoromethylphenoxy group will
increase the activity on PGF2a receptor site and give high
selectivity.
Other Substituents
11-deoxyprostaglandins, although less active than the
corresponding natural PGs have the advantage of relative
stability and ease of synthesis. These analogues, when
combined with other features in the <W-side chain (15- and
16-methyl substituents)have an interesting level of activity
and selectivity (Bartmann, Beck, Lerch, Teufel, Babej,
Beckel, Schoelkens & Seeger, 1979).
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Other approaches in analogue synthesis has been to design
of P<qrHi hi\J- T>Aa
compounds with substitution of the oxygen in the ring with
nitrogen (Bundy & Baldiwin, 1978), sulphur (Nicolaou,
Barnette, Gasic & Magolda, 1977; Hamanaka, Ohuchida &
Hayashi, 1982), and carbon (Morton, Bundy & Nishizawa, 1979;
Corey, Shibasaki, Nicolaou, Malmsten & Samuelsson, 1976;
Bundy, Kimball, Robert, Aiken, Maxey, Sebek, Nelson, Sih,
Miller & Hsi, 1980), to make configurationally rigid
arylprostaglandins (Schaaf, Johnson, Constantine, Bindra,
Hess & Elger, 1983), N-(methanesulfonyl)- 16-phenoxy
prostaglandincarboxamides (Schaaf, Bindra, Eggler, Plattner,
Nelson, Johnson. Constantine, Hess & Elger, 1981) and
13-aza- 14-oxo- prostaglandins (Favara, Guzzi, Ciabatti,
Battaglia, Depaol, Gallico & Galliani, 1983). These compounds
should be tested in preparations where PG receptors have
been defined, or better in preparations with a single type
of PG receptor, to estimate their potency and selectivity.
Schillinger, Prior, Speckenbach and Wellershoff (1979) have
reported the one of the N-methanesulfonyl-16- phenoxy
compounds, sulprostone, seems to have increased affinity for
PGE2 as well as PGF2a binding site.
The aim of studying receptors is to ey{end our knowledge of
receptor theory and to discover selective and efficacious
drugs. Owing to the successful synthesis of selective TxA2
receptor antagonists with high affinity the investigations
of PG receptors have entered a new stage. More work remains
to be done in this field in order to synthesize and screen
more selective and potent agonists and antagonists for
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